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Pregnant women and their children are at risk for devastating health consequences 
when pregnancy is associated with poor mental health and substance use problems. Yet, 
most of what is known about these significant issues in pregnant women came from 
clinical samples which limits the generalizability of the findings to the national 
population. Therefore, the purposes of this dissertation were to examine trends from 2008 
to 2014 in mental health and substance use disorders and treatment receipt, and explore 
factors associated with treatment receipt in pregnant women aged 18-44 years in the 
United States. This dissertations contains three manuscripts: (1) a systematic review of 
trend and population-based studies on mental health and substance use disorders and 
treatment receipt in pregnant women in the United States; (2) a trend study on mental 
health and substance use disorders and treatment receipt among pregnant and 





study of factors associated with mental health and substance use treatment receipt in 
pregnant women.  
The review of trend studies showed that illicit drug use disorder increased in 
pregnant women over the past decade, particularly opioid and marijuana use disorders. 
Despite the increase in treatment admissions for these disorders from 1992 to 2012, the 
overall treatment admission rate for pregnant women remained relatively stable at 4%.  
Although antidepressant use increased from 1995 to 2010 in pregnant women, there is a 
lack of trend studies addressing the changes in mental health disorders over the same time 
period. A review of population-based studies revealed that White ethnicity, older 
reproductive age, college education, and health insurance coverage are associated with 
mental health and substance use treatment receipt.  
In the second manuscript, trends in mental health and substance use disorders and 
treatment receipt were compared across one-to-two pairs of matched groups of pregnant 
(n = 5,520) and non-pregnant women (n = 11,040) who participated in the 2008-2014 
National Survey on Drug Use and Health (NSDUH). There was no difference in these 
trends by pregnancy status from 2008 to 2014. Yet, past-year anxiety disorder, past-
month psychological distress, and illicit drug use disorder increased in the total sample of 
pregnant and nonpregnant women from 2008 to 2014, whereas trends in mental health 
treatment receipt and unmet need for substance use treatment did not change over the 
same time period.  
In the final manuscript, secondary analysis of the 2008-2014 NSDUH was 
conducted with data from 5,520 pregnant women (1,106 with mental health problems and 





receipt of mental health treatment included: past-year anxiety disorder, major depressive 
episode, serious psychological distress, college education, health insurance coverage, and 
White ethnicity. Predictors of substance use treatment receipt were: illicit drug abuse and 
dependence, alcohol dependence, comorbid anxiety/depression, White ethnicity, and 
urban residency. Compared to Whites, nonWhite pregnant women with major depressive 
episode, serious psychological distress, substance use disorders, and/or comorbid mental 
health and substance use disorders had lower odds of receiving mental health treatment.  
The findings of this dissertation indicate that there is a gap between the need and 
the receipt of mental health and substance use treatment in pregnant women. Improved 
recognition and access to treatment for mental health and substance use disorders in this 
vulnerable population is critical. Preventive and interventional strategies are required to 
address the mental health needs of ethnic minority pregnant women with mental health 
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Mental health and substance use disorders are significant public health issues that 
have deleterious effects on the mother and her child. However, there is hope to improve 
maternal mental health and promote better futures for mothers and their children. This 
message of hope for women is created and advanced by researchers, policy makers, 
healthcare providers, and women themselves (United States Department of Health and 
Human Services [USDHHS], 2009). In response to this message of hope, the purposes of 
this dissertation were to examine trends in mental health and substance use disorders and 
treatment receipt, and explore factors associated with treatment receipt in pregnant 
women aged 18-44 years in the United States.  
This dissertation consists of an introduction, three manuscripts, and a discussion 
chapter in which the findings of the three chapters are integrated. First, a systematic 
review of trend and population-based studies was conducted to describe mental health 
and substance use disorders and treatment receipt among pregnant women in the United 
States. Second, trends from 2008 to 2014 in mental health and substance use disorders 
and treatment receipt among pregnant and nonpregnant women in the United States were 
examined. Third, the Behavioral Model of Health Services Use (Andersen, 1995) was 
used to examine factors associated with the receipt of treatment for mental health and 
substance use disorders among pregnant women in the United States.  
 2 
Serious mental health conditions disproportionately affect women (Hasin, 
Goodwin, Stinson, & Grant, 2005; Kessler, Berglund, et al., 2003) and are common 
among women of childbearing age (Farr, Bitsko, Hayes, & Dietz, 2010; Ko, Farr, Dietz, 
& Robbins, 2012). In the United States, up to 12.4% of pregnant women suffer from 
depression (Ko et al., 2012; Le Strat, Dubertret, & Le Foll, 2011; Melville, Gavin, Guo, 
Fan, & Katon, 2010; Vesga-Lopez et al., 2008), and anxiety often occurs with depression 
(Bowen et al., 2014; Le Strat et al., 2011). These serious mental health conditions are 
associated with substance use problems (Connelly, Hazen, Baker-Ericzen, Landsverk, & 
Horwitz, 2013; Le Strat et al., 2011) and increase the risk for developing chronic 
disorders such as diabetes (Farr, Hayes, Bitsko, Bansil, & Dietz, 2011).  
Prenatal mental illness takes a toll on maternal-child health. Maternal 
complications associated with poor mental health during pregnancy include preterm 
delivery (Accortt, Cheadle, & Dunkel Schetter, 2015; Grigoriadis et al., 2013), low birth 
weight (Accortt et al., 2015), and postpartum depression (Goodman, Chenausky, & 
Freeman, 2014). The mother-child relationship also is negatively affected (Grigoriadis et 
al., 2013; Rossen et al., 2016), and children of depressed mothers are at risk for 
behavioral and cognitive disorders (Csaszar, Melichercikova, & Dubovicky, 2014; 
Kingston, Tough, & Whitfield, 2012). Substance use disorders comorbid with mental 
health problems (Connelly et al., 2013), and children of substance using mothers are also 
at risk for mental disorders and harmful substance use, even after controlling for other 
childhood experiences (Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016).  
The Substance Abuse and Mental Health Services Administration (SAMHSA, 
2014b) reported that 5.4% of pregnant women used illicit drugs in the past month and a 
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higher percentage of them (9.4%) used alcohol in 2012 and 2013. Alcohol use during 
pregnancy can cause fetal alcohol syndrome (Lehikoinen, Orden, Heinonen, & 
Voutilainen, 2016). Prenatal marijuana use is also associated with intrauterine growth 
restriction (IUGR) (Metz & Stickrath, 2015) and may adversely affect children’s 
neurodevelopment (Jaques et al., 2014). In addition, cocaine-using women are at risk for 
placental abruption, preterm birth, IUGR, and impaired neurodevelopment in exposed 
infants (Lambert & Bauer, 2012).   
Prenatal exposure to psychotherapeutic drugs, particularly opioids, is associated 
with preterm birth and Neonatal Abstinence Syndrome (NAS) (Narkowicz, Plotka, 
Polkowska, Biziuk, & Namiesnik, 2013). NAS is characterized by extreme irritability, 
tremors, seizures, vomiting, diarrhea, and inconsolability from drug withdrawal (Hudak 
& Tan, 2012). Infants with NAS stayed in the hospital for an average of 16.9 days with a 
mean hospitalization cost of $66,700 in 2012 (Patrick, Davis, Lehmann, & Cooper, 
2015). Hence, prenatal substance use is an ongoing public health problem (Narkowicz et 
al., 2013) representing burden to society because of costs associated with health care for 
substance-exposed infants (Patrick et al., 2015) and child protective services 
interventions (Ondersma, Simpson, Brestan, & Ward, 2000). 
Despite ongoing medical recommendations (American College of Obstetricians 
and Gynecologists [ACOG], 2015b) and state screening initiatives (Agency for 
Healthcare Research and Quality, 2016), maternal depression is rarely diagnosed (Ko et 
al., 2012) or treated (Glasheen, Colpe, Hoffman, & Warren, 2015; Ko et al., 2012; Vesga-
Lopez et al., 2008); anxiety also is more often ignored than screened or studied 
(Fairbrother, Janssen, Antony, Tucker, & Young, 2016; Fairbrother, Young, Janssen, 
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Antony, & Tucker, 2015). Moreover, pregnant women with substance use disorders are 
rarely screened and referred to treatment by health care providers (McCabe & Arndt, 
2012; Terplan, Smith, Kozloski, & Pollack, 2010). Unfortunately, numerous obstacles 
(e.g., stigma and cost) impede pregnant women from receiving treatment for mental 
health (Ko et al., 2012) and substance use problems (Jackson & Shannon, 2012a). In 
addition, there are scant drug treatment programs targeting these women (Guttmacher 
Institute, 2017). This is of critical concern in the presence of health care disparities 
experienced by ethnic and racial minorities of pregnant women with mental health 
problems (Chang, Tabet, Elder, Kiel, & Flick, 2016).   
Given the vulnerability of pregnant women and the complexity of mental health 
and substance use disorders, understanding the seriousness of these disorders and the 
pattern of treatment receipt among pregnant women over time is warranted. Such 
information is critical for proper allocation of prevention and treatment resources 
nationwide. Yet, there is a paucity of review studies that shed the light on recent trends in 
mental health and substance use disorders and treatment receipt among pregnant women 
in the United States. The majority of review studies focused on the screening of 
depression during pregnancy or postpartum (Lancaster et al., 2010; O’Connor, Rossom, 
Henninger, Groom, & Burda, 2016; Thombs et al., 2014; van der Zee-van den Berg, 
Boere-Boonekamp, Haasnoot-Smallegange, & Reijneveld, 2017), while a few addressed 
barriers and facilitators to depression care during pregnancy (Byatt, Levin, Ziedonis, 
Simas, & Allison, 2015; Byatt, Simas, Lundquist, Johnson, & Ziedonis, 2012). 
 Chapter Two presents a systematic review of the literature on mental health and 
substance use disorders and treatment receipt among pregnant women in the United 
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States. The purpose of this review was to synthesize findings of trend and population-
based studies on mental health and substance use disorders and treatment receipt among 
pregnant women in the United States. Trend and population-based studies were selected 
for this systematic review to inform policy makers, healthcare providers, researchers, and 
others about the seriousness of maternal mental health and substance use disorders and 
what factors influencing access to treatment among pregnant women. The hope is to 
inspire future research and spur a change in maternal mental health through developing 
preventive and intervention strategies.  
The passage of the Mental Health Parity and Addiction Equity Act (MHPAEA) 
(2008) and the Patient Protection and Affordable Care Act (PPACA) (2010) indicates 
major implications to enhance women’s access to health care such as health coverage 
expansion and integrating mental health and substance use treatment services with 
primary medical care. However, there is limited literature addressing recent trends in 
mental health and substance use disorders and receipt of treatment in the United States 
(Mojtabai & Jorm, 2015), particularly among pregnant women. It is crucial to examine 
the difference in these patterns between pregnant and nonpregnant women. Such 
information will help in designing unique preventive strategies and program interventions 
according to the specific needs of pregnant women.   
Chapter Three presents a trend study of mental health and substance use disorders 
and treatment receipt among pregnant and nonpregnant women in the United States. 
Secondary analysis of the 2008-2014 National Survey on Drug Use and Health (NSDUH) 
was conducted to compare trends in mental health and substance use disorders and 
treatment receipt by pregnancy status. One-to-two pairs of pregnant (n = 5,520) and non-
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pregnant women (n = 11,040) were matched using propensity score matching. Pregnancy 
status was regressed onto age, ethnicity, marital status, education level, employment 
status, income, health insurance, and county urbanicity. A series of logistic regression 
models was conducted to examine potential interactions between pregnancy status and 
time in predicting: past-year major depressive episode (MDE); anxiety disorder; past-
month serious psychological distress; past-year any mental illness; past-year alcohol use 
disorder; illicit drug use disorder; mental health treatment receipt; and unmet need in the 
receipt of substance use treatment. This study also compared trends in mental health 
treatment receipt by pregnancy status among women with past-year any mental illness. 
Furthermore, barriers to mental health and substance use treatment were compared 
among women of childbearing age across two time periods, 2008-2010 and 2011-2014.  
Although prenatal mental health has been given little attention compared to 
postpartum depression, most of what is known is about factors associated with poor 
mental health during pregnancy (Fairbrother et al., 2016; Fairbrother et al., 2015; Le Strat 
et al., 2011; Vesga-Lopez et al., 2008) rather than factors related to mental health 
treatment receipt. Likewise, there is sparse evidence about factors associated with the 
receipt of substance use treatment among pregnant women. In Chapter Four, the 
Behavioral Model of Health Services Use (Andersen, 1995) was used to examine factors 
associated with mental health and substance use treatment among pregnant women with 
mental health and substance use disorders in the United States. This model was chosen 
because it integrates individual and contextual determinants of health services use: (a) 
predisposing characteristics (e.g., ethnicity); (b) enabling factors (e.g., health insurance 
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coverage); and (c) need factors (e.g., MDE, substance use disorders, and perceived need 
for treatment). 
Secondary analysis of the 2008-2014 NSDUH was conducted. A sample of 1,106 
pregnant women with mental health problems (i.e., past-year MDE, anxiety disorder, or 
serious psychological distress) and 521 pregnant women with substance use disorders 
(i.e., alcohol use disorder or illicit drug use disorder) were included in this study. A series 
of logistic regression models was used to identify predictors of mental health/substance 
use treatment receipt as well as ethnic disparities in the receipt of mental health treatment 
among pregnant women with mental health and/or substance use disorders. In addition, 
barriers to mental health treatment were compared and contrasted across types of mental 
health and/or substance use disorders and ethnicity.  
Finally, Chapter Five is an integration of the findings of Chapters Two, Three, 
and Four. Research, practice, and policy implications generated from the three 
manuscripts were summarized and discussed.  
 8 
CHAPTER II 
MENTAL HEALTH AND SUBSTANCE USE DISORDERS AND TREATMENT 
RECEIPT AMONG PREGNANT WOMEN IN THE UNITED STATES: A 
SYSTEMATIC REVIEW OF TREND AND POPULATION-BASED STUDIES 
Introduction 
Mental health problems affect 8.2% to 13.0% of pregnant women (Cook et al., 
2010; Le Strat, Dubertret, & Le Foll, 2011, 2011; Vesga-Lopez et al., 2008) and have 
devastating health consequences on the mother and her child (Csaszar, Melichercikova, 
& Dubovicky, 2014; Goodman, Chenausky, & Freeman, 2014; Grigoriadis et al., 2013; 
Rossen et al., 2016). Prenatal substance use is common among pregnant women with 
mental health issues (Connelly, Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013) and 
represents a perennial public health concern (Narkowicz, Plotka, Polkowska, Biziuk, & 
Namiesnik, 2013). In 2012 and 2013, 5.4% of pregnant women reported past-month use 
of illicit drugs and 9.4% of them drank alcohol (Substance Abuse and Mental Health 
Services Administration [SAMHSA], 2014b). 
 Alcohol consumed during pregnancy is associated with fetal alcohol syndrome 
(Lehikoinen, Orden, Heinonen, & Voutilainen, 2016) and low birth weight (Irner, 
Teasdale, Nielsen, Vedal, & Olofsson, 2012). Prenatal illicit drug use is associated with 
medical and obstetric complications (Lambert & Bauer, 2012; Metz & Stickrath, 2015), 
impaired neurodevelopment in prenatally exposed infants (Jaques et al., 2014), and costs 
related to their prolonged hospitalization (Patrick, Davis, Lehmann, & Cooper, 2015), 
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and child protective services (Ondersma, Simpson, Brestan, & Ward, 2000). Yet, mental 
health and  substance use disorders continue to be unrecognized and undertreated in 
pregnant women (Connelly et al., 2013; Glasheen, Colpe, Hoffman, & Warren, 2015; Ko, 
Farr, Dietz, & Robbins, 2012; Vesga-Lopez et al., 2008), irrespective of ongoing 
screening initiatives (Agency for Healthcare Research and Quality, 2016), legislation 
(Mental Health Parity and Addiction Equity Act [MHPAEA], 2008; Patient Protection 
and Affordable Care Act [PPACA], 2010), and available effective treatment modalities 
(Baker et al., 2010; Marais et al., 2011; May et al., 2013; Meyer, Johnston, Crocker, & 
Heil, 2015).   
 Although pregnancy represents an ideal time to screen and intervene with 
substance and mental health issues (Connelly et al., 2013), pregnant women face 
numerous obstacles to access mental health and substance use treatment (United States 
Department of Health and Human Services [USDHHS], 2009; Center for Substance 
Abuse Treatment [CSAT], 2009). Proper distribution of prevention and treatment 
resources requires an understanding of the significance of mental health and substance 
use disorders during pregnancy nationwide. Hence, a review of trend studies on mental 
health and substance use problems and treatment receipt among pregnant women in the 
United States is warranted to understand the changes in these disorders over time.  
 Prior and recent review studies focused on clinical studies addressing screening of 
depression in pregnant or postpartum women (Lancaster et al., 2010; O’Connor, Rossom, 
Henninger, Groom, & Burda, 2016; Thombs et al., 2014; van der Zee-van den Berg, 
Boere-Boonekamp, Haasnoot-Smallegange, & Reijneveld, 2017). Two recent systematic 
reviews focused on studies addressing barriers and facilitators to depression care during 
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pregnancy (Byatt, Levin, Ziedonis, Simas, & Allison, 2015; Byatt, Simas, Lundquist, 
Johnson, & Ziedonis, 2012). To our knowledge, no prior review studies examined factors 
related to mental health and substance use treatment receipt among pregnant women from 
trend and population-based studies in the United States. Understanding these factors from 
population-based samples rather than clinical samples is important to inform health 
policy so that strategies can be implemented to improve access to mental health and 
substance use treatment. Therefore, the purpose of this systematic review was to 
synthesize findings from trend and population-based studies to describe mental health 
and substance use disorders and treatment receipt in pregnant women of childbearing age 
in the United States.  
Method 
 This review was performed using the Preferred Reporting Items Systematic 
Review and Meta-analysis (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altman, 
2009). To decrease the risk of bias (Riesenberg & Justice, 2014), three databases were 
searched: CINAHL, PubMed, and PsychINFO. The search strategy was developed and 
vetted by a master’s prepared medical librarian. The search terms used in this review 
included subject headings and MeSH terms according to the requirements of each 
database (see Table 1).   
 Only peer-reviewed research articles published between 2007 and 2017 were 
included. Eligible studies were limited to population-based and trend studies on mental 
health or substance use disorders or treatment receipt for these disorders in pregnant 
women published in the last 10 years. The search was limited to English language 
publications, human subjects, and adults aged 18 years and older. This review was 
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limited to trend studies addressing mental health or substance use disorders or treatment 
receipt over time among pregnant women in the United States. If multiple trend studies 
used overlapping data sources or time points, the most recent study that reported national 
estimates was included. Studies that examined trends over less than five years and those 
that did not specifically address substance abuse or dependence during pregnancy were 
excluded from the review. 
 This review also focused on population-based studies of treatment receipt for 
mental health and substance use disorders. Population-based studies were included if they 
reported national/statewide data on mental health or substance use disorders or treatment 
receipt irrespective of the study design. Hence, population-based studies of randomly 
selected participants as well as population-based prospective/retrospective cohort studies 
were included in this review. Large national surveys comparing pregnant and 
nonpregnant women in regards treatment receipt for mental health and substance use 
disorders were also included.   
Data Extraction and Analysis 
            All primary studies were retrieved through the selected databases and screened for 
the eligibility based on the inclusion criteria. The references in each database were 
screened for duplication. Then the references list was compared between databases to 
eliminate duplicate articles. Next, the titles and abstracts were reviewed to identify 




The initial search resulted in 1,620 articles that were further screened for 
duplication. Eliminating the duplicating articles within and between databases resulted in 
1,209 articles. After removing articles with obviously irrelevant titles, a total of 450 
articles were reviewed at the abstract level. Of these, 402 articles were eliminated due to 
lack of relevance to the present review. In addition, full text review resulted in 
eliminating another 22 articles. After screening based on the inclusion criteria, 26 
research articles were included in the final review. Two additional articles identified from 
a review of reference lists of the selected articles were included (see Figure 1).    
Trends in Mental Health and Substance Use Disorders and Treatment Receipt 
Table 2 shows the characteristics of nine trend studies addressing changes in 
mental health and substance use disorders and treatment receipt in pregnant women over 
time. Among these studies, three studies addressed trends in antidepressant use during 
pregnancy (Andrade et al., 2008; Bobo et al., 2014; Meunier, Bennett, & Coco, 2013), 
and only one study focused on examining trends in psychotropic medications (Hanley & 
Mintzes, 2014). Overall, these studies showed an increase in antidepressant use during 
pregnancy from 1995 to 2010 (Andrade et al., 2008; Bobo et al., 2014; Meunier et al., 
2013). However, one study showed an inconsistent trend in antidepressant use as it 
increased from 1995 to 2004 then declined in 2007 (Bobo et al., 2014). Hanley and 
Mintzes (2014) found that the rate of psychotropic medication use was relatively stable 
between 2006 and 2011, while antidepressant use decreased slightly between 2010 and 
2011. No trend studies were found that addressed patterns of mental health treatment 
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receipt other than prescription medications over time as well as there is a lack of trend 
studies that examined changes of mental health problems in pregnant women over time.  
Among trend studies addressing substance use disorders and treatment among 
pregnant women, one study examined trends in maternal abuse of various substances 
(Pan & Yi, 2013) and another one focused on opioid dependence or abuse during 
pregnancy (Maeda, Bateman, Clancy, Creanga, & Leffert, 2014). Three studies addressed 
trends in treatment admission for different types of substances using the Treatment 
Episode Data Set (TEDS) (Martin, Longinaker, Mark, Chisolm, & Terplan, 2015; Martin, 
Longinaker, & Terplan, 2015; McCabe & Arndt, 2012).  
Based on the 1999-2008 Nationwide Inpatient Sample dataset, Pan and Yi (2013) 
reported an increase in opioid, cannabis and hallucinogens, and methamphetamine abuse 
during pregnancy over time. However, cocaine abuse declined significantly while alcohol 
abuse decreased slightly. From 1998 to 2011, the prevalence of opioid use disorders 
increased from 0.17% to 0.39% among pregnant women (Maeda et al., 2014).  
Studies of trends in substance use treatment showed an increase in admission rates 
for drug abuse whereas a decrease in alcohol-related abuse admissions occurred from 
1998 to 2008 (McCabe & Arndt, 2012). From 1992 to 2012, the rate of treatment 
admissions for marijuana as a primary substance of use increased; however, treatment 
admission for cocaine and alcohol use decreased over the same time period (Martin, 
Longinaker, Mark, et al., 2015). One study focused specifically on opioid use treatment 
and showed an increase in admission rate from 1% in 1992 to 19% in 2012 (Martin, 
Longinaker, & Terplan, 2015).  
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Mental Health and Substance Use Treatment Receipt 
 Table 3 shows the characteristics of 19 population-based studies addressing 
mental health and substance use treatment receipt among pregnant women in the United 
States. Among these studies, 11 studies addressed mental health treatment receipt, three 
studies addressed substance use treatment receipt, one study focused on mental health 
treatment receipt in substance use treatment setting, and four studies discussed barriers to 
mental health treatment.   
The rate of mental health treatment receipt ranged from 6.3% to 49.6% among 
pregnant women (Byatt, Xiao, Dinh, & Waring, 2016; Chang, Tabet, Elder, Kiel, & 
Flick, 2016; Cook et al., 2010; Glasheen et al., 2015; Ko et al., 2012; Le Strat et al., 
2011; Roberson et al., 2016). Four studies focused specifically on estimating the rate of 
antidepressant use and indicated that 2.2% to 27% of pregnant women used 
antidepressant during prenatal period (Bennett, Marcus, Palmer, & Coyne, 2010; Geier, 
Hills, Gonzales, Tum, & Finley, 2015; Wu & Davis-Ajami, 2014; Yamamoto, 
McCormick, & Burris, 2015). Two studies addressed pharmacotherapy for mental health 
problems in pregnant women; 1.4% of women used anxiolytic or antidepressant 
medications (Roberson et al., 2016), whereas 39.6% of women used prescription 
medications for any emotion, nerve, or mental health problems (Ko et al., 2012). Ko et al. 
(2012) also reported that 7.2% of pregnant women required inpatient treatment for any 
mental health problem.  
Data based on two national survey studies showed that pregnant women are less 
likely to receive mental health treatment compared to nonpregnant women even after 
adjusting for confounding variables (Glasheen et al., 2015; Vesga-Lopez et al., 2008). 
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However, two other national surveys did not show any difference between pregnant and 
nonpregnant women in the receipt of mental health treatment (Ko et al., 2012; Le Strat et 
al., 2011). Yet, a cohort study based on California State Medicaid program 2006-2009 
showed that pregnant women had a lower odds of depression diagnosis or treatment 
(Geier et al., 2015). Three studies reported the adjusted association between pregnancy 
status and mental health receipt without highlighting the contribution of other socio-
demographic characteristics (Ko et al., 2012; Le Strat et al., 2011; Vesga-Lopez et al., 
2008). Yet, Glasheen et al. (2015) found that mental health treatment receipt among 
women of childbearing age was related to White ethnicity, older reproductive age, 
college education, having a history of depression or anxiety. Likewise, Geier et al. (2015) 
reported that White ethnicity, age of 25 years or older, and urban residence were 
associated with depression treatment.  
Of studies conducted solely among pregnant women, factors associated with 
mental health treatment receipt included White ethnicity (Bennett et al., 2010; Byatt et 
al., 2016; Chang et al., 2016), older reproductive age, college education, marital status, 
tobacco use, physical or psychological abuse (Chang et al., 2016), having 
assistance/insurance coverage (Bennett et al., 2010; Chang et al., 2016), having a current 
(Byatt et al., 2016) or past mental health problem (Roberson et al., 2016), and urban 
residency (Cook et al., 2010). Among these studies, there was only one study conducted 
among a nationally representative sample of pregnant women (Byatt et al., 2016).  
Three studies explicitly addressed ethnic care disparities among pregnant women. 
A study based on the Florida Healthy Start prenatal screening program indicated that the 
rate of life-time mental health treatment receipt was highest among White pregnant 
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women, while the rate was lowest among Mexicans and other Hispanics (Chang et al., 
2016). Another study based on the 2006-2010 National Ambulatory Medical Care Survey 
and the National Hospital Ambulatory Medical Care Survey revealed that nonWhite 
pregnant women had lower odds of antidepressant use even after controlling for maternal 
age, insurance type, region of the country, and survey type (Yamamoto et al., 2015). 
Interestingly, Coleman-Cowger (2012) examined disparities in mental health treatment 
based on the 2008 Global Appraisal of Individual Needs Data among past-year pregnant 
women who entered substance use treatment. This study showed that higher proportions 
of Hispanics and African Americans had not received mental health treatment compared 
to Mixed or White women.  
Four studies addressed barriers to mental health treatment among pregnant 
women. One compared barriers to mental health treatment between pregnant and 
nonpregnant women using the 2005-2009 National Survey on Drug Use and Health 
(NSDUH) (Ko et al., 2012). The most common barriers were cost, opposition to 
treatment, stigma, time/transportation limitation, and not knowing where to go. These 
perceived barriers did not differ by pregnancy status. Two studies examined factors 
associated with provider-patient conversation regarding depression based on state (Liu & 
Tronick, 2012) and national-level data (Farr, Ko, Burley, & Gupta, 2016). These factors 
included age of less than 35 years (versus > 35 years), Medicaid coverage, White 
ethnicity (Farr et al., 2016; Liu & Tronick, 2012), and being unmarried (Farr et al., 2016). 
In addition, non-US born pregnant women and those who visited a private doctor had 
lower odds of having a conversation about depressed mood with health care providers 
(Liu & Tronick, 2012). From the healthcare providers’ perception, the 2008-2009 
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Virginia Department of Health Data showed that common barriers to treatment/referrals 
of pregnant women with depression included the lack of time, available treatment 
services, reimbursement, and provider knowledge/skills (Price, Corder-Mabe, & Austin, 
2012).   
Three studies addressed substance use treatment receipt. A study based on the 
2002-2006 NSDUH indicated that less than 20% of women of childbearing age with 
substance use disorders received substance use treatment; however, pregnant women did 
not have a lower odds of receipt of substance use treatment compared to nonpregnant 
women (Terplan, McNamara, & Chisolm, 2012). Yet, women of childbearing age who 
were employed, aged 21-25 (versus less than 20 years), had high school education or 
equivalent, and those who did not have governmental assistance had a lower odds of 
substance use treatment receipt compared to their counterpart group. A population-based 
study in Massachusetts 2003–2007 showed that pregnant women who received substance 
use treatment were more likely to be age of 30 or older, have some college education, be 
married, and have private insurance and fewer health or psychiatric conditions, and less 
likely to be Black or Hispanic compared to those who did not receive treatment 
(Kotelchuck et al., 2017).  
A study based on the 2013 TEDS compared characteristics of pregnant women 
who received treatment for opioid use disorder by United States census regions (Hand, 
Short, & Abatemarco, 2017). Compared to the South, pregnant women who received 
substance use treatment in other regions were more likely to be admitted to medication 
assisted treatment, and use heroin and injection drugs. Pregnant women with opioid use 
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disorder in the South were less likely to have health insurance coverage, have more than a 
high school education level, and be married.  
Discussion 
Trend Studies on Mental Health and Substance Use Disorder and Treatment 
Receipt 
The findings of this review demonstrated an increase from 1995 to 2010 in 
antidepressant use during pregnancy (Andrade et al., 2008; Bobo et al., 2014; Meunier et 
al., 2013). Although antidepressants were the most common psychotropic medications 
used among pregnant women, the rate of psychotropic medication use from 2006 to 2011 
was stable and antidepressant use slightly decreased between 2010 and 2011 (Hanley & 
Mintzes, 2014). Although this suggests a shift in antidepressant use, a careful 
interpretation of the pattern of antidepressant use across studies is required. For instance, 
Hanley and Mintzes (2014) used a large private insurance claims database, the Truven 
Health Market Scan Database, to examine trends in psychotropic medications and this 
limits the generalizability of trend findings to women covered by Medicaid. The only 
trend study that used a nationally representative sample of women in prenatal care 
showed an increase in antidepressant use from 2002 to 2010 (Meunier et al., 2013). Yet, 
trend studies of antidepressant use did not report medication use disparities among 
pregnant women over time. In addition, this review did not find any trend studies that 
specifically examined changes in mental health problems among pregnant women over 
time.   
Changes in the type of substance use disorders among pregnant women over the 
past decade were revealed in this review. Findings from the 1999-2008 Nationwide 
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Inpatient Sample dataset showed an increase in opioid, cannabis and hallucinogens, and 
methamphetamine related disorders over time, and a decrease in cocaine and alcohol use 
disorders among pregnant women (Pan & Yi, 2013). The highest increase in substance 
use issues was for cannabis and opioids. Congruently, marijuana was the most common 
illicit drug used in the United States among adults aged 12 or older (SAMHSA, 2014b). 
The rate of prenatal opioid use disorder also corresponds with the epidemic increase in 
opioid abuse among the general population (Centers for Disease Control and Prevention 
[CDC], 2013).  
The decrease in cocaine use disorder among pregnant women can be related to the 
increase in public awareness regarding the cocaine effects (United States Department of 
Justice, National Drug Intelligence center, 2011). However, the slight decrease in the 
national estimate of alcohol use disorder in pregnant women should be reviewed with the 
consideration that pregnant women may continue to consume low to moderate levels of 
alcohol that cannot be classified as alcohol use disorder (Pan & Yi, 2013). Yet, the 
overall decrease in alcohol use disorder can be due to the tremendous efforts in publically 
informing pregnant women about the risks of alcohol consumption on the mother and her 
infant (McCabe & Arndt, 2012).   
Notably, there were very few trend studies on national estimates of maternal 
substance use disorders, and no studies addressed recent trends of these disorders. Yet, 
ongoing trend studies show an epidemic increase in Neonatal Abstinence Syndrome 
(NAS) in the United States (Patrick, Davis, Lehman, & Cooper, 2012; Patrick et al., 
2015; Tolia et al., 2015), reflecting an increase in maternal substance use issues, 
especially opioids. Tolia et al. (2015) reported an increase in Neonatal Intensives Care 
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Unit (NICU) admissions for infants with NAS in the United States from seven cases per 
1,000 admissions in 2004 to 27 cases per 1,000 admissions in 2013. Opioid pain relievers 
were the most commonly used medications among pregnant women from 2012 through 
2013.  
Interestingly, this review revealed that trends in substance use treatment 
admissions are congruent with the trends in substance use disorders. McCabe and Arndt 
(2012) reported an increase in drug abuse admissions and a decrease in alcohol abuse 
admissions from 1998 to 2008. Other studies based on the 1992-2012 TEDS also showed 
an increase in treatment admissions for marijuana, methamphetamine, and opioids, and in 
contrast, a decrease in treatment admissions for cocaine and alcohol (Martin, Longinaker, 
Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015). Although these patterns are 
promising, a majority of pregnant women with substance use disorders do not receive 
treatment (Terplan et al., 2012), and their rate of admission for substance use treatment 
remained relatively stable at 4% from 1992 to 2012 (Martin, Longinaker, Mark, et al., 
2015). Pregnant women continue to face obstacles to access treatment such as the lack of 
availability of treatment programs and stigma (CSAT, 2009). Hence, understanding the 
characteristics of women who received treatment over time can also help to identify 
disparities and tailor intervention strategies to enhance treatment utilization.  
This review indicated that admissions for substance use treatment among pregnant 
women who were younger (Martin, Longinaker, Mark, et al., 2015; McCabe & Arndt, 
2012), White, had comorbid psychiatric illness (Martin, Longinaker, Mark, et al., 2015; 
Martin, Longinaker, & Terplan, 2015), and live in the South (Martin, Longinaker, & 
Terplan, 2015) increased over time. Unfortunately, the majority of admission referrals of 
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these women have been continued to be through criminal justice systems from 1992 to 
2012 (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015; 
McCabe & Arndt, 2012), suggesting that most health care providers did not screen 
women for substance use issues during prenatal care (McCabe & Arndt, 2012). This 
review included only trend studies of substance use treatment admission based on the 
TEDS which draws data from publically funded facilities in the United States 
(SAMHSA, Center for Behavioral Health Statistics and Quality [CBHSQ], 2017); this 
may bias the trend findings, as private funded facilities are excluded. In addition, TEDS 
does not distinguish new admissions from readmissions which may also affect the 
estimation of the rate of treatment receipt for each individual. 
Population-based Studies on Mental Health and Substance Use Treatment Receipt 
 This review of findings from national surveys revealed mixed results regarding 
the association between pregnancy status and the receipt of mental health treatment. This 
may be due to the heterogeneity of the samples and measures of mental health problems. 
For instance, studies based on National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC) measured psychiatric disorders using structured clinical 
interviews. Based on this dataset, Vesga-lopez et al. (2008) studied women with any 
psychiatric disorder while Le Start et al. (2011) only included women with major 
depression. On the other hand, the NSDUH measured mental health problems using self-
report questions operationalizing the Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV (American Psychiatric Association [APA], 1994) and included the 
Kessler Distress Scale (Kessler, Barker, et al., 2003). Glasheen et al. (2015) studied 
women of childbearing age with past-month psychological distress using data from the 
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NSDUH, while Ko et al. (2012) included women with past-year major depressive 
episode.  
 Overall, a majority of pregnant women who need mental health and substance use 
treatment do not receive it which has critical implications. First, there is a need to focus 
on socio-economically disadvantaged women and to increase health insurance coverage 
to improve treatment receipt. Further intervention strategies are also required to help 
rural, younger, and low educated women access mental health treatment. However, very 
few population-based studies identified factors associated with treatment receipt among a 
nationally representative sample of pregnant women.  
 Second, ethnic health care disparities in the receipt of mental health treatment still 
exist among pregnant women and even extend to those with substance use disorders. This 
finding is congruent with the presence of healthcare disparities among the general 
population (Snowden, 2012). Disparities in antidepressant use are also of particular 
concern, especially since the rate of antidepressant use is lower than rate of counseling 
among pregnant women (Ko et al., 2012). Both the American Psychiatric Association 
(APA) and American College of Obstetricians and Gynecologists (ACOG) recommend 
antidepressant use during pregnancy if the benefits to the mother with possible risks to 
the fetus and newborn are balanced (Yonkers et al., 2009). Yet, there is a lack of 
nationally representative studies on disparities in mental health treatment receipt among 
pregnant women.   
 Third, barriers to mental health treatment receipt are complex and involve patient-
level obstacles (i.e., opposition to treatment and stigma), logistic barriers (i.e., cost and 
lack of time/transportation), and provider-level barriers (i.e., patient-provider 
 23 
communication, providers’ competency in treatment/referrals, and inadequate available 
services). These findings are congruent with a systematic review of 49 studies on barriers 
and facilitators to perinatal depression treatment (Byatt et al., 2015).   
 Fourth, although one study based on the NSDUH did not find a difference 
between pregnant and nonpregnant women in substance use treatment receipt, trend 
findings based on the TEDS showed that the rate of treatment admissions among 
pregnant females was stable from 1992 to 2012 at only 4% (Martin, Longinaker, Mark, et 
al., 2015). Notably, there is a paucity of studies that specifically differentiate the 
characteristics of pregnant substance use treatment recipients and nonrecipients. Yet, this 
review suggested that health insurance coverage is necessary to increase treatment 
receipt. Further intervention strategies are also warranted to increase access to substance 
use treatment among ethnic minority pregnant women and other vulnerable segments 
including those with a low education level.  
Fifth, there was no population-based study that specifically addressed barriers to 
substance use treatment among pregnant women. However, using data from the 2013 
TEDS, Hand et al. (2017) reported that pregnant women in the South who have opioid 
use disorder are less likely to receive medication assisted treatment compared to pregnant 
women in other regions. In addition, the proportion of pregnant women who received 
medication assisted treatment declined nationally from 44% in 1992 to 37% in 2012 
(Martin, Longinaker, & Terplan, 2015). This may be due to a lack of health insurance 
coverage and available treatment services (Hand et al., 2017).   
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Limitations 
There are some limitations to this systematic review. Unpublished studies (e.g., 
dissertations) and articles of studies solely conducted among pregnant women under age 
18 years were not included in this review. This review included population-based studies 
and trend studies on mental health and substance use disorders among pregnant women 
and was not a meta-analysis; therefore, the effect sizes of the various studies were not 
calculated and compared. There is a lack of trend studies on mental health problems 
among pregnant women, and there is a paucity of nationally representative studies on 
recent trends in substance use disorders among pregnant women in the United States. 
Hence, a clear conclusion regarding the trend in these disorders cannot be drawn.  
Relatively few studies examined trends in antidepressant use among pregnant 
women, and no studies were found in which trends in the receipt of any treatment 
modalities (i.e., prescription medications, outpatient counseling, or inpatient treatment) 
were examined. All studies included in this review reported trends in substance use 
treatment receipt based on the TEDS which limits the true estimation of treatment receipt 
among pregnant women as privately funded treatments were not included. The paucity of 
studies conducted among nationally representative samples of pregnant women limits any 
conclusions regarding barriers to and factors influencing the receipt of mental health and 
substance use treatment in the United States. Finally, studies in this review were 
restricted to population-based and trend studies in the United States and may not be 
representative of mental health and substance use disorders and treatment receipt among 
pregnant women globally.  
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Conclusions 
This review indicates that the rates of antidepressant use have increased from 
1995 to 2010 among pregnant women in the United States. However, there was no study 
that examined trend in the receipt of any mental health treatment over time among 
pregnant women. Overall, illicit drug use has increased while alcohol use disorder 
decreased over the past decade among pregnant women. Marijuana and prescription 
opioid use disorders are ongoing public health concerns in pregnant women. Despite the 
increase in treatment admissions for these disorders from 1992 to 2012, the overall 
admission rate for pregnant women remained relatively stable at 4%.  
There is a critical need for innovative preventive interventions for mental health 
and substance use disorders, especially for vulnerable pregnant women including ethnic 
minorities and those with a low education level. There is a need for policies and treatment 
programs to increase access to health insurance and utilization of mental health and 
substance use treatment services among pregnant women. Further research is needed to 
address ethnic care disparities, barriers to, and factors associated with treatment receipt 
among a nationally representative sample of pregnant women. Future systematic reviews 
need to include studies from different countries to compare trend data and findings 
regarding factors associated with treatment receipt for mental health and substance use 







Search Terms Addressing Mental Health and Substance Use Disorders in Pregnant 
Women in the United Stated in Three Databases 
Database Search Terms 
CINAHL (MH "Depression") OR (MH "Anxiety") OR (MH "Symptom 
Distress") OR (MH "Substance Use Disorders") OR (MH 
"Substance Abuse") OR (MH "Alcohol-Related Disorders") 
OR (MH "Inhalant Abuse") OR (MH "Substance Abuse, 
Intravenous") OR (MH "Substance Abuse, Perinatal") OR (MH 
"Substance Dependence") AND (MH "Pregnancy") AND (MH 
"United States+") 
PubMed (((((((((((("Depression"[Mesh] OR "Depressive 
Disorder"[Mesh])) OR ("Anxiety"[Mesh] OR "Anxiety 
Disorders"[Mesh])) OR "Alcoholism"[Mesh]) OR "Binge 
Drinking"[Mesh]) OR "Amphetamine-Related 
Disorders"[Mesh]) OR "Cocaine-Related Disorders"[Mesh]) 
OR "Marijuana Abuse"[Mesh]) OR "Opioid-Related 
Disorders"[Mesh])) AND (("Pregnant Women"[Mesh]) OR 
"Pregnancy"[Mesh]))) AND "United States"[Mesh] 
PsychInfo ((DE "Pregnancy") AND ((DE "Major Depression" OR DE 
"Depression (Emotion)") OR (DE "Anxiety" OR DE "Anxiety 
Disorders") OR (DE "Distress") OR (DE "Drug Dependency") 
OR (DE "Alcoholism") OR (DE "Drug Abuse") OR (DE 
"Alcohol Abuse") OR (DE "Substance Use Disorder"))) AND 








Trend Studies on Mental Health and Substance Use Disorders and Treatment Receipt in Pregnant Women of Childbearing Age in 
















use among pregnant 
women in the United 
States 
  Health Maintenance 
Organization Research 






  n = 118,935 deliveries 
(2001-2005) 
  n = 148,107 deliveries 
(1996-2000) 
Rates of antidepressant drug 
use increased from 2.0% in 
1996 to 7.6% in 2004 and 
2005 
 Seven health plans were 
included across the United 
States 
 No description of women’s 
characteristics 
Bobo et al., 
2014 
Examine if the 
antidepressant 
prescription declined 
in pregnant women 
after the 
announcement of the 
U.S. and Canadian 
advisory warning 
about the risks of 
antidepressant in 2004 
 Tennessee Medicaid, 
1995–2007 




Rates per 1,000 increased 
steadily from 1995 (66.0) to 
2001 (182.8), sharply 
increased from 2002 (290.8) 
to 2004 (397.6), then 
declined post-warning 
release to 195.4 in 2007 
Antidepressant users tended 
to be mostly: Caucasian, 
married, rural residents, 
smokers, and with substance 























Examine the rate of 
psychotropic 
medication use during 
pregnancy from 2006 
to 2011   




 N = 343,299 women 
who had a live birth 
 The rate of psychotropic 
medicines use was 
relatively stable between 
2006 and 2011(10.3%).  
 A slight decrease in 
antidepressant use between 
2010 (6.7%) and 
2011(6.4%) 
 The use of stimulants 
increased from 0.4% in 
2007 to 0.9% in 2011. 
 The most common types: 
antidepressants (6.5%), 
anxiolytics (4.2%), 
antipsychotics (1.1%) and 
stimulants (0.6%).  
 Rates of use of 
psychotropic medicines 
were higher before 









Examine trends in 
opioid abuse or 
dependence during 
pregnancy in the 
United Stated from 
1998 to 2011 
 Nationwide Inpatient 
Sample of the 




 N = 56,900,512 
delivery admissions 
The prevalence of opioid use 
disorder during pregnancy 
increased from 1.7 per 1,000 
delivery admissions in 1998 
to 3.9 per 1,000 in 2011 
The most significant increase 
in opioid use disorder (from 
1.8 per 1,000 delivery 
admissions in 1998 to 4.5 per 
1,000 deliveries in 2011) 
occurred within the age 
group of 20 to 34 years  























trends in substance 
use treatment 
admissions of 
pregnant women for 
marijuana use 
in the United States 
 Treatment Episodes 
Data Set, 1992-2012 
 




 The rate of admissions 
for marijuana increased 
from 6% to 20% The rate of 
admission for other primary 
substance of use: Decreased 
for cocaine (40% to 6%) 
and alcohol (28% to 12%); 
Increased for methamphet- 
amines (4% to 13%), heroin 
(4%  to 9%), and opioids 
(<1% to 11% ) 
 The rate of treatment 
admissions of pregnant 
women stayed stable at 4%  
 Rates of admissions of 
whites and those with 
comorbid psychiatric 
illness increased overtime 
 Rates of admissions of 
non–high school graduates, 
homeless and married 







Examine recent trends 
in substance abuse 
treatment admissions 
of pregnant women 
for prescription 
opioids  
 Treatment Episodes 
Data Set, 1992-2012 
 




 The rate reporting any 
prescription opioid abuse 
increased from 2% in 1992 
to 28% in 2012  
 The rate opioids use as the 
primary substance of abuse 
increased from 1% to 19%   
 The rate of admissions 
increased overtime among: 
whites, those aged 21-29 
years, with comorbid 
psychiatric illness, and live 
in the South  
 Criminal justice referrals 
increased from 11% to 17%  


















To examine trends in 
substance abuse and 
demographic from 





 Treatment Episode 
Datasets, 1998-2008 
 
 N = 1,724,479 women 
aged 18-44  
 n = 81,818 pregnant 
women 
 Decrease in alcohol-related 
abuse rates: from 49.3% to 
37.6% of pregnant women 
 Increase in drug abuse in 
pregnant women from 
47.8% to 60.9%  
 Trends were more 
pronounced in pregnant 
women compared to 
nonpregnant women 
 Characteristics of pregnant 
women entering treatment 
compared to nonpregnant 
women: younger, 
unmarried, homeless, less 
than high school education, 
on public assistance or with 
no source of income  
 Rates of ages 21–24 
increased from 22.8% to 
31.3%; Referrals from the 
criminal justice system 





rates of antidepressant 
prescription during 
pregnancy and 
examine the trends in 
the use of prenatal 
antidepressants  
 National Ambulatory 
   Medical Care Survey 





 N = 27,328 prenatal 
visits 
The rate of visits by pregnant 
women who received a 
prescription for an 
antidepressant increased 
from .7% in 2002–2006 to 
2.1% in 2007–2010 
Characteristics of the women 
(majority): aged 21 or older 




     
     
















Pan & Yi, 
2013 
Examine trends in 
hospitalization of 
infants prenatally 
exposed to alcohol or 
drugs 




 n = 3,842,837 
hospitalized live birth 
in 1999 
 n = 4,253,656 
hospitalized live birth 
in 2008 
 Rates of maternal 
substance use-related 
problems per 10,000 
liveborn deliveries from 
1999 to 2008:  
 Cocaine decreased from 
38.9 to 23.8  
 Alcohol decreased from 
10.6 to 9.4  
 Opioids increased from 
13.7 to 22.0  
 Cannabis and 
hallucinogens: increased 
from 30.2 to 52.1  
 Methamphetamines 
increased from 6.9 to 11.2  
 






























pregnancy is related 
to the 
discontinuation of 





claims data from 
all 50 states 1999-
2000 
 
 N = 6,474 women 
aged 15–45 years  
(n = 3,237 
pregnant women; 
n = 3,237 matched 






Diseases, Ninth Revision 
(ICD-9) codes 
 Depression treatment: 
antidepressant 
medications or a 
depression care visit 
Rates of depression care: 
 Antidepressants: 27% pregnant women, 
62% nonpregnant women 
 Care visits: 31% pregnant women, 49% 
nonpregnant women 
 
Factors related to treatment receipt: 
 White women had fewer depression 
care visits during the pregnancy period 
compared to nonWhites 
 Nonwhite pregnant women had fewer 
antidepressant use in postpartum period 
compared to Whites 
 Pregnant women not receiving 







mental health care 
use and depressive 
symptoms among 
pregnant women 





 N = 463 pregnant 
women aged 20-44 
years 
 Depressive symptoms: 
Patient Health 
Questionnaire 
 Mental health care use: 
self-report of seeing or 
talking to a mental 
health professional about 
mental health 
 
Rate of mental health care use: 
 12% of women with depressive 
symptoms; 4% of non-depressed   
 Women with depressive symptoms had 
higher adjusted odds ratio of care use 
compared to those without depressive 
symptoms 
 Only multiracial and other ethnicity 
had lower adjusted odds of care use 























services use in 















 Depressive symptoms: 
one question addressed 
feeling down, depressed, 
or hopeless in the last 
month 
 Mental health treatment: 
self-report of lifetime 
use of mental health 
services or counseling 
 Rates of mental health services use: 26 
% all sample, 42.5 % Whites, 11.5% 
Mexican and other Hispanics 
 
Predictors of mental health care: 
 Tobacco use, physical or psychological 
abuse, and illness across ethnic groups  
 Demographics (age of 30 years or 
older, college education, unmarried 
status among non-Hispanic 







in mental health 
treatment exist in 
pregnant women 
entered substance 
use treatment across 
ethnicity and age 
groups 
 Global Appraisal 
of Individual 
Needs Data, 2008 
 
 N = 502 past-year 
pregnant women 
aged 12-43 years 
 Mental health: Internal 
Mental Distress Scale, 
Behavioral Complexity 
Scale, or endorsing 
suicidal thoughts 
 Treatment receipt: self-
report of treatment 
receipt for mental or 
psychological problem  
 Rate of mental health treatment need 
vs. receipt: 78.3% vs. 38.3% 
 Treatment disparities: Hispanic and 
African American had higher 
proportions of no treatment receipt than 
the Mixed or Whites  
 No difference in treatment receipt by 
age groups among those who needed 
treatment 
     














Rates/Factors Associated with Treatment 
Receipt  
Cook et al., 
2010 





women and the rate 
of treatment receipt  
 Cross-sectional  
 
 N = 744 low 








 Diagnostic and 
Statistical Manual of 
Mental Disorders: DSM-
IV  
 Broad definition of 
treatment: speaking with 
a doctor or other 
professionals about 
psychiatric symptoms.  
Prevalence of treatment in pregnant 
women: 
 28.9% for any anxiety disorder 
 37.7% for major depressive episode 
 22.2% for any substance use disorder 
 26.2% for any psychiatric disorder 
excluding nicotine 
 Rural women with a psychiatric 
disorder were less likely to receive 
treatment than urban women (20.7% 








depression with a 
prenatal care 
provider  
 A secondary 
analysis of 2011 





 N = 32,827  
 Prenatal education: self-
report of whether a 
health care provider 
talked with the women 
about her depressive 
feeling during pregnancy 
or after birth.  
 Rate of prenatal education: 71.9 % 
Predictors of discussing depressive 
symptoms (higher adjusted odds): 
 Demographics (age < 35 years vs. > 35 
years, unmarried status, Medicaid 







Determine rates and 
predictors of 
depression detection 










2009N = 76,493 
 
 Depression: ICD-9 code 
for any depressive 
illness 




 Rate of antidepressant use: 2.7% 
pregnant, 10.8% nonpregnant  
Predictors of depression diagnosis/ 
treatment (higher adjusted odds) 
 Pregnant women had lower odds  
 Demographics (Age of 25 years or 
older, White/African/Asian vs. 







     
















Examine the rates 
and correlates of 
mental health 
treatment receipt 


















 Serious psychological 
distress: Kessler Distress 
6 Scale (past-month)  
 Mental health treatment: 
self-report of the receipt 
of treatment for 
emotions, nerves, and 
mental health problems  
Prevalence of past-year mental health 
treatment receipt:  
 38.5% pregnant women; 49.5% 
postpartum women; 51.5% 
nonpregnant women 
Predictors of mental health treatment 
(sample included childbearing-aged 
women):  
 Pregnancy status (pregnant women had 
lower odds of treatment receipt)  
 Demographics (white ethnicity, older 
age, college graduates, health 
insurance, history of depression/ 





Compare data related 




of pregnant women 
entering treatment 
for opioid use 
disorder between 





 N = 8,656 pregnant 
women with opioid 
use disorder 
 Substance use: self-
report by the individual 
 Treatment modalities for 
the current admission: 
methadone-assisted 
treatment and 
detoxification.   
 
 Pregnant women received treatment in 
the South were less likely to: have 
health insurance, be married, and have 
an education level of more than high 
school   
 Compared to the South, pregnant 
women entering treatment in other 
regions were more likely to: be 
admitted to medication assisted 
treatment, use heroin, and inject drugs 






































depressive episode  
 n = 375 pregnant 
women 
 n = 8,657 
nonpregnant 
women) 
 Major depressive 
episode: nine questions 
based on the DSM-IV 
criteria 
 
 Mental health treatment: 
self-report of the receipt 
of treatment for 
emotions, nerves, and 
mental health problems.  
 Past-year mental health treatment 
receipt rates in women with major 
depressive episode:  
49.6% pregnant women; 53.7%  
nonpregnant women  
 
 Rates by treatment modality in 
pregnant vs. nonpregnant women:  
39.6% vs. 47.4% for prescription 
medication;  
36.3% vs. 35.5% for counseling;  
7.2% vs.4.7% for inpatient treatment 
(No difference by pregnancy status in 
the receipt of any treatment, after 
adjusting for socio-demographic 
characteristics)  
 
 Barriers to treatment in women:  
cost, opposition to treatment, stigma 
concerns, time or transportation 
limitations, and not knowing where to 
go for treatment   
     














Rates/Factors Associated with 
Treatment Receipt  
Kotelchuck 
et al., 2017 
Examine prevalence 
of substance use 
disorders and 
substance use 
treatment prior to 







Center for Health 
Information and 
Analysis case mix 
data;  








 N = 375,851  
 Substance use disorders: 
(a) positive neonatal 
toxicology screen or 
fetal alcohol syndrome;  
(b) BSAS treatment 
system admission 
record; or  
(c) ICD-9 
 
 Substance use treatment: 
professional services 
received in a treatment 
facility or hospital-based 
program or 
detoxification.  
 Rate of treatment receipt: 66.3%  
 
Factor associated with treatment 
receipt:  
 Demographics (age of 30 or older, 
some college education, married health 
status, private insurance) 
 Having fewer health or psychiatric 
conditions 
     
     
     
     
     
     














Rates/Factors Associated with 







and correlates of 
Major Depressive 











 N = 1,524 pregnant 




 DSM-IV  
 Receiving treatment for 
anxiety or mood in 
health professional 
clinic, hospital, 
emergency room, or 
prescribed medication  
 
 Receiving treatment for 




program, or 12-steps 
meeting 
Rates of treatment receipt in pregnant 
vs. nonpregnant women with major 
depression:  
 36.98% vs. 44.83% for any disorder 
 23.76% vs. 33.77% for depression  
 26.55% vs. 31.68% for anxiety  
 12.85% vs. 9.80% for alcohol/drug use  
 
Differences in treatment receipt: 
 Pregnant women with depression had 
higher adjusted odds of treatment 
receipt compared to pregnant women 
without depression 
 Pregnant women with depression had 
lower odds of the receipt of treatment 
compared to nonpregnant women (but 










mood during the 
perinatal period 






 N = 3,597 
 
Conversation about mood: 
self-report if a health 
care provider talked with 
respondents about blues 
or depression during 
pregnancy or after.  
 About 50% of women had conversation 
 Predictors of having conversation 
(lower odds): age of 35 years or above, 
non-US born women, and private 
doctor, and no prenatal assistance, 
Asian/Pacific Islander vs. Whites (less 
likely). 
 

























and confidence in 
screening, treatment, 







 N = 1,498 
healthcare 
providers 
 36-item survey 
instrument: demo- 
graphics, self-reported 
attitudes and beliefs 
regarding perinatal 
depression, barriers and 
facilitators to treatment, 
and satisfaction with 
training 
Rate of treatment/referral 
 51.6% routine treatment/referral  
 33.5% occasional treatment/referral 
 12.7% rare or no treatment/referral 
 
 Common barriers: Inadequate time 
(41.4%), inadequate available treatment 
services (24.4%), inadequate 
reimbursement (17.8%), and 









perinatal period in 
multiethnic women 
in Hawaii 





 N = 4,735 women  
 Anxiety/depression 
symptoms: Self-report of 
having depression or 
anxiety, feeling of 
sadness  
 
 Treatment: self-report of 
receiving treatment for 
anxiety or depression or 
taking prescription drugs 
Rate of mental health care: 
 7.3 % for visiting a healthcare worker  
 1.4 % for antianxiety or antidepression 
prescription  
 
Factors associated with prescription 
drugs use: 
 Pre-pregnancy depression or anxiety 
     
     
     
     















Rates/Factors Associated with 







use, treatment need, 
and treatment receipt 
in pregnant and 
nonpregnant women. 
 2002-2006 
National Survey on 








 Operationalization of 
substance abuse or 
dependence based on 
DSM-IV criteria 
 Substance use treatment 
receipt: self-report of 
receiving substance use 
treatment  
 Rate of treatment receipt < 20% 
Factors associated with substance use 
treatment receipt in women of 
childbearing age (after adjusting for 
other variables in regression model) 
 Pregnant had lower odds of treatment 
receipt (but not significant) 
 Demographics (employed women, age 
of 21-25 compared to < 20, high school 
or equivalent) (lower odds) 
Vesga-lopez 




estimate lifetime and 
12-month rates of 
treatment utilization 












 N = 14,895 women 
of childbearing age 
(18-50 years)  
 DSM-IV criteria  
 Mental health treatment 





emergency room, or 
asked help from a 
therapist or doctor, or 
needed prescribed 
medication.  
Rates of past-year treatment seeking in 
pregnant, postpartum, and nonpregnant 
women: 
 10.5%, 11.1%, 16.5% for any 
psychiatric disorder 
 14.3%, 15.0%, 25.5% for mood 
disorder 
 6.1%, 7.5%, 11.6% for anxiety disorder 
 9.9%, 8.3%, 6.0% for alcohol use 
disorder 
 30.3%, 17.0%, 34.6% for illicit drug 
use 
  
 Pregnant women had lower odds of 
treatment receipt for mood disorders 
















Rates/Factors Associated with 


















 N = 804 pregnant 
women aged 18 
years or older  
 
 Major depression:  




Rate of antenatal depressants use 
behaviors: 
 20% used more than one antidepressant 
 45% treatment nonpersistence 
 
 Predictors of treatment nonpersistence: 
Nonwhite ethnicity, previous antenatal 





k, & Burris, 
2015 
Determine the rate of 
antidepressants  use 
in pregnant women 
during outpatient 
care visits and if 












 N = average of 
37.8 million visits 
per year  for 
pregnant women  
 Depression: ICD-9 
 Antidepressants use and 
cognitive behavioral 
therapy 
Rate of mental health care:  
 2.2% of all visits, antidepressants use 
 .2% of all visits, cognitive behavioral 
therapy 
 
 Compared to visits for White women, 
Non-White women had lower odds of 
antidepressant use while depressed 
controlling maternal age, insurance 






Figure 1. PRISMA flow chart for studies selection process. Adapted from “Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement” 
by D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, 2009, 




























CINAHL (n = 267) 
Records after duplicates removed 
(n =  1,209) 
Records screened at the 
title level  
(n = 1,205) 
Titles clearly irrelevant  
(n = 755) 
Full-text articles 
assessed for eligibility 
(n =  48) 
Full-text articles excluded, 
with reasons  (n = 22) 
4 clinical-based studies 
1 population-based study: not 
address pregnancy status 
5 population-based studies: 
not address treatment 
receipt 
4 population-based studies: 
not examine factors related 
to treatment receipt 
1 trend study: not specify 
pregnancy status 
3 trend studies: focused on 
any substance use  
1 trend study: examined 
trend over three years  
3 trend studies: overlapping 
time points/data source 
Studies included in 
synthesis  
(n = 28) 
PubMed (n = 449) PsychINFO (n = 904) 
Manual search  
(n = 2) 
Records screened at the 
abstract level  
(n = 450) 
 
Records excluded 




TRENDS IN MENTAL HEALTH AND SUBSTANCE USE DISORDERS AND 
TREATMENT RECEIPT AMONG PREGNANT AND NONPREGNANT WOMEN IN 
THE UNITED STATES, 2008-2014 
Introduction 
 Treatment for mental and substance use disorders will cost the nation $280.5 
billion in 2020, an increase from the $171.7 billion cost in 2009 (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2014a). Mental health and substance 
use problems are major public health issues affecting women of childbearing age. 
Depression is prevalent among women of childbearing age in the United States. Data 
from large national surveys indicate the prevalence of depression in childbearing-aged 
women is between 7.3% to 12.4% (Cook et al., 2010; Ko, Farr, Dietz, & Robbins, 2012; 
Le Strat, Dubertret, & Le Foll, 2011; Mota, Cox, Enns, Calhoun, & Sareen, 2008; Vesga-
Lopez et al., 2008). Women living with depression are at increased risk of having chronic 
medical conditions (Farr, Hayes, Bitsko, Bansil, & Dietz, 2011) and substance use 
disorders (Connelly, Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013; Le Strat et al., 
2011). These interrelated disorders need to be recognized and treated using an integrated 
approach to ensure effective treatment (United States Department of Health and Human 
Services [USDHHS], 2009). The purpose of this study was to compare trends in mental 
health and substance use disorders and treatment receipt of pregnant and nonpregnant 
women from 2008 to 2014. 
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Among mothers, mental illness and substance use disorders have a profound 
negative effect on the mother and her child (Connelly et al., 2013; Homish, Cornelius, 
Richardson, & Day, 2004; Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016). Pregnant 
women with poor mental health are at increased risk for preterm birth (Grigoriadis et al., 
2013), postpartum depression (Goodman, Chenausky, & Freeman, 2014; Norhayati, 
Hazlina, & Asrenee, Emilin, 2015), and diminished quality of life (Goodman et al., 
2014). Prenatal alcohol use is associated with deleterious effects such as fetal alcohol 
syndrome (Lehikoinen, Orden, Heinonen, & Voutilainen, 2016). Illicit drug use during 
pregnancy is also associated with preterm birth and Neonatal Abstinence Syndrome 
(NAS) (Narkowicz, Plotka, Polkowska, Biziuk, & Namiesnik, 2013).  
The American College of Obstetricians and Gynecologists (ACOG, 2015a, 
2015b) endorses a universal screening for mental health and substance use problems 
during pregnancy. However, findings based on large national surveys indicated that most 
women who needed mental health and substance use treatment did not receive them 
(Glasheen, Colpe, Hoffman, & Warren, 2015; Ko et al., 2012; Le Strat et al., 2011; 
Vesga-Lopez et al., 2008). This indicates that women face unique barriers (e.g., cost and 
stigma) to receipt of mental health (USDHHS, 2009) and substance use treatment (Center 
for Substance Abuse Treatment [CSAT], 2009). Yet, recent health reforms have 
mandated increased availability for mental health and substance use treatment services, 
while emphasizing the importance of integrating both treatments with primary medical 
care (Mental Health Parity and Addiction Equity Act [MHPAEA], 2008; Patient 
Protection and Affordable Care Act [PPACA], 2010).  Little is known about recent trends 
in mental and substance use disorders and treatment receipt, particularly mental health 
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treatment in pregnant women. Indeed, previous research on trends in mental health and 
utilization of mental health treatment in the United States has been conducted among the 
general population in the 1990s (Kessler, Demler, et al., 2005). The most recent research 
indicated that there was an increase in the use of mental health treatment from 2001 to 
2012 along with an increase in the prevalence of poor mental health for 15 days or more 
in the past month among the general population (Mojtabai & Jorm, 2015). These puzzling 
trends question the efficacy of mental health treatment (Mojtabai & Jorm, 2015) and raise 
the question of whether the same pattern of trends occurs among pregnant women.   
A growing body of research is beginning to shed light on trends in substance use 
treatment among childbearing-aged women (Martin, Longinaker, Mark, Chisolm, & 
Terplan, 2015; Martin, Longinaker, & Terplan, 2015; McCabe & Arndt, 2012), yet 
without highlighting how the unmet need for substance use treatment has also changed 
over time in the general population of women. This is of critical concern because less 
than 20% of childbearing-aged women with substance use disorders received treatment 
(Terplan, McNamara, & Chisolm, 2012).   
Understanding trends in mental health and substance use disorders as well as 
treatment receipt while comparing pregnant women and their non-pregnant counterparts 
may help in generalizing conclusions specific to pregnant women. In addition, addressing 
barriers to treatment can inform health reform and help programs facilitate treatment and 
tailor interventions according to the needs of pregnant women. The specific aims of this 
study were to: 
1. Compare trends from 2008 to 2014 in mental health problems (i.e., past-year major 
depressive episode [MDE], anxiety disorder, and past-month psychological 
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distress), past-year substance use disorders, receipt of mental health treatment, and 
unmet need for substance use treatment of women by pregnancy status. 
2. Compare trends from 2008 to 2014 in the receipt of mental health treatment of 
women with mental illness by pregnancy status, controlling for severity of mental 
illness.  
3. Compare and contrast barriers to mental health treatment and substance use 
treatment as perceived by pregnant and non-pregnant women from 2008-2010 to 
2011-2014.  
Background 
Women suffer disproportionately from depression and anxiety (Kessler, Berglund, 
et al., 2003), and they develop substance use disorders as likely as men after the initiation 
of substance use (CSAT, 2009). Given the vulnerability of pregnant women (Lokuge, 
Frey, Foster, Soares, & Steiner, 2011), more evidence is needed to understand how 
mental health and substance use disorders affect them in comparison with non-pregnant 
women over time. In addition, more information is needed about pattern of treatment 
receipt among pregnant and nonpregnant women and what barriers impede their receipt 
of mental health and substance use treatment over time.  
Trends in Mental Health and Substance Use Disorders 
Research suggests that hormonal changes in pregnant women may increase their 
vulnerability to develop poor mental health (Lokuge et al., 2011). Yet, there is an 
inconsistent pattern in the prevalence of psychiatric disorders between pregnant and 
nonpregnant women (Ko et al., 2012; Mota et al., 2008; Vesga-Lopez et al., 2008), 
reflecting heterogeneity in study populations and methods. For instance, using the 2001 
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to 2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 
Vesga-Lopez et al. (2008) found no significant differences in the 12-month prevalence of 
depression and anxiety between past-year pregnant (8.4%, 13.0%, respectively) and 
nonpregnant women (8.1%, 14.9%, respectively). Yet, Mota et al. (2008) compared past-
year prevalence of psychiatric disorders between current pregnant and nonpregnant 
women using the 2001-2002 NESARC. They found significant differences in the 
prevalence of depression (7.3% versus 11.4%) but not for anxiety disorders (13.2% 
versus 16.6%) between pregnant and nonpregnant women. Similarly, Ko et al. (2012) 
used the National Survey on Drug Use and Health (NSDUH) 2005 to 2009 and found that 
pregnant women (7.7%) were less likely to have MDE compared to nonpregnant women 
(11.1%).   
There is scarce evidence about prenatal depressive and anxiety symptoms from a 
national sample of pregnant women. Glasheen et al. (2015) used the NSDUH and found 
that the prevalence of past-month serious psychological distress in pregnant women 
(4.8%) was lower than nonpregnant women (7.4%); however, pregnant women may feel 
more reluctant to report mental health problems than nonpregnant women (Ko et al., 
2012). Hence, in addition to the social desirability effect, inconsistent findings across 
studies may be related to other variables that account for the relationship between 
pregnancy status and psychiatric disorders but that were not measured in these studies. 
Further, addressing and comparing psychiatric disorders between past-year or current 
pregnant and nonpregnant women across studies make it difficult to draw conclusions 
about the differences between the two groups.     
 48 
  
Pregnant women generally tend to underreport substance use to avoid 
stigmatization and losing child custody (Wendell, 2013). National studies revealed that 
the prevalence of substance use disorders in pregnant women (3.7% to 14.6%) was lower 
than nonpregnant women (9.5% to 19.9%) (Mota et al., 2008; Vesga-Lopez et al., 2008). 
However, these studies showed that pregnant women were less likely to have alcohol use 
disorders but not illicit drug use disorders compared to nonpregnant women. Yet, 
psychiatric disorders are prevalent in women of childbearing age regardless of pregnancy 
status; however, little is known about the comparison of trends in these disorders between 
the two groups over time.   
Trends in Mental Health and Substance Use Treatment Receipt    
The proportion of pregnant women exposed to atypical antipsychotics increased 
dramatically from 2001 to 2007 (Toh et al. 2013).  However, the rate of psychotropic 
medicines use was fairly stable from 2006 to 2011 in pregnant women (Hanley & 
Mintzes, 2014). Nevertheless, no studies were found indicating if the prevalence of 
mental health disorders in pregnant women declined over the same periods. Indeed, 
studies based on the 2001-2002 NESARC indicated that pregnant women with 
psychiatric disorders were less likely to receive mental health treatment (Le Strat et al., 
2011; Vesga-Lopez et al., 2008). Another study based on the 2005-2009 NSDUH 
indicated that major depression was unrecognized more often in pregnant women 
(65.9%) than nonpregnant women (58.6%), while only half of depressed mothers 
received mental health treatment (Ko et al., 2012). Notably, these studies relied on old 
national data and did not examine the trends in psychiatric disorders or mental health 
treatment among pregnant women over time.  
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Concerning substance use disorders in pregnancy, McCabe and Arndt (2012) 
retrieved the Treatment Episode Data Set (TEDS) which indicated that alcohol abuse 
markedly declined from 1998 to 2008 while drug abuse increased in pregnant women; 
yet, this trend was more obvious in pregnant than nonpregnant women controlling for 
age. In addition, referrals from health care providers of substance abusing pregnant 
women were consistently lower compared to referrals from the criminal justice system 
over the same time period. A few investigators have focused on examining trends in 
treatment admission based on the 1992-2012 TEDS for marijuana (Martin, Longinaker, 
Mark, et al., 2015) and opioid use in pregnant women (Martin, Longinaker, & Terplan, 
2015), but without a comparison group of nonpregnant women. Findings of these studies 
showed that pregnant admissions for substance use treatment were stable over time at 
4%; however, admissions of pregnant women increased significantly for prescription 
opioids (2% to 28%) and marijuana use (29% to 43%) from 1992 to 2012. Yet, little is 
known about recent trends in substance use treatment among pregnant and nonpregnant 
women. In addition, given the low rates of treatment for substance use, it is essential to 
examine if the unmet need for treatment has changed over time from a general sample of 
pregnant and nonpregnant women.   
In the consideration of the ongoing public concerns related to mental health and 
addiction, the PPACA (2010) builds on the MHPAEA (2008) and mandates early 
identification and treatment for mental health and substance use disorders for all adults. 
This broad mandates covers perinatal mental health and substance use. Yet, the PPACA 
(2010) section 2952 focuses on research and clinical screening of postpartum depression, 
giving little attention to mental health during pregnancy. Yet, pregnancy provides the 
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appropriate time to screen for these issues (Connelly et al., 2013). Thus, trends in mental 
health and treatment for mental health and substance use disorders need to be further 
examined in pregnant women to inform medical and legal initiatives.  
Barriers to Mental Health and Substance Use Treatment  
  Although pregnancy can provide an optimum opportunity to offer mental health 
and substance use treatment (Connelly et al., 2013; Kuo et al., 2013), pregnant women 
have low treatment utilization rates (Glasheen et al., 2015; Vesga-Lopez et al., 2008) and 
may face barriers to access treatment (Ko et al., 2012; Kuo et al., 2013). In their 
qualitative study, Kuo et al. (2013) found that pregnant women revealed their need for 
treatment of both mental illness and substance use. However, judgmental family 
relationships, time and transportation challenged these women from seeking treatment for 
depression and substance use problems.  
There is an ongoing evidence addressing barriers to mental health treatment 
among pregnant women (Goodman, 2009; Jesse, Dolbier, & Blanchard, 2008; Kim et al., 
2010; Kingston et al., 2015; Ko et al., 2012; Kopelman et al., 2008; O'Mahen & Flynn, 
2008; Rosen, Tolman, & Warner, 2004). Common barriers reported in the literature 
include cost (Kim et al., 2010; Ko et al., 2012; Kopelman et al., 2008; O'Mahen & Flynn, 
2008), opposition to treatment (Jesse et al., 2008; Kingston et al., 2015; Ko et al., 2012; 
Rosen et al., 2004), lack of time (Kim et al., 2010; Ko et al., 2012; Rosen et al., 2004) 
and childcare issues (Goodman, 2009; Kopelman et al., 2008), as well as stigma concerns 
(Goodman, 2009; Jesse et al., 2008; Ko et al., 2012). Little is known regarding perceived 
barriers to mental health treatment and substance use treatment from a national sample of 
childbearing-aged women. A study based on the 2005-2009 NSDUH showed that 
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pregnant and non-pregnant women face similar barriers to mental health treatment (Ko et 
al., 2012). Among these women, cost was the most common barrier, followed by 
opposition to treatment, and stigma.  
Women face numerous obstacles in accessing substance use treatment services 
such as a lack of gender-specific services, the cost of treatment, stigmatization, and 
punitive legal actions for substance use (Otiashvili et al., 2013). According to World 
Health Organization (WHO, 2014), stigmatization is a significant issue that should be 
prevented when providing treatment to pregnant women with substance use disorders. 
Yet, pregnancy itself is a barrier for seeking substance use treatment (Steverson & 
Rieckmann, 2009). Fear of losing child custody and prosecution may lead pregnant 
women to avoid treatment (Tuchman, 2010). The Guttmacher Institute (2017) reported 
that 24 states consider substance use in pregnancy as child abuse and three states consider 
it a civil commitment. In addition, 23 states mandate reporting of suspected substance 
abuse to the state, while seven require testing of pregnant women.  
In response to inconsistent legislations across states, there are growing 
professional efforts to advocate for pregnant women and support treatment rather than 
criminalization for this vulnerable population (Advocates for Pregnant Women, 2011; 
American Nurses Association, 2011; National Perinatal Association, 2013). Beyond these 
efforts, there are limited treatment facilities to serve pregnant women with substance use 
disorders (Guttmacher Institute, 2017). In a qualitative study of 85 rural pregnant women 
in Kentucky, approximately 26% had availability issues with substance use treatment 
services (Jackson & Shannon, 2012a). Moreover, 51.4% of women considered stigma 
and denial as common acceptability barriers, while 49.4% of them experienced 
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accessibility barriers including family responsibilities, and lack of social support and 
transportation.   
Little is known about the pattern of obstacles that impede women of childbearing 
age to receive mental health and substance use treatment over time. One population-
based study showed that the proportion of women-centered services in drug treatment 
facilities declined slightly from 43% in 2002 to 40% in 2009 (Terplan, Longinaker, & 
Appel, 2015). Findings from the Health Reform Monitoring Survey showed that the 
uninsured rate among childbearing-aged women declined from 19.6% in summer 2013 to 
13.3% in winter 2014–15 along with the perceived unmet need for care due to cost; 
however, access to care remained stable over the same period of time (Shartzer, Garro, 
Pellegrini, & Long, 2015). Notably, further studies are needed to address barriers to 
mental health and substance use treatment in pregnant and non-pregnant women from the 
general population.  
Methods 
Design  
Secondary analysis of a large population-based dataset, the NSDUH, of 
childbearing-aged women in the United States from 2008 to 2014 was conducted. 
SAMHSA sponsored and designed the NSDUH as a national cross-sectional survey to 
provide population estimates of mental health and substance use in U.S household 
populations aged 12 or over (Center for Behavioral Health Statistics and Quality 
[CBHSQ], 2015). In this study, the NSDUH data were analyzed over time from 2008 as 
past-month psychological distress was included in the survey beginning in 2008 
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(CBHSQ, 2015). In addition, past-year mental illness estimates were developed using a 
clinical follow-up study that started in 2008 and continued until 2012.  
Sample 
The NSDUH samples participants in each of the 50 states and the District of 
Columbia using multistage probability stratified sample (CBHSQ, 2015). Surveys are 
administered in person using computer-assisted personal interviewing and audio 
computer-assisted self-interviews (ACASI) (CBHSQ, 2015). Pregnant women aged 12 to 
17 years were excluded from this study as a specific mental health module was designed 
in the NSDUH to provide information on mental health measures (i.e., serious 
psychological distress and mental illness) among adults aged 18 or older. The response 
rate for the survey ranged from 71.2% to 75.6% between 2008 to 2014 (USDHHS, 
SAMHSA, Office of Applied Studies, 2013, 2014a, 2014b, 2014c, 2014d, 2014e, 2015). 
The sample for this study included data from 5,520 pregnant women and 11,040 matched 
nonpregnant women aged 18 to 44 years. Among these women, 1,003 pregnant and 2,634 
nonpregnant women suffered from past-year mental illness.  
Measures  
Pregnancy status. Women self-reported their pregnancy status (yes/no) based on 
the following question: “Are you currently pregnant?” SAMHSA (2010) reported 
substantial test-retest reliability of this question (Cohen’s Kappa = .85).  
Major depressive episode. The NSDUH uses nine questions addressing MDE 
symptoms based on the Diagnostic and Statistical Manual of Mental Disorders: DSM IV 
criteria (CBHSQ, 2015). A participant met DSM-IV criteria for MDE (yes/no) if she 
reported experiencing at least five or more of nine symptoms nearly every day in the 
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same 2-week period in the last 12 months, with at least one of these five symptoms being 
depressed mood or loss of interest in daily activities (American Psychiatric Association 
[APA], 1994). The MDE measure in the adult depression module of the NSDUH 
demonstrated moderate test-retest reliability (Cohen’s Kappa = .52) (SAMHSA, 2010).  
Anxiety disorder. Anxiety disorder was measured using one item indicating if a 
participant received a diagnosis of anxiety disorder from a doctor or other medical 
professionals in the past 12 months. This measure demonstrated acceptable test-retest 
reliability (Cohen’s Kappa = .73) (SAMHSA, 2010). 
Serious psychological distress. The symptoms of psychological distress in the 
past month were measured using the Kessler-6 (K6) Psychological Distress Scale 
(Kessler, Barker, et al., 2003). The K6 Scale consists of six items each followed by a 4-
point scale ranging from “all of the time” to “none of the time.” These items indicate the 
frequency of feeling: nervous, hopeless, restless or fidgety, sad or depressed, that 
everything was an effort, and no good or worthless; thus, higher scores indicate greater 
psychological distress. The total score for the K6 scale ranges from 0 to 24; the cut-off 
score of 13 is the indicator of serious psychological distress (CBHSQ, 2015). The validity 
of K6 was supported by its prediction of serious mental illness (Kessler, Barker, et al., 
2003). Cronbach’s alpha for the K6 in this study was excellent (α = .91).   
Mental illness. The NSDUH defines mental illness in adults aged 18 or older 
based on two criteria: (a) the presence of any mental disorder as determined in the 
Structured Clinical Interview (SCID) for DSM-IV, excluding substance use disorders; and 
(b) the level of functional impairment as determined by the Global Assessment of 
Functioning (GAF) scale (Endicott, Spitzer, Fleiss, & Cohen, 1976). Based on these 
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mental illness clinical measurements, a regression model was developed to predict the 
probability of mental illness among approximately 50,000 cases in a follow-up clinical 
study from 2008 to 2012 (CBHSQ, 2015). Specifically, this statistical model predicted 
mental illness measurements in the NSDUH: K6 Scale, the abbreviated version of the 
World Health Organization Disability Assessment Schedule (WHODAS) (Rehm et al., 
1999), past-year MDE, and suicidal thoughts. Cutpoints were derived from this model to 
indicate any mental illness in the past year; based on the level of functional impairment, 
mental illness was differentiated into serious, moderate, or mild mental illness. These 
cutpoints then were used among the entire adult sample participated in the NSDUH 
(CBHSQ, 2015).  
Substance use disorders. The NSDUH operationalizes substance use disorders as 
an abuse or dependence on alcohol or illicit drugs based on the DSM-IV criteria (CBHSQ, 
2015). The participant is considered dependent on a substance if she reported that at least 
three out of seven symptoms occurred in a 12-month period: engaging in activities related 
to substance use, tolerance, withdrawal, larger or longer use, unsuccessful attempts to cut 
down, physical health or emotional problems, and reduced activities (APA, 1994). 
Substance abuse and dependence criteria are mutually exclusive. Substance abuse is 
defined as reporting at least one of four abuse criteria occurred in a 12-month period: 
roles obligations, hazardous use, legal problems, and social problem (APA, 1994). The 
validity of the NSDUH in assessing substance use disorders was supported (Jordan, Karg, 
Batts, Epstein, & Wiesen, 2008). The test-retest reliability of substance dependence or 
abuse measures showed substantial agreement (Cohen’s Kappa = .67) (SAMHSA, 2010).  
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Receipt of mental health treatment. Mental health treatment receipt refers to 
any treatment received in an inpatient or outpatient setting, or use of prescription drugs 
for any problem related to mental health, emotions, or nerves in the past 12 months 
(yes/no). These measures demonstrated excellent test-retest reliability (Cohen’s Kappa = 
.85) (SAMHSA, 2010).  
Unmet need for substance use treatment. The unmet need for substance use 
treatment is defined as having the need for treatment for alcohol or illicit drug use that 
met the DSM-IV criteria for dependence or abuse, but not receiving that treatment at a 
specialty facility (i.e., hospital, rehabilitation facility, or mental health center) (USDHHS, 
SAMHSA, Office of Applied Studies, 2015). This measure was used in this study rather 
than the receipt of substance use treatment to have larger sample size and better powered 
statistical analysis when comparing trends over time by pregnancy status, especially since 
few numbers of pregnant women received the treatment for alcohol or illicit drug use 
despite their need.  
Perceived barriers to mental health and substance use treatment. The 
NSDUH includes 28 items addressing reasons for not getting mental health treatment (14 
items) and substance use treatment (14 items) among those who perceived treatment need 
(USDHHS, SAMHSA, Office of Applied Studies, 2015). Perceived barriers include 
factors such as treatment beliefs, readiness for treatment, lack of knowledge about 
treatment programs, confidentiality concerns, lack of openings in the substance use 
treatment programs, lack of time, and lack of transportation. The majority of items 
addressing the barriers to mental health treatment demonstrated good test-retest reliability 
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(Cohen’s Kappa ≥ .65); however, the reliability of the items addressing substance use 
treatment was not reported (SAMHSA, 2010).  
The classification of perceived barriers in this study was adapted from Ko et al. 
(2012). Any items measuring perceived barriers that were scored “yes” were classified 
into the following categories: (a) cost (three items for mental health treatment; two items 
for substance use treatment); (b) stigma (four items for mental health treatment; three 
items for substance use treatment); (c) opposition to treatment (four items for each 
treatment type); (d) time or transportation limitation (two items for each treatment type); 
(e) not knowing where to go (one item for each treatment type); and (f) lack of substance 
use treatment programs (two items for substance use treatment).  
Procedure 
The NSDUH has been conducted by the Federal Government since 1971 
(SAMHSA, 2010) and is managed by SAMHSA’s Office of Applied Studies. 
Participation in the NSDUH is voluntary and all randomly selected participants are 
encouraged to participate regardless of their substances use status. Interviews are 
completed in private, as participants answer most of the interview questions using a 
laptop computer; hence, the interviewer does not know the answers entered. No prior 
computer skills are required to answer the questions. The interviews last approximately 
one hour and the participant receives $30 cash at the end of the interview (CBHSQ, 
2015). Confidentiality of the answers is protected by law and participants do not give 
their full names (NSDUH, 2016).  
Given that the current study used de-identified public use data from the 2008-
2014 NSDUH, the study was exempt from the University of Louisville Institutional 
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Review Board. In congruence with the terms of use of this dataset as proposed by the 
Interuniversity Consortium for Political and Social Research (ICPSR), the principal 
investigator (PI) analyzed the NSDUH only for the purpose of research and prevented 
any unauthorized access to the data by maintaining it in encrypted files on the PI’s 
computer.  
Data Analysis  
Considering the complex survey design and weighting, statistical analysis was 
conducted using complex sample analysis with SPSS software, version 22.0 (IBM Corp., 
2013). As multiple NSDUH survey years were used, the person-level analysis weight was 
divided by the numbers of years of survey data used in analyses (i.e., seven years) 
(CBHSQ, 2015). Because Bonferroni correction was deemed so conservative (Bland & 
Altman, 1995), p-values < .05 were considered statistically significant for analyses even 
in the presence of multiple comparisons. Recoded and imputed demographic and 
substance use variables were analyzed. Missing data for mental health measures were 
excluded from analysis. The NSDUH uses an imputation methodology called “predictive 
mean neighborhoods (PMN)” which was developed for the survey in 1999 (CBHSQ, 
2015, p.11). PMN combines a regression model imputation and a random nearest 
neighbor hot-deck procedure. The hot-deck procedure involves replacing the missing 
values with a corresponding value from a donor randomly selected from a set of 
candidate donors called the “neighborhood” (CBHSQ, 2015, p.12). The potential donors 
in the neighborhood have complete data with a predicted mean close to that of the item of 
the nonrespondent.   
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Propensity score matching was conducted to match pregnant and nonpregnant 
women before analyzing the data. Propensity Score Matching for SPSS (Version 1.0; 
Thoemmes, 2012) was used to calculate propensity scores by regressing pregnancy status 
onto: age, ethnicity, marital status, education level, employment status, income, health 
insurance, and county urbanicity. One-to-two pairs of pregnant and non-pregnant women 
were matched. One-to-two pairs matching was selected because it is recommended when 
the sample size between the two groups differ substantially, hence reducing bias (Ming & 
Rosenbaum, 2000). Compared to adjustment for covariates, propensity score matching 
helps in assessing covariate balance between groups without looking at outcomes and 
thereby protects against Type I error (Vittinghoff, Glidden, Shiboski, & McCulloch, 
2012). Good balance between matched and control groups was indicated in this study as 
the standardized mean differences between the groups’ covariate means were of less than 
.25 (Ho, Imai, King, & Stuart, 2007).   
Descriptive statistics were conducted for the matched sample using weighted 
percentages and standard errors (SEs) to describe all categorical variables. Bivariate 
analyses using chi-square were conducted to examine differences between pregnant and 
nonpregnant women for covariates.   
A total of eight logistic regression models were conducted to test the interaction 
between time and pregnancy status for the dichotomous outcomes of: MDE, anxiety 
disorder, any past-year mental illness, alcohol use disorder, illicit drug use disorder, past-
month psychological distress, past-year receipt of mental health treatment, and the unmet 
need for past-year substance use treatment. The test of model coefficients was conducted 
for each model to determine goodness of fit (Vittinghoff et al., 2012). 
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Among women with mental illness, a logistic regression model was run to test the 
interaction between time and pregnancy status to predict the receipt of mental health 
treatment controlling for severity of mental illness. Finally, weighted percentages were 
calculated for each type of barrier to mental health and substance use treatment and 
compared across two time periods, 2008-2010 and 2011-2014, using chi-square and rank 
ordering. The purpose of aggregating data into two time periods was to have an adequate 
sample size to describe different types of barriers. Because a small number of pregnant 
women reported perceived barriers to substance use treatment, these barriers were 
compared across 2008-2010 and 2011-2014 among the total sample of pregnant and 
nonpregnant women.  
Results 
There was a satisfactory balance with the propensity score matching using age, 
ethnicity, education, income, employment, health insurance, and county urbanicity (see 
Table 4). The majority of the matched sample was white, married, college educated, and 
employed. Most of women had an income level of less than $50,000, had health 
insurance, and lived in a large urban area.   
The rates of past-year MDE decreased slightly from 7.2% in 2008 to 5.9% in 
2014 among pregnant women, and remained relatively stable from 2008 (9.4%, 8.7%) to 
2014 (9.3%, 8.3%) among nonpregnant women and the total sample of women, 
respectively (see Figure 2). The rate of MDE was lowest at 2.7% in 2010 among pregnant 
women. However, the rates of anxiety disorder increased from 2008 to 2014 among 
pregnant women (4.7% to 6.8%), nonpregnant women (7.3% to 11.2%), and the total 
sample (6.5% to 9.9%). Likewise, rates of past-month psychological distress increased 
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from 5.4%, 4.9%, and 5.6% in 2008 to 6.7%, 5.1%, and 7.5% in 2014 among the entire 
sample as well as pregnant and nonpregnant women, respectively. The rates of past-year 
mental illness showed only a slight increase from 2008 to 2014 in the total sample 
(21.0% to 22.0%), pregnant (17.5% to 18.3%) and nonpregnant women (22.7% to 23.6%) 
(see Figure 2). 
   Alcohol use disorder remained relatively stable at approximately 6% among the 
total sample of childbearing-aged women from 2008 to 2014 regardless of pregnancy 
status (see Figure 3). Although the rate of illicit drug use decreased in pregnant women 
from 3.6% in 2008 to 2.4% in 2014, it increased in non-pregnant women from 2.0% to 
3.3%, reflecting an overall increase among the total sample by 1.2 fold.  
The rates of the receipt of mental health treatment remained relatively stable from 
2008 to 2014 among pregnant women, nonpregnant women, and the total sample, 
respectively, at approximately 12%, 18%, and 16% (see Figure 4). Among those with 
mental illness, the rates of the receipt of mental health treatment increased from 2008 
(36.6%, 39.0%, 38.4) to 2014 (39.6%, 44.5%, 43.2%) among pregnant, nonpregnant 
women, and the total sample, respectively. The rate of unmet need for substance use 
treatment remained stable at 7% from 2008 to 2014 among pregnant women. However, 
among nonpregnant women as well as the total sample, respectively, the rates increased 
from 6.5% and 6.8% in 2008 to 6.8% and 8.3% in 2014.  
Comparing trends in mental health problems, substance use disorders, and 
treatment receipt over time by pregnancy status, there were no significant interactions 
between time and pregnancy status; thus, only main effects are reported (see Table 5). Of 
mental health problems, only trends in past-year anxiety disorder (p = .003) and past-
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month psychological distress (p = .009) were significant. For a one-year increase from 
2008 to 2014, the odds of anxiety disorder increased by 7.0% (Adjusted Odds Ratio 
[AOR]: 1.07; 95% Confidence Interval [CI]: 1.02-1.12), and pregnant women had lower 
odds of anxiety disorder (AOR: .62; 95% CI: .51-.75) compared to nonpregnant women. 
Likewise, for a one-year increase, the odds of past-month psychological distress 
increased by 1.06 times (95% CI: 1.01-1.10). Compared to nonpregnant women, pregnant 
women had lower odds of past-month serious psychological distress (AOR: .68; 95% CI: 
.56-.82). The likelihood of past-year MDE (AOR: 1.01; 95% CI: .96-1.05) and any 
mental illness (AOR: 1.02; 95% CI: .98-1.05) did not change over the seven years; 
however, pregnant women had significantly lower odds of MDE (AOR: .53; 95% CI: .43-
.65) and any mental illness (AOR: .65; 95% CI: .58-.74) compared to nonpregnant 
women.  
There was a significant increase in the odds of illicit drug use disorder from 2008 
to 2014 (for one-year increase) (AOR: 1.05; 95% CI: 1.004-1.10); yet, the odds of illicit 
drug use disorder was not significantly higher in pregnant women than nonpregnant 
women (AOR: 1.06; 95% CI: .83-1.35). There was no significant change in the 
probability of alcohol use disorder over time (AOR: 1.02; 95% CI: .97-1.07) or by 
pregnancy status (AOR: 1.04; 95% CI: .87-1.24). There were no significant trends in the 
mental health treatment receipt (AOR: 1.01; 95% CI: .98-1.04) and the unmet need for 
substance use treatment over time (AOR: 1.03; 95% CI: .99-1.08). Pregnant women had 
lower odds of receipt of mental health treatment (AOR: .60; 95% CI: .52-.69) compared 
to nonpregnant women; yet, there was no significant difference between pregnant and 
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nonpregnant women in predicting the probability of the unmet need for substance use 
treatment (AOR: 1.01; 95% CI: .86-1.18).   
Seventeen percent of pregnant women versus 23.6% of nonpregnant women had 
past-year mental illness. There were no significant differences between pregnant and 
nonpregnant women with mental illness in any of the covariates (i.e., age, ethnicity, 
education, employment status, income level, county urbanicity), except marital status. 
Pregnant women (50.2%) were less likely to be married compared to nonpregnant women 
(56.7%) [χ2 (1, N = 3,637) = 11.48, p = .031]. However, marital status was not associated 
with the receipt of mental health treatment [χ2 (1, N = 3,637) = 3.955, p = .224], and thus 
was not including as a covariate in the regression model. Among those with mental 
illness, there was no significant interaction between time and pregnancy status and 
therefore only main effects are reported in Table 6. The odds of mental health treatment 
did not significantly change over time (AOR: 1.04, 95% CI: .98-1.09). Yet, pregnant 
women with mental illness had lesser odds of the receipt of mental health treatment 
compared to nonpregnant women (AOR: .66; 95% CI: .52-.84). Women with moderate 
(AOR: 1.94; 95% CI: 1.51-2.50) and severe mental illness (AOR: 3.87; 95% CI: 3.04-
4.92) had higher odds of the receipt of mental health treatment compared with women 
with mild mental illness.  
Perceived barriers to mental health treatment among women of childbearing age 
ranked similar in 2008-2010 and 2011-2014 in regards: (a) cost (45.2%, 50.6%), (b) 
opposition to treatment (41.9%, 41.4%), and (c) stigma (28.2%, 24.7%) (see Figure 5). In 
2008-2010, the perceived barrier of not knowing where to go ranked last (19.2%), while 
time/transportation limitations had the lowest percentage in 2011-2014 (19.7%). 
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However, the order of perceived barriers to substance use treatment among childbearing-
aged women differed from 2008-2010 to 2011-2014. In 2008-2010, the perceived barriers 
ranked in the following order: cost (38.7%), stigma (18.2%), time/transportation 
limitations (17%), opposition to treatment and lack of treatment programs (3%), and 
finally not knowing where to go (.9%). By 2011-2014, stigma ranked first (35.5%), 
followed by cost (25.9%), time/transportation limitations (22.2%), lack of treatment 
programs (17.7%), not knowing where to go (8.2%), and opposition to treatment (7.6%). 
Perceived barriers to mental health treatment among pregnant women had the 
same order as the total sample in 2008-2010 across the two time periods, 2008-2010 and 
2011-2014 (see Figure 6). Nonpregnant women had the same order of perceived barriers 
to mental health treatment in 2008-2010 and 2011-2014: cost (44.6%, 49.3%), opposition 
to treatment (40.8%, 41.3%), stigma (28.6%, 26.4%), not knowing where to go (20.7%, 
21.6%), and time/transportation limitations (19.7%, 20.1%).  
There were no significant differences in the perceived barriers to mental health 
treatment across 2008-2010 to 2011-2014 among the total sample, and pregnant and 
nonpregnant women (see Table 7). However, in 2011-2014 women of childbearing age 
were significantly more likely to report not knowing where to go (8.2% vs. .9%) and a 
lack of treatment programs (17.7% vs. 3.0%) as perceived barriers to substance use 
treatment than women in 2008-2010. Other perceived barriers to substance use treatment 
did not differ between the two time periods. In 2011-2014, women of childbearing age 
who perceived a need for substance use treatment were more likely to live in a nonmetro 
(23.2% vs. 9.0%) or small county area (32.7% vs. 13.5%) compared to their counterpart 
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groups in 2008-2010 (p < .001). There were no significant differences in other socio-
demographic characteristics between the two groups in 2008-2010 and 2011-2014.  
Discussion 
The purpose of this study was to compare trends in mental health problems, 
substance use disorders, mental health treatment receipt, and unmet needs for substance 
use treatment by pregnancy status from 2008 to 2014. Among a matched sample of 
pregnant and non-pregnant women, there was no significant interaction between time and 
pregnancy status in predicting the probability of mental health, substance use disorders, 
and treatment receipt. This means that the proportional change in these outcome 
measures was the same for pregnant and nonpregnant women over time. However, to our 
knowledge, there are no comparable trend studies specifically addressing the difference 
between pregnant and nonpregnant women in having mental health problems and 
receiving mental health treatment over time.  
This study showed that compared to nonpregnant women, pregnant women had 
lesser odds of MDE, anxiety disorder, past-year mental illness, and past-month 
psychological distress. This is inconsistent with a previous population-based study that 
showed no significant difference in the prevalence of psychiatric disorders between 
pregnant and nonpregnant women who participated in NESARC (Vesga-Lopez et al., 
2008). Yet, another NESARC-based study (Mota et al., 2008) as well as NSDUH-based 
study (Ko et al., 2012) found that pregnant women were less likely to have major 
depression compared to nonpregnant women. However, Mota et al. (2008) found that 
pregnant women were as likely as nonpregnant women to have anxiety disorder. These 
discrepancies may be due to different measures of psychiatric disorders, sample 
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characteristics, and controlling for different confounding variables. For instance, the 
NSDUH used one question addressing if a healthcare provider told the respondent she 
had anxiety disorder or not, while NESARC used structured clinical interviews in 
assessing anxiety disorders. Further, the current study analyzed the NSDUH among a 
matched sample of pregnant and nonpregnant women, while other population-based 
studies adjusted for confounding variables. 
 In addressing psychological distress symptoms, a population study based on the 
NSDUH (Glasheen et al., 2015) was in accord with the current study by suggesting that 
pregnant women had lesser odds of past-month psychological distress compared to 
nonpregnant women. These findings from general population samples suggest an 
interesting comparison with the evidence from clinical samples, as the later captured 
advanced clinical symptoms among only pregnant women who received treatments 
(Connelly et al., 2013; Fairbrother, Janssen, Antony, Tucker, & Young, 2016; 
Fairbrother, Young, Janssen, Antony, & Tucker, 2015; Gavin et al., 2011; Melville, 
Gavin, Guo, Fan, & Katon, 2010; Qiu, Gelaye, Fida, & Williams, 2012). Given that these 
clinical studies lack comparison groups of nonpregnant women, drawing a clear 
conclusion about the association between pregnancy and mental disorders is limited.   
In the present study, there was a significant increase in the probability of past-year 
anxiety disorder and past-month psychological distress over the seven years among the 
total sample of pregnant and nonpregnant. Anxiety is among the most prevalent disorders 
in the United States and women are 1.5 times more likely to have an anxiety disorder 
compared to men (Kessler, Berglund, et al., 2005). Yet, a previous trend study showed no 
significant increase in any psychiatric disorder from 1990 to 2003 among the general 
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population (Kessler, Demler, et al., 2005), whereas a recent trend study did not focus on 
examining trends in anxiety disorders (Mojtabai & Jorm, 2015). This emphasizes the 
need for further studies to examine the magnitude of anxiety disorder among women of 
childbearing age, particularly pregnant women.  
In the current study, there was a significant increase in the probability of past-
month psychological distress but not past-year MDE or mental illness. Yet, Mojtabai and 
Jorm (2015) found no significant change in the proportion of past-month psychological 
distress or past-year MDE among the general population from 2001 to 2012. This 
suggests that childbearing-aged women in this study tended to report non-specific recent 
distress symptoms rather than past-year mental health conditions. Moreover, the increase 
in the probability of anxiety disorder and past-month psychological distress, as well as 
the absence of significant change in the proportion of MDE and mental illness may be 
related to unsubstantial increase in the receipt of mental health treatment. The link 
between trends in the receipt of mental health treatment and in mental health problems 
should be interpreted with caution. Previous trend studies revealed puzzling findings in 
which the receipt of mental health treatment increased while the proportion of mental 
health problems either did not change (Kessler, Demler, et al., 2005; Mojtabai & Jorm, 
2015) or increased (Mojtabai & Jorm, 2015) over the same period of time. Therefore, the 
quality of mental health treatment provided to women may be more important in 
assessing the change in mental health problems.  
Research suggests that although women have more frequent contact with health 
care providers, obstetric providers lack training in care of women with depression 
(ACOG, 2010) and anxiety (Leddy, Lawrence, & Schulkin, 2011). Mental health care 
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providers are also reluctant to treat depression during pregnancy (Byatt, Biebel, 
Debordes-Jackson, et al., 2013; Palladino et al., 2011). Literature also indicated an 
absence of standardized procedures for depression care (Palladino et al., 2011) as well as 
inadequate referral systems and coordinated follow-up care (Palladino et al., 2011; Price, 
Corder-Mabe, & Austin, 2012), all of which may influence the status of mental health 
among women of childbearing age.  
The nonsignificant increase in the receipt of mental health treatment in this study 
is incongruent with previous trend studies among the general population that showed an 
increase in the receipt of mental health treatment from 1990-2003 (Kessler, Demler, et 
al., 2005) and from 2000 to 2014 (Mojtabai & Jorm, 2015). This suggests that women of 
childbearing age have specific mental health needs (USDHHS, 2009) and may experience 
unique multilevel barriers to access treatment (Byatt, Simas, Lundquist, Johnson, & 
Ziedonis, 2012). A systematic review revealed that screening alone for depression among 
perinatal women was associated with only 22% mental health treatment receipt; yet, this 
rate was doubled in the presence of patient engagement interventions, on-site 
assessments, and training for perinatal care providers (Byatt, Levin, Ziedonis, Simas, & 
Allison, 2015). This emphasizes the need for interventions that address strategies 
identified by both patient and health care providers to increase mental health treatment 
use (Byatt, Biebel, Friedman et al., 2013).  
In contrast with previous trend studies that examined trends in the use of 
antipsychotic drugs during pregnancy (Hanley & Mintzes, 2014; Toh et al., 2013), the 
current study has focused on the receipt of any mental health treatment including 
outpatient counseling, inpatient treatment, and prescription drugs for mental health 
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problems. Hence, these studies are not comparable with the current study due to different 
measures of mental health treatment as well as the time of examining trends.  
In the current study, pregnant women were as likely as nonpregnant women to 
have alcohol and illicit drug use disorders. This finding is in accord with previous 
population studies based on the 2001-2002 NESARC that found no significant difference 
between pregnant and nonpregnant women in developing illicit drug use disorders (Mota 
et al. 2008; Vesga-lopez et al., 2008). However, these studies revealed that pregnant 
women were less likely to have alcohol use disorders compared to nonpregnant women. 
It is noteworthy that these studies relied on an old national dataset that used structured 
clinical interviews in assessing substance use disorders rather than self-report 
questionnaires that may result in this discrepancy. Yet, there is a dearth of updated 
literature that compared substance use disorders among pregnant and nonpregnant 
women from the general population. Most of what is known about substance use 
problems is based on admission data that focused on illicit drug use among only pregnant 
women (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015). 
One study included a comparison group of nonpregnant women and suggested that 
treatment admission rate for illicit drug abuse increased more profoundly among pregnant 
women compared to nonpregnant women from 1998 to 2008 (McCabe & Arndt, 2012). 
However, these findings should not be generalized to the population as the majority of 
childbearing-aged women with substance use disorders do not receive treatment (Terplan 
et al., 2012).  
The present study showed a significant increase in the probability of illicit drug 
use disorder from 2008 to 2014 among women of childbearing age. SAMHSA (2013) 
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also reported based on TED an increase in the percentage of illicit drug abuse but not 
alcohol abuse among pregnant and nonpregnant women from 2000 to 2010. These 
findings indicate a critical need for interventions to help women of childbearing age with 
substance use disorders, hence preventing devastating health consequences associated 
with substance use during pregnancy.  
The present study showed that the gap between the need and receipt of substance 
use treatment did not change from 2008 to 2014 among both pregnant and nonpregnant 
women. The rate of treatment admission among pregnant women was relatively stable 
from 2000 (4.4%) to 2010 (4.8%) (SAMHSA, 2013). Women in this study experienced 
an unmet need for substance use treatment over the seven years, despite treatment 
initiatives (ACOG, 2015a, 2015b) and legislation (MHPAEA, 2008; PPACA, 2010). This 
emphasizes the need for prevention and interventional strategies tailored according to the 
specific needs of childbearing-aged women.  
Mental Illness and Trends in the Receipt of Mental Health Treatment 
Among women with mental illness, there was no significant interaction between 
time and pregnancy status in predicting the probability of mental health treatment receipt. 
This indicates that the change in the odds of the receipt of mental health treatment over 
time was similar for pregnant and nonpregnant women. Yet, pregnant women had a lower 
odds of the receipt of mental health treatment despite their mental illness. This is 
congruent with previous studies indicating that pregnant women with psychiatric 
disorders (Mota et al., 2008; Vesga-Lopez et al., 2008) or psychological distress 
(Glasheen et al., 2015) were less likely to receive mental health treatment compared to 
nonpregnant women.  
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However, the present study found that pregnant women, regardless of having 
mental illness, had a lower odds of receipt of mental health treatment compared to 
nonpregnant women. This raises a question in regards the relationship between treatment 
need and the severity of mental illness. Given the fact that psychiatric disorders in 
women are rarely recognized (Ko et al., 2012) or treated (Glasheen et al., 2015; Ko et al., 
2012; Vesga-Lopez et al., 2008), women of childbearing age may not access treatment 
due to structural, system, and personal barriers until their mental condition is advanced 
(Byatt et al., 2012). This is also of critical concern as the present study also showed no 
significant increase in the likelihood of mental health treatment receipt among women of 
childbearing age with mental illness from 2008 to 2014, while pregnant women had a 
lower odds of mental health treatment receipt compared to nonpregnant women.  
Although this study covered a period of time that coincided with policy initiatives 
including MHPAEA (2008) and PPACA (2010), it did not show a substantial increase in 
the receipt of mental health treatment. This study did not specifically address the effect of 
these policies; however, it yielded a critical concern reflecting that there are complex 
integrated obstacles that may affect the receipt of both mental health and substance use 
treatment among women of childbearing age.  
Barriers to Mental health and Substance Use Treatment 
 This study showed that the most common barriers to mental health treatment in 
2008-2010 and 2011-2014 included cost, followed by opposition to treatment, and 
stigma. These barriers did not differ in their rank or percentages between 2008-2010 and 
2011-2014 among pregnant and nonpregnant women. Other barriers included time and 
transportation limitations that had lower proportions than not where to go among 
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pregnant women in the two time periods. One clinical study showed that perinatal women 
reported more concerns regarding structural barriers to depression care (i.e., insurance, 
inability to pay, transportation, and childcare) than knowledge (not sure whom to contact 
and not knowing the best treatment) and attitudinal barriers (lack of motivation and 
hopelessness that treatment would work) (O’Mahen & Flynn, 2008). However, the same 
rank of barriers found in this study was reported in a previous population study based on 
2005-2009 NSDUH of women of reproductive age (Ko et al., 2012), suggesting that 
strategies provided to enhance access to treatment for mental health problems among 
women of childbearing age might be inadequate over the nine years.  
 Despite the enactment of PPACA in 2010, cost had the highest percentage as a 
perceived barrier to mental health treatment across 2008-2010 and 2011-2014. Findings 
from 2013 Kaiser Women’s Health Survey, conducted just before the start of the 
PPACA’s major coverage expansion, showed that cost was a major obstacle to getting 
mental health care among 23% of uninsured women, 6% of women with private 
insurance, and 9% of Medicaid covered women (Salganicoff, Ranji, Beamesderfer, & 
Kurani, 2014). Beyond coverage and affordability, this national representative survey 
suggested that logistical barriers such as time, transportation, sick leave, and childcare 
also impeded access to care. Interestingly, between summer 2013 and winter 2014–2015, 
the Health Reform Monitoring Survey revealed that the uninsurance rate decreased from 
19.6% to 13.3% among women of childbearing age and the unmet need for care due to 
cost decreased by 10.4% (Shartzer et al., 2015). This coverage improvement was not 
translated into significant enhancement in the access to care, and nearly one in four low-
income women was uninsured in winter 2014–2015. This suggests the need for efforts to 
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enroll uninsured women on the one hand, and on the other hand to design interventions 
and strategies to overcome other structural, attitudinal, and knowledge barriers to mental 
health care.  
 The present study showed that the rank of barriers to substance use treatment 
among women of childbearing age changed from: cost, stigma, time/transportation 
limitation, opposition to treatment/lack of treatment programs, and not knowing to go in 
2008-2010 to: stigma, cost, time/transportation limitation, lack of treatment programs, not 
knowing where to go, and opposition to treatment in 2011-2014. Beyond the limited 
health insurance coverage of substance use problems (CSAT, 2009) women perceived 
stigma as the most important barrier to substance use treatment in 2011-2014. Given that 
these women also reported opposition to treatment as the least important barrier, this 
suggests that even when women are willing to accept treatment; the stigma linked with 
their substance use impeded them. According to the CSAT (2009), stigma toward 
substance use women is greater than that toward men, and women have feelings of 
shame, guilt, and low self-esteem because of their substance use, all of which create more 
treatment needs to be addressed. Congruently, WHO (2014) and SAMHSA (2014c) 
emphasized the importance of minimizing a judgmental attitude and stigmatization when 
providing care for women of childbearing age. According to SAMHSA (2014c), public 
institutions and health service systems need to adapt the framework of trauma-informed 
care to help resolve and not aggravate trauma related issues among women with 
substance use disorder.  
Cost was rated as the second barrier to substance use treatment. Corresponding 
with the PPACA that requires the coverage of preventive measures such as substance use 
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screening without cost sharing, the awareness about these rules is still inadequate and 
only 31% of women were screened for alcohol or drug use from 2011 to 2013 
(Salganicoff et al., 2014).  
Importantly, lack of treatment programs had a significantly higher percentage in 
2010-2014 (17.7%) than 2008-2010 (3.0%). This is congruent with recent findings from 
qualitative studies revealing that the availability of substance use treatment services is a 
challenge to women seeking treatment (Jackson & Shannon, 2012a; Otiashvili et al., 
2013). Although the proportion of facilities that provided substance abuse treatment 
services for adult women and pregnant or postpartum women increased from 35% and 
15%, respectively, in 2010 (SAMHSA, 2011b) to 46% and 21% in 2014(SAMHSA, 
2015), these rates are still low and a number of states have sought to increase the 
availability of drug treatment services especially for pregnant women (Guttmacher, 
2017). In 2011-2014, childbearing-aged women in the current study were more likely to 
live in nonmetro and small county areas than women in 2008-2014. This suggests that 
these women were likely to face a massively different group of barriers than residents in 
large urban areas such as access to and perceived effectiveness of treatment (Fortney & 
Booth, 2001).  
Another significant finding from the current study is that more women in 2011-
2014 than 2008-2010 did not know where to go to get substance use treatment. This is of 
critical concern as compared to men, women with substance use disorders have a higher 
incidence of poverty and childcare responsibilities (SAMHSA, 2011a). Unfortunately, 
only 3.4% of substance use treatment facilities in 2014 provided residential beds for 
clients’ children (SAMHSA, 2015). Hence, even if women are highly motivated to get 
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treatment, they face additional barriers in finding treatment programs that can address 
their specific needs (CSAT, 2009).  
Limitations 
A number of limitations should be considered when interpreting the results of this 
study. First, data were analyzed only over seven years because mental illness measures 
were only included in the NSDUH in 2008. Second, although this study used one-to-two 
matching between pregnant and nonpregnant women to increase the sample size and 
power of the analyses, perceived barriers to substance use treatment among pregnant 
women were not examined over time due to the small sample size of pregnant women 
reported perceived need for substance use treatment. Third, other variables not included 
in this study may have affected the propensity scores. Yet, the two groups were well-
matched as indicated by balanced statistics, suggesting that the variance in the control 
group was reduced. Fourth, pregnancy status was measured based on self-report; thus, it 
was susceptible to recall bias. Fifth, postpartum women could not be identified from 
other nonpregnant women using publicly available data. However, a study based on the 
2008-2012 NSDUH reported that only approximately 8,000 postpartum women of 18-44 
years old participated in the survey, indicating an approximate rate of less than 10% of 
nonpregnant women (Glasheen et al., 2015).  
Sixth, measurement of MDE and substance use disorder in the NSDUH relied on 
questionnaires to operationalize the DSM-IV criteria rather than conducting clinical 
interviews. In addition, measurement of anxiety relied on one item which might also 
increase recall bias. Seventh, women answered questions about their mental health and 
substance use disorder and treatment receipt in the past year, while they specified their 
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current pregnancy status. These events may be occurred during or before pregnancy. 
However, this study included past-month psychological distress to increase the possibility 
of assessing prenatal mental health, although this also cannot be captured if the woman 
was pregnant in the first few weeks. Yet, the majority of pregnant women in this study 
(68.7%) were in their second and third trimester. Eighth, pregnant women might tend to 
under report their mental health and substance use problems and treatment receipt due to 
a social desirability effect; yet, the NSDUH uses ACASI to reduce this response bias. 
Finally, mental health problems may increase access to treatment which in turn may 
affect these problems. However, due to the cross-sectional nature of the NSDUH, a 
cause-effect relationship between treatment receipt and mental health cannot be 
concluded.  
Recommendations 
 The findings from this study showed increased trends in anxiety disorder and 
past-month psychological distress, underscoring the need for preventive and 
interventional strategies addressing these mental health problems among women of 
childbearing age. Pregnant women tended to report fewer mental health problems than 
nonpregnant women; however, differences in the receipt of mental health treatment of 
pregnant and nonpregnant women suggested that screening and treatment should not be 
generalized across women of childbearing broadly. More programs and initiatives are 
needed to increase the receipt of mental health treatment among a vulnerable population 
of pregnant women especially since cost, stigma, and opposition to treatment continued 
to be the most important obstacles to mental health treatment over time.  
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 Trend data presented in this study emphasized the importance of addressing the 
needs of women with illicit drug use disorder. Women had higher concerns regarding 
availability of substance use treatment services in 2011-2014 than 2008-2010, 
emphasizing that parity legislation and treatment initiatives should seek to increase 
services tailored according to the need of childbearing-aged women. Findings from this 
study also highlight the importance of additional strategies addressing stigma, cost, and 
time/transportation limitations to improve access to substance use treatment. This study 
coincided with important health reforms, MHPAEA (2008) and PPACA (2010); 
however, future research is needed to specifically explore how these policies affect the 

















Sociodemographic Characteristics of Matched Samples of Pregnant and Non-pregnant 








Characteristics Wtd. % (SE) Wtd.% (SE) Wtd.% (SE) χ2 p-value 
Age      
18-25 36.5 (0.6) 37.5(1.0) 36.0 (0.6) 3.44 .178 
26-44 63.5 (0.6) 62.5 (1.0) 64.0 (0.6)   
Ethnicity      
White 59.0 (0.7) 58.8 (1.2) 59.1 (0.9) 1.96 .885 
African American 13.7 (0.4) 14.3 (0.8) 13.5 (0.5)   
Other nonHispanicsa 8.9 (0.4) 8.7 (0.6) 9.0 (0.5)   
Hispanics 18.4 (0.5) 18.3 (0.8) 18.4 (0.7)   
Marital status      
Married  61.2 (0.7) 60.7 (1.1) 61.5 (0.7) .88 .497 
Unmarried 38.8 (0.7) 39.3 (1.1) 38.5 (0.7)   
Education      
Less than high 
school  
15.8 (0.4) 15.5 (0.7) 16.0 (0.5) 1.19 .714 
High school 26.2 (0.6) 26.0 (0.9) 26.3 (0.6)   
College graduate 58.0 (0.7) 58.6 (1.0) 57.7 (0.7)   
Employment      
Employed full time 43.0 (0.7) 42.8 (1.1) 43.1 (0.8) .85 .935 
Employed part time 17.9 (0.5) 17.6 (1.0) 18.0(0.6)   
Other 32.5 (0.5) 32.7 (1.0) 32.4 (0.7)   
Unemployed  6.7 (0.3) 6.9 (0.5) 6.6(0.3)   
Income      
<$20,000 22.6 (0.5) 22.4 (0.9) 22.7 (0.7) 1.96 .885 
$20,000-49,999 29.8 (0.7) 30.4 (1.2) 29.5 (0.8)   
≥$50,000 47.6 (0.8) 47.2 (1.2) 47.9 (0.9)   
Health insurance      
Insured 89.9 (0.4) 90.2 (0.5) 89.8 (0.5) .62 .546 
Uninsured 10.1 (0.4) 9.8 (0.5) 10.2 (0.5)   
County type      
Large 52.8 (0.9) 53.2 (1.2) 52.6 (0.9) 2.24 .526 
Small 31.6 (0.7) 31.8 (1.0) 31.5 (0.7)   
Nonmetro 15.6 (0.5) 15.0 (0.7) 15.9 (0.6)   
Note. No covariates exhibited a large imbalance (|Standardized Mean Differences| > .25). 
Imputed and recoded variables were used. NSDUH = National Survey on Drug Use and 
Health; Wt. % = Weighted Percentage; SE = Standard Error. 
aOther nonHispanics included Native American/Alaska Native, Native Hawaiian/Pacific 
Islander, Asian, and more than one race.  









Figure 2. Trends in mental health problems rates from 2008 to 2014 among a matched sample of pregnant and nonpregnant 
women aged 18-44, National Survey on Drug Use and Health. Frequencies and weighted percentages do not include missing data 







Figure 3. Trends in substance use disorders rates from 2008 to 2014 among a matched sample of pregnant and nonpregnant women, 
National Survey on Drug Use and Health. Imputed and recoded variables addressing substance use were used. Substance use 
disorder includes alcohol or illicit drug use dependence or abuse measured based on questions operationalized the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) criteria. Illicit drugs include heroin, marijuana, cocaine, inhalants, sedatives, 







Figure 4. Trends in rates of treatment receipt for mental health and substance use disorders from 2008-2014 among a matched 
sample of pregnant and nonpregnant women, National Survey on Drug Use and Health. Imputed and recoded variables were used. 







Logistic Regression Modeling the Probability of Mental Health and Substance Use Disorders and Treatment Receipt from 2008-
2014 among a Matched Sample of Pregnant and Nonpregnant Women, NSDUH (N = 16,560) 
  
Pregnant vs. Nonpregnant Womena 
  















1. Major depressive episode 
.53 .43-.65 <.001  1.01 .96-1.05 .791 
2. Anxiety disorder 
.62 .51-.75 <.001  1.07 1.02-1.12  .003 
3. Serious psychological 
distress (past month) 
.68 .56-.82 < .001  1.06 1.01-1.10 .009 
4. Past-year mental illness .65 .58-.74 <.001 
 
1.02 .98-1.05 .331 
5. Alcohol use disorderb 1.04 .87-1.24 .660  1.02 .97-1.07 .375 
6. Illicit drug use disorderb,c 1.06 .83-1.35 .645  1.05 1.004-1.10 .034 
7. Mental health treatment .60 .52-.69 < .001  1.01 .98-1.04 .445 
8. Unmet need for substance use 
treatment  
1.01 .86-1.18 .939  1.03 .99-1.08 .125 
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data addressing 
mental health. NSDUH = National Survey on Drug Use and Health.  
aNonpregnant women were the reference group. bSubstance use disorder includes substance use dependence or abuse measured 
based on questions operationalized the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. cIllicit drugs 




Logistic Regression Modeling the Probability of the Receipt of Mental Health Treatment 
by Pregnant and Nonpregnant Women with Mental Illness from 2008 to 2014, 
Controlling for Severity of Illness, NSDUH (N = 3,637) 
Characteristics AOR  95% CI p-value 
Pregnancy status    
Nonpregnant women Reference Reference  .001 
Pregnant women .66 .52-.84  
Time (one year increase) 1.04 .98-1.09  .176 
Severity of mental illness    
Mild mental illness Reference Reference <.001 
Moderate mental illness 1.94 1.51-2.50  
Severe mental illness 3.87 3.04-4.92  
Note. Imputed and recoded variables were used. Frequencies and weighted percentages 
do not include missing data addressing mental health. NSDUH = National Survey on 





A. Perceived barriers to mental health treatment among women of childbearing age (N = 1,436) 
 
B. Perceived barriers to substance use treatment  among women of childbearing age (N = 103) 
 
Figure 5. Weighted percentages and rank ordering of perceived barriers to mental health and substance use treamtent from 
2008-2010 to 2011-2014 among women of childbearing age perceived need for treatment, National Survey on Drug Use and 
Health. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data 
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A. Perceived barriers to mental health treatment among pregnant women (N = 390) 
 
B. Perceived barriers to mental health treatment among nonpregnant women (N = 1046) 
 
Figure 6. Weighted percentages and rank ordering of perceived barriers to mental health treatment from 2008-2010 to 2011-
2014 among pregnant and nonpregnant women perceived need for treatment, National Survey on Drug Use and Health. 
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Perceived Barriers to Mental Health Treatment and Substance Use Treatment in Pregnant and Nonpregnant Women 
Perceived Need for Treatment from 2008-2010 to 2011-2014 (NSDUH) 







































Mental health treatment  
(N = 1,436) 
            
Cost 45.2 50.6 3.95 .261 47.0 54.8 2.30 .317 44.6 49.3 2.13 .400 
Stigma 28.2 24.7 2.24 .368 27.3 19.3 3.40 .185 28.6 26.4 .59 .636 
Opposition to treatment 41.9 41.4 .03 .914 44.8 41.6 .40 .711 40.8 41.3 .03 .926 
Time/transportation  20.2 19.7 .05 .899 21.5 18.6 .50 .643 19.7 20.1 .09 .941 
Not knowing where to go  19.2 20.3 .28 .768 14.8 16.4 .18 .768 20.7 21.6 .11 .851 
Substance Use Treatment  
(N = 103) 
            
Cost 38.7 25.9 1.80 .356 42.8  41.9  NA NA 37.0  20.3  2.30 .325 
Stigma 18.2 35.5 3.30 .211 18.6  63.3  NA NA 18.0  25.7  .53 .616 
Opposition to treatment 3.0 7.6 .88 .286 5.5  .30  NA NA 1.9  10.2  1.56 .098 
Time/transportation  17.0 22.2 .37 .758 5.5  16.7  NA NA 21.9  24.1  .04 .921 
Not knowing where to go .90 8.2 4.45 .003 6.9  6.4  NA NA 1.4  21.6  5.06 <.001 
Lack of treatment 
programs  
3.0 17.7 2.28 .014 0.0 7.3  NA NA 1.2  8.5  1.44 .055 
Note. Imputed and recoded variables were used. NSDUH = National Survey on Drug Use and Health; Time 1 = 2008-2010; Time 2 = 
2011-2014; Wt. % = Weighted Percentage; SE = Standard Error; NA = Statistical differences were not examined due to small sample 
size of pregnant women.  
an = 390 pregnant women perceived need to mental health treatment; bn =  31 pregnant women perceived need to substance use treatment; 





PREDICTORS OF MENTAL HEALTH AND SUBSTANCE USE TREATMENT 
RECEIPT AND ETHNIC DISPARITIES IN MENTAL HEALTH TREATMENT IN A 
NATIONAL SAMPLE OF PREGNANT WOMEN WITH MENTAL HEALTH 
AND/OR SUBSTANCE USE DISORDERS 
Introduction 
The purpose of this study was to examine factors associated with the receipt of 
mental health and substance use treatment and determine ethnic disparities in mental 
health treatment among pregnant women with mental health and/or substance use 
disorders. Pregnant women with mental health and/or substance use disorders are a 
vulnerable population. Depression affects 8.2% to 12.4% of pregnant women in the 
United States (Cook et al., 2010; Le Strat, Dubertret, & Le Foll, 2011; Vesga-Lopez et 
al., 2008) and is associated with co-occurring anxiety and substance use disorders (Le 
Strat et al., 2011). 
 Poor mental health during pregnancy is linked with reduced quality of life 
(Goodman, Chenausky, & Freeman, 2014), preterm delivery (Grigoriadis et al., 2013), 
high risk for postpartum depression (Goodman et al., 2014), impaired maternal-child 
bonding (Grigoriadis et al., 2013; Rossen et al., 2016), and behavioral and cognitive 
disorders in children of depressed mothers (Csaszar, Melichercikova, & Dubovicky, 
2014). These adverse health consequences may become more complex and prevalent for
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the mother and her child when are associated with prenatal substance use (Connelly, 
Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013; Homish, Cornelius, Richardson, & 
Day, 2004; Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016). In 2012 and 2013, 5.4% 
of pregnant women used illicit drugs and 9.4% of them used alcohol in the past month 
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2014b).  
Despite effective treatments for mental health and substance use disorders (Baker 
et al., 2010; Marais et al., 2011; May et al., 2013; Meyer, Johnston, Crocker, & Heil, 
2015), only 10.3% to 39% of pregnant women with these complex health issues receive 
treatment (Cook et al., 2010; Glasheen, Colpe, Hoffman, & Warren, 2015; Le Strat et al., 
2011, Rosen, Tolman, & Warner, 2004; Song, Sands, & Wong, 2004; Vesga-Lopez et al., 
2008). Low rates of treatment for mental health problems occur despite ongoing medical 
recommendations (American College of Obstetricians and Gynecologists [ACOG], 
2015b) and state screening initiatives (Agency for Healthcare Research and Quality, 
2016). Moreover, pregnant women who use substances are often involved with the law 
before they are screened or referred to treatment by health care providers (McCabe & 
Arndt, 2012; Terplan, Smith, Kozloski, & Pollack, 2010). Inadequate treatment for 
prenatal substance use is associated with prolonged hospitalizations of prenatally affected 
infants (Patrick, Davis, Lehmann, & Cooper, 2015) and expensive child protective 
services (Ondersma, Simpson, Brestan, &Ward, 2000), making prenatal substance use a 
significant public health problem.   
Pregnant women face barriers (e.g., stigmatization) to access treatment for mental 
health problems (Ko, Farr, Dietz, & Robbins, 2012), and those who are ethnic and racial 
minorities continue to experience health care disparities (Chang, Tabet, Elder, Kiel, & 
 89 
  
Flick, 2016). However, little is known regarding factors associated with mental 
health/substance use treatment receipt, perceived barriers to mental health treatment, and 
ethnic care disparities in a general population of pregnant women.    
 Numerous studies have focused on the correlates of mental health problems 
during pregnancy (Fairbrother, Janssen, Antony, Tucker, & Young, 2016; Fairbrother, 
Young, Janssen, Antony, & Tucker, 2015; Le Strat et al., 2011; Melville, Gavin, Guo, 
Fan, & Katon, 2010; Witt et al., 2010), but few have given attention to factors associated 
with mental health treatment receipt. Mental health treatment may motivate pregnant 
women with substance use disorders to access treatment for substance use issues (Rade et 
al., 2015). Hence, addressing factors associated with the receipt of mental health 
treatment can be used to establish preventive and interventional strategies to overcome 
under-utilization of mental health treatment and thereby improve access to substance use 
treatment. This is of critical concern because the growing literature, despite its 
importance, has focused on factors related to retention in treatment programs for 
substance use disorders (Brigham, Winhusen, Lewis, & Kropp, 2010; Kissin, Svikis, 
Moylan, Haug, & Stitzer, 2004; Knight, Logan, & Simpson, 2001; Ondersma, Winhusen, 
& Lewis, 2010) rather than examining the rate and predictors of the receipt of treatment 
in a general population of pregnant women. A clear understanding of these factors, while 
addressing ethnic care disparities and reasons for the unmet need for mental health 
treatment, may help identify solutions to the under-treatment for mental health and 





Pregnant women with mental health and substance use disorders remain 
undertreated despite the adverse health consequences associated with their condition and 
the availability of different treatment modalities (Glasheen et al., 2015; Le Strat et al., 
2011; Terplan, McNamara, & Chisolm, 2012; Vesga-Lopez et al., 2008). Therefore, it is 
vital that pregnant women with these disorders are not only recognized but also treated. 
Much information remains to be understood regarding how pregnant women’s socio-
demographic and clinical characteristics influence the receipt of mental health and 
substance use treatment.   
Previous population-based studies either only reported the prevalence of mental 
health treatment in pregnant women with psychiatric disorders (Cook et al., 2010; Le 
Strat et al., 2011; Vesga-Lopez et al., 2008) or examined predictors of the receipt of 
mental health (Glasheen et al., 2015) and substance use treatment (Terplan et al., 2012) in 
women of childbearing age while adjusting for pregnancy status. Several factors may 
specifically bear on whether pregnant women are able to receive treatment for mental 
health and substance use disorders including predisposing (e.g., age, ethnicity, marital 
status, and education level), enabling (e.g., income and health insurance), and need 
factors. The specific aims of this study were to: 
1. Identify predictors of the receipt of mental health treatment and substance use 
treatment among pregnant women with mental health or substance use disorders 
given predisposing characteristics (i.e., age, ethnicity, marital status, education 
level, and employment status), enabling resources (i.e., income, health insurance, 
and county type), and perceived and actual need for treatment, controlling for time.   
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2. Examine differences in the receipt of mental health treatment among White and 
nonWhite pregnant women with mental health (i.e., depression, anxiety, and 
serious psychological distress) and/or substance use disorders, controlling for time 
and confounding variables (i.e., age, marital status, education level, employment 
status, income, health insurance, county type, self-rated health status, and severity 
of distress symptoms). 
3. Compare and contrast perceived barriers to mental health treatment among 
pregnant women who perceived need for treatment across mental health and/or 
substance use disorders and ethnicity.  
Predisposing Characteristics  
Pregnant women become more vulnerable because of reported disparities in 
antenatal depression (Cook et al., 2010; Mukherjee, Trepka, Pierre-Victor, Bahelah, & 
Avent, 2016) and substance use problems (Cook et al., 2010; Connelly et al., 2013). 
However, there is sparse evidence on racial/ethnic differences in the receipt of mental 
health/substance use treatment among this population. Studies based on the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) did not report the 
differences across racial/ethnicity groups in the receipt of mental health treatment (Le 
Strat et al., 2011; Vesga-Lopez et al., 2008). Other studies examined race/ethnicity as a 
correlate of mental health treatment utilization among perinatal women, suggesting that 
Hispanic (Geier, Hills, Gonzales, Tum, & Finley, 2015; Glasheen et al., 2015) and Black 
women reported receipt of mental health treatment proportionately less than their 
counterparts (Glasheen et al., 2015).   
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A few studies focused explicitly on examining racial/ethnic differences in the 
receipt of mental health treatment (Chang et al., 2016; Song et al., 2004). Using data from 
the Florida Healthy Start prenatal screening program 2008-2012, Chang et al. (2016) 
reported that White pregnant women with depressive symptoms had the highest rates of 
mental health services utilization compared to Mexicans and other Hispanics. Ethnic 
minority pregnant women who entered substance use treatment also reported unmet need 
for mental health treatment (Coleman-Cowger, 2012). Because mental health treatment 
receipt is a key factor in enhancing the participation in substance use treatment (Rade et 
al., 2015), further research is needed to address racial disparities in mental health care 
among pregnant women with a broad range of psychiatric problems.  
Compared to Whites, African American pregnant women with substance use 
problems were less likely both to be motivated to enroll in (Mitchell, Severtson, & 
Latimer, 2008) and receive substance use treatment (McCabe & Arndt, 2012). These 
ethnic differences in the receipt of substance use treatment showed a significant trend 
among pregnant women between 1998 (34.4% Blacks vs. 54.1% Whites) to 2008 (20.5% 
Blacks vs. 60.3% Whites) (McCabe & Arndt, 2012).  
Prior research revealed inconsistent findings regarding the associations among the 
receipt of mental health treatment and maternal age (Flynn, Blow, & Marcus, 2006; 
Glasheen et al., 2015; Rosen et al., 2004), educational level (Flynn et al., 2006; Glasheen 
et al., 2015; Goodman, 2009; Smith et al., 2009), employment status (Flynn et al., 2006; 
Glasheen et al., 2015; Smith et al. 2009), and marital status (Chang et al., 2016; Flynn et 
al., 2006; Glasheen et al., 2015; Smith et al., 2009), reflecting the heterogeneity in the 
design and sample across studies.  
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The relationship between predispositional characteristics and substance use 
treatment is also unclear. One study found that unmarried women were more likely to 
receive treatment than married women (Messer, Clark, & Martin, 1996), whereas 
Kotelchuck et al. (2017) found them less likely to receive treatment; other studies showed 
no significant association between marital status and treatment receipt in pregnant 
(Haller, Miles, & Dawson, 2001) and childbearing-aged women (Terplan et al., 2012). 
Although a few population-based studies revealed that women of reproductive age who 
had at least a high school education (Kotelchuck et al., 2017; Terplan et al., 2012) and 
who were employed had higher odds of receipt of substance use treatment (Terplan et al., 
2012), other studies did not find a significant relationship among pregnant women who 
received current (Haller et al., 2001; Messer et al., 1996) or lifetime substance use 
treatment (Walton-Moss & McCaul, 2006). Maternal age in a few population-based and 
clinical studies did not influence the receipt of substance use treatment (Messer et al., 
1996; Rosen et al., 2004). Yet, McCabe and Arndt (2012) reported that pregnant women 
aged 21–24 years had an 8.5% point increase in the receipt of substance use treatment 
from 1998 to 2008.   
Enabling Factors  
 Economically disadvantaged pregnant women are unlikely to access mental health 
(Song et al., 2004) and substance use treatment (Center for Substance Abuse Treatment 
[CSAT], 2009). However, a few studies showed that income was not associated with the 
receipt of mental health (Glasheen et al., 2015; Goodman, 2009; Smith et al., 2009) or 
substance use treatment (Haller et al., 2001). These findings may be related to the 
homogeneity of the clinical samples (Haller et al., 2001; Smith et al., 2009) or the 
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influence of other mediators or moderators on the relationship between income and 
treatment receipt that were not examined. Uninsured women of childbearing age also 
demonstrated unmet need for mental health (Farr, Bitsko, Hayes, & Dietz, 2010) and 
substance use treatment (CSAT, 2009). A population-based study showed that health 
insurance coverage was associated with and predicted mental health treatment receipt in 
perinatal women and childbearing-aged women, respectively (Glasheen et al., 2015). 
However, another study showed that health insurance coverage did not increase the 
probability of the receipt of substance use treatment in women of childbearing age after 
adjusting for other socio-demographic characteristics (Terplan et al., 2012). 
Unfortunately, substance use treatment services impose additional financial requirements 
that may not be covered by health insurance, thus creating other financial barriers to 
treatment (CSAT, 2009).  
Rural women received mental health treatment later in the development of their 
health condition and therefore need more intensive treatments (United States Department 
of Health and Human Services [USDHHS], 2003). However, Heil, Sigmon, Jones, and 
Wagner (2008) found that rural opioid-using pregnant women when compared with urban 
women might have characteristics associated with better treatment outcomes; however, 
they face more barriers to access treatment due to larger distance from treatment service. 
In qualitative studies of rural pregnant women, barriers to mental health (e.g., 
dissatisfaction with the health care system and lack of trust) (Jesse, Dolbier, & Blanchard, 
2008) and substance use treatment (e.g., availability, stigma, and lack of transportation) 
(Jackson & Shannon, 2012a) were identified. To date, very few population-based studies 
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examined the relationship between urban residency and mental health or substance use 
treatment receipt in women of childbearing age (Rosen et al., 2004).  
Perceived and Clinical Needs for Mental Health/Substance Use Treatment  
 Approximately, 39% of women of childbearing age with past major depressive 
episode (MDE) reported unmet treatment needs (Ko et al., 2012) and less than 20% of 
women who needed substance use treatment received it (Terplan et al., 2012). Yet, little 
is known about the relationship among the perceived need for and receipt of treatment for 
mental health and substance use disorders in pregnant women.   
Research on pregnant women’s mental health gives little attention to how mental 
health or substance use issues differentiate the receipt of treatment in the general 
population. A study based on the NESARC showed that pregnant women with major 
depression and any other psychiatric disorders had higher odds of the receipt of mental 
health treatment compared to those without these disorders (Le Strat et al., 2011). 
Moreover, a study based on the National Survey on Drug Use and Health (NSDUH) 
revealed that history of depression or anxiety disorders was associated with the receipt of 
mental health treatment in perinatal women with serious psychological distress (Glasheen 
et al., 2015). Yet, these population-based studies did not indicate that substance use 
problems were associated with the receipt of mental health treatment. However, Rosen et 
al. (2004) reported that comorbid mental health and substance use disorders increased the 
probability of receipt of substance use and mental health treatment in women aged 18-54 
years. Nevertheless, the authors did not specify pregnancy status or the correlates of each 
type of mental health and substance use treatment.  
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 A few clinical studies suggest that substance-related factors play a vital role in 
pregnant women’s utilization of substance use treatment. The type of substance used 
appears to influence this relationship; illicit drug use was related to substance use 
treatment acceptance, but alcohol use showed an inconsistent pattern in this relationship 
(Haller et al., 2001; Messer et al., 1996; Walton-Moss & McCaul, 2006). For instance, 
Haller et al. (2001) found that the drug severity composite score was related to treatment 
among pregnant women who used drugs while alcohol use did not affect receipt of 
treatment. Pregnant women with comorbid mental health and substance use problems 
were more likely to receive substance use treatment (Haller et al., 2001; Rade et al., 
2015). However, these findings of these clinical studies cannot be generalized to the 
general population. To date, little is known regarding how need factors are related to the 
receipt of substance use treatment in pregnant women from the general population.  
Perceived Barriers to Mental Health Treatment 
 The receipt of mental health treatment among perinatal women is a complex 
phenomenon involving individual, healthcare provider, and health system barriers (Battle, 
Salisbury, Schofield, & Ortiz-Hernandezet, 2013; Kim et al., 2010). Clinical studies that 
specifically examined perceived barriers to mental health treatment among pregnant 
women indicated the most common barriers include: cost/lack of insurance (Kim et al., 
2010; Kopelman et al., 2008), stigma (Battle et al., 2013; Goodman, 2009; Jesse et al., 
2008), lack of time (Goodman, 2009; Kim et al., 2010; Kopelman et al., 2008) and 
transportation (Kopelman et al., 2008), opposition to treatment (Jesse et al., 2008), 
dissatisfaction with the health care (Jesse et al., 2008; Kopelman et al., 2008), and not 
knowing where to go (Kopelman et al., 2008). The only population-based study  of 
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perceived barriers to mental health treatment among childbearing-aged women revealed 
consistent findings in which cost (54.8%), opposition to treatment (41.7%), stigma 
(26.3%), lack of time or transportation (18.1%), and not knowing where to go for 
treatment (16.7%) were the common barriers to mental health treatment (Ko et al., 2012). 
These perceived barriers did not differ by pregnancy status.   
To date, research has focused on women with depression; hence, whether 
perceived barriers to treatment differ between mental health and/or substance use 
disorders is not known nor have ethnic differences in mental health treatment barriers 
been fully explored in pregnant women (O’Mahen, Henshaw, Jones, & Flynn, 2011). 
Recent research identified important barriers to mental health care for comorbid women 
(e.g., cost and fear from treatment) (Rosen et al., 2004) and ethnic minority pregnant 
women (e.g., stigma and lack of trust) (Jesse et al., 2008). However, O’Mahen and Flynn 
(2008) did not find differences between White and African American perinatal women 
regarding perceived structural (e.g., insurance, cost, transportation, and childcare), 
knowledge, and attitudinal barriers with respect to treatment of depression.   
Theoretical Framework 
This study used the Behavioral Model of Health Service Use (Andersen, 1995) to 
explain ethnic/racial care disparities and predictors of the receipt of mental health and 
substance use treatment among pregnant women (see Figure 7). Andersen’s (1995) 
behavioral model incorporates individual and contextual determinant of health services 
use.  
This model postulates that there are three components of individuals’ health 
services utilization. First, predisposing factors include: (a) demographic characteristics of 
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age and sex representing “biological imperatives” (p. 2); (b) social factors such as 
education, ethnicity, and employment; and (c) attitudes, values, and knowledge related to 
health and health services that might affect individuals’ subsequent perceptions of need 
and use of health services. According to Andersen’s (1995) model, social factors 
determine the persons’ ability to cope with problems and influence their enabling 
resources which in turn facilitate or impede health services’ use. Second, enabling factors 
include: (a) availability and accessibility of services; (b) income; (c) health insurance 
status; (d) transportation; and (e) travel time to and waiting times for health care. The 
third component is the individual’s treatment needs which involve perceived and 
evaluated need.  
Andersen’s (1995) behavioral model has been extensively used in studies 
addressing health services utilization (Babitsch, Gohl, & von Lengerke, 2012). In this 
study predisposing characteristics (i.e., age, ethnicity, marital status, education level, and 
employment status), enabling resources (i.e., income, health insurance, and county type), 
and perceived and actual need for treatment were examined as predictors of the receipt of 
mental health and substance use treatment (see Figure 8).  
Methods 
Design  
Secondary analysis of existing data from the NSDUH 2008-2014 was conducted. 
The NSDUH is a national cross-sectional survey funded by SAMHSA (Center for 
Behavioral Health Statistics and Quality [CBHSQ], 2015). This large population-based 
survey provides information about mental health and substance use problems along with 
treatment for mental health and substance disorders among the civilian, 
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noninstitutionalized population aged 12 years old or older (CBHSQ, 2015). Data were 
aggregated for seven years to obtain a large sample size, thus enabling the detection of 
rare events such as substance use treatment among pregnant women as well as ethnic care 
disparities.   
Sample 
An independent, multistage probability stratified sample was used to collect data 
from participants in each of the 50 states and the District of Columbia (CBHSQ, 2015). 
The data were collected using both face-to-face interviews and audio computer-assisted 
self-interviews (ACASI) (CBHSQ, 2015). The sample for this study was restricted to 
pregnant women aged 18 to 44 years old who had mental health or substance use 
disorders. Pregnant women aged 12 to 17 years were excluded because the NSDUH 
included a different mental health module administered only to adults aged 18 and over. 
A total of 5,520 pregnant women participated in the survey from 2008 to 2014, including 
1,106 pregnant women with mental health problems and 521 women with substance use 
disorders.   
Measures 
Pregnancy status. Women who participated in the NSDUH were classified based 
on their self-report of pregnancy status (yes/no). The self-report of pregnancy status 
showed substantial test-retest reliability (Cohen’s Kappa = .85) (SAMHSA, 2010).  
Predisposing characteristics. Predisposing characteristics included: (a) age 
category (18-25; 26-44); (b) ethnicity (Hispanic, White, African American, and other 
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander, 
Asian, and more than one race; (c) education level (less than high school, high school 
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graduate, and college graduate); (d) marital status (married and unmarried, i.e., never 
been married, divorced or separated, and widowed), and (e) employment status 
(unemployed and employed, i.e., full-time, part-time, and not in labor force). 
Enabling factors. Enabling factors included: (a) total family income (< $20,000; 
$20,000–49,999; $50,000-$74,999; and ≥$75,000); (b) health insurance (uninsured and 
insured); and (c) county urbanicity (large, small, and nonmetro). The socio-demographic 
characteristics were grouped accordingly based on the sample size in each category. The 
demographic variables demonstrated almost perfect test-retest reliability (Cohen’s Kappa 
ranging from .95 to 1.0) (SAMHSA, 2010). 
Need factors. Need factors included self-rated health status (poor/fair and 
excellent/good/very good), mental health and substance use disorders, as well as 
perceived need for treatment.   
Substance use disorders. The NSDUH includes structured questions designed to 
operationalize the Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 
(American Psychiatric Association [APA], 1994) criteria for abuse and dependence of 
alcohol and illicit drugs (CBHSQ, 2015). Dependence on a substance is defined as 
reporting at least three out of seven dependence symptoms occurred in a 12-month period 
(i.e., engaging in activities related to substance use, tolerance, withdrawal, larger or 
longer use, unsuccessful attempts to cut down, physical health or emotional problems, 
and reduced activities) (APA, 1994). Substance abuse involves not meeting the criteria 
for dependence on that substance but reporting at least one of four abuse criteria occur in 
a 12-month period (i.e., roles obligations, hazardous use, legal problems, and social 
problem) (APA, 1994). The validity of the NSDUH in assessing substance use disorders 
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was supported (Jordan, Karg, Batts, Epstein, & Wiesen, 2008). In addition, the test-retest 
reliability of substance dependence or abuse measures showed substantial agreement 
(Cohen’s Kappa = .67) (SAMHSA, 2010).  
Mental health problems (i.e., major depressive episode, anxiety disorder, or 
serious psychological distress). The NSDUH adapted questions from the National 
Comorbidity Survey Replication (NCS-R) to measure symptoms of MDE (yes/no) 
consistently with the DSM-IV criteria (CBHSQ, 2015). The adult MDE measure 
demonstrated moderate test-retest reliability (Cohen’s Kappa = .52) (SAMHSA, 2010).  
Anxiety disorder (yes/no) was measured using a single item addressing whether a doctor 
or other medical professional told participants that they had anxiety disorder in the past 
12 months. This measure demonstrated substantial test-retest reliability (Cohen’s Kappa 
= .73) (SAMHSA, 2010). 
The NSDUH uses Kessler-6 (K6) Psychological Distress Scale (Kessler, Barker, 
et al., 2003) to measure symptoms of psychological distress during the past year. The K6 
Scale is a 6-item self-report instrument that ranks items on a 4-point scale ranging from 
“all of the time” to “none of the time.” These items ask about the frequency of feeling: 
nervous, hopeless, restless or fidgety, sad or depressed, that everything was an effort, and 
no good or worthless. The range of the total scores is 0 to 24; higher scores indicate 
greater psychological distress. The cut-off score of 13 is the indicator of serious 
psychological distress (CBHSQ, 2015). The K6 predicted serious mental illness (Kessler, 
Barker, et al., 2003) thereby supporting its validity. Cronbach’s alpha for the K6 in the 
present sample had excellent reliability (α = .91). In this study, serious psychological 
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distress was examined as an outcome variable and included as a confounding variable to 
control severity of distress symptoms when addressing ethnic care disparities.  
Perceived need for treatment. The NSDUH includes two items addressing 
whether participants perceived a need for the treatment for alcohol (one item) and illicit 
drugs (one item) (yes/no). The recorded variable addressing the perceived need for 
treatment for alcohol or illicit drug use was used in this study. The perceived need for 
mental health treatment was measured using a single item addressing whether 
participants perceived a need for mental health treatment or counseling during the past 12 
months but did not get it (yes/no). Measures of perceived need for treatment 
demonstrated substantial test-retest reliability (Cohen’s Kappa = .86 for substance use 
treatment; Cohen’s Kappa = .65 for mental health treatment) (SAMHSA, 2010).  
Receipt of mental health treatment. The NSDUH includes three items 
addressing whether participants received treatment for any problem with emotions, 
nerves, or mental health in the past 12 months in an inpatient or outpatient setting, or 
used prescription medication for mental health problems (yes/no). These measures 
demonstrated excellent test-retest reliability (Cohen’s Kappas = .85) (SAMHSA, 2010).  
Receipt of substance use treatment. The NSDUH includes 18 items (yes/no) 
addressing the receipt of treatment for alcohol (nine items) and illicit drugs use problems 
(nine items) during the past 12 months in any of the following venues: hospitals, inpatient 
or outpatient residential drug or alcohol rehabilitation facilities, outpatient mental health 
facilities, emergency departments, private doctor's offices, prisons/jails, self-help groups 
such as Alcoholics Anonymous (AA), Narcotics Anonymous (NA), or some other places. 
The substance use treatment measures showed strong test-retest reliability (Cohen’s 
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Kappa = .87) (SAMHSA, 2010). In this study, the recoded variable that indicates the 
receipt of treatment for alcohol or illicit drug use at any venue during the past 12 months 
was used.   
Perceived barriers to mental health treatment. The NSDUH includes 14 items 
addressing reasons for not getting mental health treatment (USDHHS, SAMHSA, Office 
of Applied Studies, 2015). Perceived barriers include factors such as treatment beliefs, 
readiness for treatment, lack of knowledge about treatment programs, confidentiality 
concerns, lack of time, and lack of transportation. The majority of items addressing the 
barriers to mental health treatment demonstrated good test-retest reliability (Cohen’s 
Kappa ≥ .65) (SAMHSA, 2010).  
The classification of perceived barriers used by Ko et al. (2012) was adapted for 
use in this study. Any items measuring perceived barriers that were scored “yes” were 
classified into the following categories: (a) cost (three items: could not afford cost, 
insurance did not cover at all, and insurance did not pay enough); (b) stigma (four items: 
fear of neighbors’ negative opinion, fear of negative effects on job, confidentiality 
concerns, and did not want others to find out); (c) opposition to treatment (four items: 
didn’t think treatment was needed at the time, could handle problems without treatment, 
didn’t think treatment would help, and fear of being committed/medicated); (d) time or 
transportation limitation (two items: didn’t have time, and no transportation or 
inconvenient); (e) and did not know where to go.  
Procedure 
This study used existing de-identified, publicly available data from the NSDUH 
2008-2014. Hence, an exemption certification was received for the current study from the 
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University of Louisville Institutional Review Board. Approval to use these data for the 
proposed research was obtained from SAMHSA through the Interuniversity Consortium 
for Political and Social Research (ICPSR). The principal investigator (PI) agreed to: (a) 
use the data only for research purposes; (b) report to the ICPSR if the identity of any 
subject is discovered accidentally; and (c) keep the data safe from unauthorized access. 
Thus, the data were saved as encrypted file on the investigator’s computer. 
Data Analysis  
Statistical analysis was conducted using complex sample analysis with SPSS 
software, version 22.0 (IBM Corp., 2013). Considering the complex survey design and 
probability of sampling, a weighting variable was included by diving the final person-
level analysis weights by seven (i.e., the number of years of pooled data), according to 
the guidelines of the NSDUH (CBHSQ, 2015). P-values < .05 were considered 
statistically significant for all analyses. Bonferroni correction was deemed conservative 
(Bland & Altman, 1995); hence, multiple comparisons were considered when interpreting 
ethnic care disparities across mental health and/or substance use disorders. The recoded 
and imputed variables for demographic and substance use variables were analyzed, while 
missing data for mental health variables were excluded from analyses.  
 Descriptive statistics were conducted for the entire sample using weighted 
percentages and standard errors (SEs) to describe all categorical variables; means and SEs 
were used to describe psychological distress. Bivariate analyses using chi-square and t-
test were performed to examine the associations/differences among predisposing, 
enabling, and need factors and receipt of treatment groups.  
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Two logistic regression models were conducted to model the probability of the 
receipt of mental health treatment and substance use treatment. Unadjusted and adjusted 
odds ratios were calculated for best predictors. The full model contained characteristics 
with p-value less than .15 in bivariate analyses, confounding variables, and time. 
Multicollinearity was assessed by tolerance and variance inflation factor (VIF). A 
backward selection method was used to determine which variables to include in the final 
model. All models were compared using the likelihood ratio test and the Akaike 
Information Criterion (AIC) and Bayesian Information Criterion (BIC) fit statistics 
(Vittinghoff, Glidden, Shiboski, & McCulloch, 2012).  
Five separate logistic regression models were run to model the probability of the 
receipt of mental health treatment among each group of pregnant women with: major 
depression, anxiety disorder, serious psychological distress, and/or substance use 
disorders, controlling for time and confounding variables (i.e., age, income, education, 
marital status, employment status, health insurance, county type, self-rated health status, 
severity of distress symptoms, and time). Ethnicity was included as the main variable in 
each model. Finally, weighted percentages were calculated for each type of perceived 
barrier and compared across types of disorders and ethnicity using chi-square.  
Results 
Sample Characteristics  
A total of 5,520 pregnant women of childbearing age (18-44 years) participated in 
the NSDUH 2008-2014. Most participants were white (58.8%), college graduates 
(58.6%), employed (93.1%), and had a family income of less than $50,000 (see Table 8). 
Approximately 17% of pregnant women had mental health problems in the past year (i.e., 
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MDE, anxiety, or serious psychological distress), 7.6% of them met the DSM-IV criteria 
for the substance use disorders, and 4.1% of them had comorbid mental health and 
substance disorders. Only 44.5% and 13.1% of pregnant women with mental health or 
substance use disorders received treatment for mental health and substance use problems, 
respectively.   
Among pregnant women with mental health problems (i.e., MDE, anxiety, or 
serious psychological distress) (N = 1,106), the majority aged 26-44 years, were white, 
unmarried, college educated, employed, insured, had income of less than $50,000, and 
lived in urban residency. Most of pregnant women with mental health problems 
perceived their health status as good or excellent. Approximately, 34% of them had MDE 
or anxiety disorder in the previous year. Only, 20% of pregnant women had comorbid 
mental health and substance use disorders. Approximately 75% of pregnant women had 
serious psychological distress (K-6 score ≥ 13); the mean score for the K-6 scale of 15.54 
(see Table 9).   
Most of pregnant women with substance use disorders (N = 521) aged 18 to 25 
years, were white, unmarried, college educated, employed, had health insurance 
coverage, lived in urban residency, and had an income of less than $50,000. The majority 
perceived their health as excellent or good and did not perceive a need for substance use 
treatment (95.5%). Forty-one percent of pregnant women had alcohol abuse and 34.9% of 
them had alcohol dependence, while 10% and 31.1% met the DSM-IV criteria for illicit 
drug abuse and dependence, respectively. Around 28% of women had comorbid 
depression/anxiety and substance use disorders (see Table 10).   
Factors Associated with Mental Health/Substance Use Treatment 
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 Compared to pregnant women with mental health problems who did not receive 
mental health treatment, those who received the treatment were significantly more likely 
to be age 26 to 44 years (p = .001), white (p < .001), and married (p = .13); have college 
education (p = .002); have a higher income (p = .008); and have health insurance 
coverage (p = .036). Pregnant women who received mental health treatment were more 
likely to: perceive need for treatment (p < .001); have a past-year MDE (p = .014); and 
have anxiety disorder (p < .001) compared to those who did not receive treatment. They 
also had lower scores on serious psychological distress (M = 15.44, SE = .43) than non-
treatment recipients (M = 15.62, SE = .29) (p < .001) (see Table 9). Pregnant women with 
substance use disorders who received substance use treatment were significantly more 
likely to have illicit drug abuse or dependence (p = .002) and have comorbid 
depression/anxiety and substance use disorders (p = .007) compared to those who did not 
receive the treatment (see Table 10).  
Predictors of Mental Health/Substance Use Treatment 
  A binary logistic regression analysis was conducted to examine the ability of 
variables to predict the likelihood of the receipt of mental health treatment. The full 
model contained 14 variables: five predisposing characteristics, three enabling, and six 
need factors. Using backward elimination, variables were removed one at a time 
according to the least significant p-value in the following order: income, age, self-rated 
health status, substance use disorders, urban residency, employment status, perceived 
need for treatment, and marital status. In the final model, ethnicity, educational level, 
health insurance status, past-year serious psychological distress, MDE, and anxiety 
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disorder provided the best predictive model of the receipt of mental health treatment. 
Both the AIC and BIC were assessed to choose the more parsimonious final model.  
 The adjusted odds ratios in the final model (see Table 11) indicated that anxiety 
disorder was the strongest predictor of the receipt of mental health treatment. After 
controlling for other variables in the model, pregnant women with past-year anxiety 
disorder had over 17 times the odds of the receipt of mental health treatment compared 
with those who did not have anxiety (Adjusted Odds Ratio [AOR]: 17.34; 95% 
Confidence Interval [CI]: 8.64-34.81). Compared to White pregnant women, African 
Americans (AOR: .38; 95% CI = .20-.74) and other NonHispanics (AOR: .17; 95% CI: 
.05-.59) had much lesser odds of mental health treatment receipt. Pregnant women who 
had a college education had almost three times the odds of mental health treatment 
receipt compared to those who had less than a high school education (AOR: 2.84; 95% CI 
= 1.36-5.91). MDE (AOR: 2.48; CI: 1.44-4.27) and health insurance coverage (AOR: 
2.34; 95% CI: 1.16-4.71) increased the likelihood of mental health treatment receipt. 
After adjusting other variables in the model, for a one-unit increase in the psychological 
distress score, the odds of mental health treatment receipt increased significantly by 1.06 
times (95% CI: 1.003-1.12).  
 To predict the likelihood of the receipt of substance use treatment, the full 
regression model contained 13 variables: five predisposing characteristics, three enabling 
factors, and five need factors. Backward elimination was used to remove one variable at a 
time based on the least significant p-value in the following order: educational level, 
employment, health insurance, marital status, perceived need, age, income, and self-rated 
health status. In the final model, ethnicity, urban residency, alcohol use disorders, illicit 
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drug use disorders, and comorbid mental health and substance use disorders were the best 
predictors of the receipt of substance use treatment. The AIC and BIC were assessed to 
choose the best predictive model.  
 After controlling for other variables in the final model (see Table 12), illicit drug 
dependence was the strongest predictor of the likelihood of substance use treatment 
(AOR: 8.83, 95% CI: 3.10-25.16), followed by illicit drug abuse (AOR: 7.89, 95% CI: 
1.81-34.4), large urban residency (versus small urban) (AOR: 4.40, 95% CI: 1.82-10.62), 
comorbid depression/anxiety and substance use disorders (AOR: 3.13, 95% CI: 1.40-
7.02), alcohol use dependence (AOR: 2.99, 95% CI: 1.37-6.49), and finally nonWhite 
ethnicity (vs. Whites) (AOR: .39, 95% CI: .19-.80).   
Ethnic Disparities in Mental Health Treatment Receipt  
 Regardless of mental health or substance use disorders and ethnicity background, 
a higher percentage of pregnant women received prescription drugs or outpatient 
counseling rather than inpatient treatment (see Table 13). Overall, nonWhite pregnant 
women with mental health and/or substance use disorders were less likely to receive any 
mental health treatment, outpatient mental health treatment, or prescription drugs than 
Whites. NonWhite pregnant women with serious psychological distress were 
significantly less likely to receive any mental health treatment (23.8% vs. 47.3%) (p < 
.001) or prescription drugs (18.2% vs. 37.7%) (p < .001). Compared to nonWhites, White 
pregnant women with substance use disorders (31.3% vs. 18.5%; p = .019) and comorbid 
mental health and substance use disorders (54.8% vs. 30.7%; p = .003) were more likely 
to receive any mental health treatment.   
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 Bivariate associations with ethnicity and predisposing, enabling, and need 
factors. White pregnant women with any mental health problem were more likely to be 
age of 26-44 years (57.3% vs. 42.3%) (p = .008), married (53.3% vs. 31.7%) (p <.001), 
and college graduates (56.1% vs. 40%) (p = .005); have a family income of ≥ $50,000 
(48.2% vs. 19.1%) (p <.001); and live in nonmetropolitan and small urban areas (62.5% 
vs. 40.5) (p <.001). The same pattern of the relationship was found between ethnicity 
(Whites vs. nonWhites) and age of 26-44 (58.1% vs. 41.4% (p = .018), married-marital 
status (56.6% vs. 31.2%) (p < .001), college education (60.1% vs. 41.3%) (p = .033), 
income of ≥ $50,000 (45.7% vs. 16.3%) (p < .001), and small urban and nonmetropolitan 
residency (68.4% vs. 38.5%) (p = .001) in pregnant with MDE. Similarly, 26-44 years 
age (54.1% vs. 39.2%) (p = .018), married-marital status (51.3% vs. 30.5%) (p < .001), 
high income (45.7% vs. 16.3%) (p <.001), and large urban residency (39.1% vs. 58.9%) 
(p = .001) differentiated White and nonWhite ethnicity in pregnant women with serious 
psychological distress.  
Likewise, compared to nonWhites, White pregnant women with substance use 
disorders were more likely to be 26-44 years old (54.0% vs. 35.5%) (p = .012), have a 
college education (59.7% vs. 42.2%) (p = .030), and income of ≥ $50,000 (50.3% vs. 
27.0%) (p = .002), and live in small urban and nonmetropolitan residency (55.8% vs. 
37.8%) (p = .015). Yet, only large urban residency (61.1% vs. 31.3%) (p = .002) and high 
income level (23.1% vs. 48.8%) (p = .002) differentiated nonWhite and White ethnicity 
among women with comorbid mental health and substance use disorders, respectively. 
Finally, there was no significant association between ethnicity and self-rated health status 
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and severity of distress symptoms in pregnant women, regardless of the type of mental 
health and/or substance use disorders.  
 Odds of mental health treatment receipt. Unadjusted and adjusted logistic 
regression models were constructed for MDE, anxiety disorder, serious psychological 
distress, substance use disorders, and comorbid mental health and substance use disorders 
to examine the effect of ethnicity on mental health treatment receipt. As indicated in 
Table 14, after controlling predisposing, enabling, and need factors in the model, 
nonWhite pregnant women with MDE (AOR: .49, 95% CI: .27-.92), serious 
psychological distress (AOR: .34, 95% CI: .20-.59), substance use disorders (AOR: .46, 
95% CI: .23-.93), and comorbid mental health and substance use disorders (AOR: .27, 
95% CI: .13-.57) had a much lower odds of receipt of mental health treatment compared 
to Whites.   
Perceived Barriers to Mental Health Treatment 
 Among pregnant women who perceived need for treatment because of mental 
health, substance use disorders, and comorbid mental health and substance use disorders, 
respectively, cost (52.8%, 57.5%, 54.8%), opposition to treatment (40.6%, 45.2%, 
43.2%), and stigma (22.6%, 38.1%, 36.7%) were the most frequent self-reported barriers 
to mental health treatment (see Table 15). Pregnant women with MDE were significantly 
more likely to self-report cost (p = .025) and not knowing where to go (p = .002) as 
barriers to mental health treatment compared to those without depressive episode. 
However, depressed pregnant women were less likely to have opposition to treatment 
compared to non-depressed women (p = .012). Pregnant women with anxiety disorder 
were more likely to perceive time/transportation limitations to the receipt of mental 
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health treatment compared with those without anxiety (p = .014). Pregnant women who 
perceived a need for treatment and had substance use disorders (p < .001) or comorbid 
mental health and substance use disorders (p = .035) were significantly more likely to 
experience stigma to mental health treatment receipt in comparison with those without 
these disorders.   
 White and nonWhite pregnant women with mental health problems did not differ 
in the perceived barriers of: opposition to treatment, time/transportation limitations, and 
not knowing where to go (see Figure 9). However, White pregnant women were 
significantly more likely to perceive cost as a barrier to mental health treatment. 
Although Whites were less likely to self-report stigma as a barrier to mental health 
treatment compared to nonWhites, the difference was not significant. There were no 
significant differences in perceived barriers to mental health treatment among White and 
nonWhite pregnant women with substance use disorders (see Figure 10) or comorbid 
mental health and substance disorders (see Figure 11).  
Discussion 
Despite their needs, pregnant women with mental health and substance use 
disorders had low rates of mental health and substance use treatment receipt. In this 
study, 45% of pregnant women with mental health problems received mental health 
treatment and only 13% of those with substance use disorders received substance use 
treatment. These rates are comparable with rates reported in studies based on the NSDUH 
addressing mental health treatment (Glasheen et al., 2015; Ko et al., 2012) and substance 
use treatment (Terplan et al., 2010) and vary in comparison with other population-based 
studies focusing on mental health treatment (Cook et al., 2010; Le Strat et al., 2011; 
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Rosen et al., 2004; Song et al., 2004; Vesga-Lopez et al., 2008). For instance, studies 
based on the NESARC reported lower rates of mental health treatment (6.1% to 26.5%) 
(Le Strat et al., 2011; Vesga-Lopez, 2008).This discrepancy may be due to differences 
between the NSDUH and NESARC (as well as other surveys) in the survey design and 
measures used to assess mental health and substance use disorders (e.g., DSM-IV based 
self-report instrument in the NSDUH vs. diagnostic interview in the NESARC). 
Nevertheless, the gap between the need for and receipt of treatment has been found 
consistently across studies of pregnant women with these complex health issues (Cook et 
al., 2010; Glasheen et al., 2015; Le Strat et al., 2011, Rosen et al., 2004, Song et al., 
2004, Vesga-Lopez et al., 2008), suggesting an urgent call to address their needs.  
Predisposing and Enabling Predictors of Treatment Receipt 
Of the predisposing characteristics, only ethnicity predicted the receipt of both 
mental health treatment and substance use treatment. African Americans and other non-
Hispanics had a lower odds of the receipt of mental health treatment; nonWhite pregnant 
women with substance use disorders had .39 times the odds of substance use treatment 
receipt, yet only after controlling for other variables in the model. This ethnic disparity in 
treatment receipt is consistent with prior population-based studies (Chang et al., 2016; 
Geier et al., 2015; Glasheen et al., 2015; McCabe & Arndt, 2012; Song et al., 2004).  
 Educational level and health insurance coverage predicted the receipt of mental 
health treatment but not substance use treatment. This supports findings of prior research, 
namely that perinatal women with mental health issues who received mental health 
treatment, compared to those who did not receive any treatment, were more likely to have 
a higher educational level (Glasheen et al., 2015) and health insurance coverage 
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(Glasheen et al., 2015; Smith et al., 2009). In this study health insurance was not related 
to the receipt of substance use treatment which may be due to the homogenous sample of 
pregnant women who had health insurance. Other possible explanations for the 
differences in how health insurance differentiated the receipt of mental health treatment 
versus substance use treatment may include that: (a) health insurance benefits tend to 
cover mental health care rather substance use treatment (Clark, Power, Le Fauve, & 
Lopez, 2008); and (b) some Medicaid programs do not cover treatment for substance use 
disorders which also hinders the access to treatment (CSAT, 2009).   
The findings are congruent with prior clinical studies in indicating no significant 
relationship between educational level and substance use treatment receipt (Haller et al., 
2001; Messer et al., 1996; Wolton-Moss et al., 2006), although in contrast, Terplan et al. 
(2012) found that higher educational level predicted receipt of substance use treatment. 
Although income was significantly associated with the receipt of mental health treatment, 
it was not one of the predictors of treatment receipt in the final model. This indicates that 
there were stronger predictors (e.g., health insurance) that increased the likelihood of the 
receipt of mental health treatment in this study sample.    
After controlling for other predisposing and need factors, large urban residency 
increased the probability of substance use treatment receipt. This finding extends the 
growing evidence on the effect of residency on pregnant women’s ability to access 
treatment (Heil et al., 2008; Jackson & Shannon, 2012b). Interestingly, the urban 
residency was not associated with the receipt of mental health treatment, suggesting that 
substance use treatment programs are less available than mental health services and 
therefore this creates a greater challenge to access treatment (CSAT, 2009). A review of 
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literature indicates that individuals residing in rural areas have distinctive beliefs, 
attitudes, and financial constrains that might influence their access to substance use 
treatment (Fortney & Booth, 2001). There is a need for more research that sheds the 
lights on factors influencing the likelihood rural pregnant women seek treatment.   
Maternal age was not associated with substance use treatment, yet it differentiated 
the receipt of mental health treatment but not after controlling other variables in the 
regression model. Similarly, previous studies of the relationships of receipt of mental 
health and substance use treatment with maternal age (Flynn et al., 2006; Glasheen et al., 
2015; McCabe & Arndt, 2012; Messer et al., 1996; Rosen et al., 2004), employment 
status (Flynn et al., 2006; Glasheen et al., 2015; Goodman, 2009; Haller et al., 2001; 
Messer et al., 1996; Smith et al. 2009; Terplan et al., 2012), and marital status (Flynn et 
al., 2006; Glasheen et al., 2015; Messer et al., 1996; Smith et al. 2009; Terplan et al., 
2012) are inconclusive. The current study adds to the literature by shedding light on these 
relationships.  
Need Factors Predicting Treatment Receipt  
To date, little is known regarding how perceived need for treatment contributes to 
the receipt of treatment in pregnant women. In a clinical sample of perinatal women, only 
40% of those who perceived a need for treatment of depression or anxiety received that 
treatment (Goodman & Tyer-Viola, 2010). Yet, perceived need for mental health 
treatment in the present study failed to be in the final best predictive model, suggesting 
that other predisposing, enabling, and need factors are more significant predictors of the 
receipt of mental health treatment. Unfortunately, in the present study, the majority of 
pregnant women with substance use disorders (96%) did not perceive a need for 
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treatment and did not receive it. Importantly, pregnant women with substance use 
disorders continue to deny their needs for treatment which serves as an obstacle to 
treatment (CSAT, 2009).  
  Need factors markedly differentiated the receipt of mental health and substance 
use treatment. Anxiety disorder was the strongest predictor of the receipt of mental health 
treatment, accounting for other predisposing and enabling factors in the model. It had 
almost 17 times the odds of receipt of mental health treatment, while MDE and serious 
psychological distress (for one-unit increase) had 2.48 and 1.06 times the odds of 
treatment receipt, respectively. There are no previous population-based studies 
comparable to this study with respect to the design and sample to contrast these findings. 
The only NSDUH-based study that has focused on examining predictors of mental health 
treatment receipt among childbearing-aged women with past-month serious 
psychological distress showed that anxiety disorder had 3.5 times the odds of mental 
health treatment while depression disorder had 5.5 times the odds, controlling for 
pregnancy status (Glasheen et al., 2015). However, depression disorder was measured in 
this study based on the self-report of receiving a diagnosis of depression rather than 
meeting the DSM-IV criteria for MDE, and therefore the differences in the measures and 
sample may contribute to the discrepancy in the results between our study and Glasheen’s 
et al. (2015) study. Of studies conducted solely among pregnant women, Byatt, Xiao, 
Dinh, and Waring (2016) found that pregnant women with depressive symptoms who 
participated in the National Health and Nutrition Examination Survey 2005-2012 had 
higher odds of mental health care compared to those without depressive symptoms. 
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Consistent with another population-based study (Le Strat et al., 2011), comorbid 
mental health and substance use disorders were not associated with the receipt of mental 
health treatment in childbearing-aged women. However, in this study, pregnant women 
with comorbid mental health and substance use disorders had 3.13 the odds of substance 
use treatment receipt. This is reflected in a clinical study that showed that despite 
pregnant women’s need for mental health treatment they only received a substance use-
focused treatment (Coleman-Cowger, 2012).   
 The results of this study also echo those of other studies that examined the 
associations among the type and severity of substance use and substance use treatment, 
namely that drug use disorders increased the likelihood of substance use treatment in 
pregnant women (Haller et al., 2001; Messer et al. 1996; Wolton-Moss et al., 2006). In 
this study, illicit drug dependence rather than abuse was the strongest predictor of the 
receipt of substance use treatment. It had 8.83 the odds of the receipt of treatment while 
abuse had 7.89 the odds. Furthermore, only alcohol dependence but not abuse predicted 
the receipt of treatment. A study based on the Treatment Episode Data Set (TEDS) 1998-
2008 showed that there was an increase in the treatment rate for illicit drug disorder while 
a decline for alcohol use disorder in women of childbearing age and particularly among 
pregnant women (McCabe & Arndt, 2012). The link between substance dependence 
diagnoses and treatment receipt was anticipated because dependence is associated with 
more problems related to substance use (Dawson, Saha, & Grant, 2010). On the other 
hand, this may indicate that pregnant women did not access treatment until the severity of 
their substance use became paramount, suggesting a delayed access to treatment due to 
numerous barriers (CSAT, 2009). Given that alcohol abuse was the most common 
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substance use disorder among pregnant women in the current study, screening and brief 
intervention are recommended to help pregnant women decrease antenatal alcohol 
consumption (Marais et al., 2011).   
Ethnic Disparities in Mental Health Treatment 
  Consistent with previous research (Chang et al., 2016; Coleman-Cowger, 2012; 
Geier et al., 2015; Glasheen et al., 2015; Song et al., 2004), nonWhite pregnant women 
were less likely to receive any mental health treatment compared to Whites. Interestingly, 
the data in the present study showed that nonWhite pregnant women compared with 
Whites were less likely to receive prescription drugs for mental health and substance use 
problems and this relationship was significant among those with serious psychological 
distress. Research findings also indicate that ethnic minorities in the general population 
(Cooper et al., 2003) and in pregnant women (Goodman, Dimidjian, & Williams, 2013; 
Yamamoto, McCormick, & Burris, 2015) are less likely to find prescription drugs 
acceptable to treat mental health problems, suggesting negative cultural beliefs toward 
treatment.  
Aggregating data for seven years of the NSDUH enabled examination of ethnic 
differences in the receipt of any mental health treatment, controlling for predisposing, 
enabling, and need factors. Among White and nonWhite pregnant women with mental 
health and/or substance use disorders, the findings indicated differential pattern in the 
receipt of mental health treatment. NonWhite pregnant women were less likely to receive 
any mental health treatment for MDE and serious psychological distress. These 
differences were reflected in other studies in which ethnicity was examined as a 
correlates of treatment receipt (Geier et al., 2015; Glasheen et al., 2015) and in another 
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study that focused explicitly on ethnic care disparities among pregnant women with 
depressive symptoms (Chang et al., 2016). However, in the current study there were no 
differences between White and nonWhite pregnant women with anxiety disorder in the 
receipt of mental health treatment. This can be due to recall bias in reporting anxiety 
disorder, as this study relied only on one item addressing whether participants received a 
diagnosis of anxiety disorder in the past year. In addition, this can be also explained by 
the fact that ethnic minorities, particularly African Americans, tend to voluntary seek 
treatment specifically for anxiety-like symptoms, whether from a physician or mental 
health specialists, or in an emergency room (Snowden, 2001). Therefore, this might 
account for the discrepancy between the two groups.  
This study also extends prior research that has studied ethnic care disparities 
(Chang et al .2016; Song et al., 2004) in emphasizing that nonWhite pregnant women are 
less likely to use mental health treatment for substance use disorders and comorbid 
mental health and substance use disorders. This finding is consistent with those of a study 
in which Black women with substance use disorders did not receive mental health 
treatment despite their needs compared to Whites (Coleman-Cowger, 2012).   
The current study showed that the greatest ethnic care discrepancy was for 
comorbid mental health and substance use disorders. NonWhite pregnant women had .27 
times the odds of receipt of treatment compared to Whites. Taking the inverse of these 
odds, White pregnant women were almost four times more likely to receive mental health 
treatment compared to nonWhites. It is noteworthy, that even after applying the formal 
correction for multiple comparison, the differences in mental health treatment for 
comorbid mental health and substance use disorders would still have been significant (p = 
 120 
  
.001). Furthermore, it is of particular interest that ethnic disparities in the receipt of 
mental health treatment persisted after controlling other characteristics and particularly 
indicators of socioeconomic status. This perennial problem of mental health disparities 
for ethnic and racial minorities has remained for decades in the United States (Leong & 
Kalibatseva, 2011; Snowden, 2012), suggesting that significant changes should be made 
in the mental health care system, especially for pregnant women.    
Perceived Barriers to Mental health treatment  
The common barriers reported by pregnant women in this study included 
perceived cost, opposition to treatment, and stigma, regardless of their disorder, i.e., 
mental health and/or substance use disorders, and ethnicity. This perception is also 
common among pregnant women from clinical samples (Battle et al., 2013; Goodman, 
2009; Jesse et al., 2008; Kim et al., 2010; Kopelman et al., 2008) and the general 
population (Ko et al., 2012).  
Pregnant women who perceived a need for mental health treatment because of 
MDE were significantly more likely to report cost and not knowing where to go as 
barriers to mental health treatment. This is congruent with research reports that focused 
specifically on women with depressive symptoms (Kim et al., 2010; Kopelman et al., 
2008). However, in contrast with these studies, the current study showed that pregnant 
women with MDE compared to those without depression but with a perceived need for 
treatment were significantly less likely to have an opposition to treatment. This suggests 
that depressive symptoms may motivate pregnant women to accept treatment. However, 
research suggests that depression or anxiety disorders of pregnant women, despite their 
perceived need for mental health treatment, are unidentified by clinicians (Goodman & 
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Tyer-Viola, 2010). Moreover, findings from clinical samples proposed that care providers 
themselves are reluctant to provide mental health treatment to pregnant women, 
particularly pharmacotherapy, which creates additional barriers to treatment receipt 
(Byatt, Biebel, Debordes-Jackson, et al., 2013; Weinreb, Byatt, Moore Simas, Tenner, & 
Savageau, 2014).  
 Although little is known regarding barriers to mental health treatment specifically 
in pregnant women with anxiety disorders, this study extends prior research in 
demonstrating that time/transportation limitations are significant barriers perceived by 
these women. Similarly, time was the most common barrier to receive treatment for 
anxiety or depression among a clinical sample of perinatal women (Goodman, 2009). In 
addition, results from the NCS-R showed that transportation significantly impeded the 
receipt of mental health treatment in respondents from the general population with 
moderate to severe mental illness (Mojtabai et al., 2011).  
Pregnant women with substance use disorders and comorbid substance use 
disorders were more likely to perceive stigma as a barrier to mental health treatment. The 
CSAT (2009) also reported that stigma linked with substance use among pregnant women 
impeded the access to treatment. The current study signifies the role of stigma when these 
women have specific mental health needs because of substance use issues.    
Despite ethnic disparities in the receipt of mental health treatment, perceived 
barriers to treatment were similar among White and nonWhite pregnant women with 
substance use disorders and comorbid mental health and substance use disorders. 
However, compared to nonWhites, White pregnant women with mental health problems 
were more likely to perceive cost as a barrier to mental health treatment. Although 
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nonWhite pregnant women had lower income compared to Whites, those who are poor 
are eligible to Medicaid (American Pregnancy Association, 2017) and therefore this may 
lessen their perception of financial constrains with respect to mental health treatment. In 
addition, regardless of health insurance status, ethnic minorities often believe that they 
can treat their mental illness through willpower and evading morbid thoughts rather than 
seeking mental health treatment (Snowden, 2001). Moreover, most of the White pregnant 
women in this sample were married which means that they may face more financial 
constrains when they are in need to access mental health treatment. Consistently, 
Mojtabai et al. (2011) found that married respondents in the NCS-R had higher odds of 
reporting structural barriers (e.g., financial barrier) to mental health treatment than 
unmarried respondents from the general population.  
A higher percentage of nonWhite pregnant women with mental health problems 
perceived stigma as a barrier to mental health treatment than Whites, although the 
difference between these two groups was not significant. This is similar to the perception 
in the general population in the United States (Leong & Kalibatseva, 2011). Yet, the data 
in this study showed an opposite pattern in which White pregnant women with substance 
use disorders perceived stigma as a greater barrier than nonWhites. Although the 
difference was not significant, it is consistent with one population-based study that 
reported nonBlacks with alcohol use disorders were more likely to report stigma as a 
reason for not seeking substance use treatment than Blacks (Grant, 1997). The findings of 
the current study provide an interesting perspective in regards how ethnicity and type of 
disorder relate to the perception of stigma as a barrier to mental health treatment. Further 
clinical and population-based studies are needed to examine how cultural and 
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predisposing beliefs shape the access to treatment across ethnic groups of pregnant 
women.  
Limitations 
The NSDUH measured pregnant at the time of interview but assessed mental 
health and substance use disorders in the past year so that these problems may not have 
occurred during pregnancy. Second, the diagnosis of pregnancy was based on self-report; 
thus, recall bias may affect the estimation of the number of pregnant women in this 
survey. Social desirability effect might cause pregnant women to be reluctant to disclose 
issues related to mental health and substance use issues. However, the NSDUH uses 
computer-assisted interviews to lessen this bias. Fourth, the NSDUH measures MDE and 
substance use disorders using a DSM-IV based self-report instrument rather than clinical 
interview which may introduce bias. This bias may be increased in measuring anxiety 
disorder as this depended on one self-report item--receiving a diagnosis from a health 
care provider.  
Although aggregating data allowed examination predictors of mental health 
receipt, caution should be taken when interpreting the predictors of substance use 
treatment due to the small sample size of pregnant women who received the treatment. In 
addition, even though this study sheds light on ethnic care disparities, the small sample 
sizes in ethnic groups led us to group them in only two categories (nonWhites vs. 
Whites). This study also focused on any mental health treatment rather than specific 
treatment modalities when examining predictors of treatment and ethnic care disparities. 





These findings reinforce that low rates of treatment receipt for mental health and 
substance use disorders remain a significant public health problem among pregnant 
women in the United States. Given that anxiety disorder and illicit drug dependence are 
the best predictors of mental health and substance use treatment, respectively, pregnancy 
provides a unique opportunity not only to screen but also to intervene with pregnant 
women who have these and other mental health and substance use problems. The findings 
from the present study document ethnic care disparities, suggesting the need for public 
education and preventive and interventional strategies to address the needs of ethnic 
minority pregnant women.  
Expansion of health insurance coverage for mental health treatment is essential as 
cost was the most common barrier to treatment. Screening, outreach, and treatment 
efforts should focus on pregnant women with substance use disorders to increase 
recognition and early treatment. As stigma is attached to substance use disorders, it is 
important to educate health care providers regarding prenatal substance use and trauma-
informed care (SAMHSA, 2014c), thus facilitating the receipt of treatment.  
Further research is needed to understand cultural and belief barriers to mental 
health treatment as perceived by ethnic minorities. In addition, future research is 
recommended to examine the association between the receipt of mental health and 
substance use treatment.  
Finally, the Behavioral Model of Health Services Use of Andersen (1995) was 
useful in predicting the receipt of mental health/substance use treatment given 
predisposing, enabling, and need factors among pregnant women with mental health/ 
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substance use disorder. It also identified ethnic disparities in the receipt of mental health 
treatment among these women and thereby can be used to guide future research 


























Socio-demographic Characteristics of Pregnant Women Aged 18-44, NSDUH 2008- 
2014 (N = 5,520) 
Characteristics Categories Weighted % SE 
Age in years 18-25 37.4 1.0 
 26-44 62.6 1.0 
Ethnicity White 58.8 1.2 
 African American 14.2             0.8 
 Other nonHispanica 8.6             0.6 
 Hispanic 18.3             0.9 
Marital status Married  60.7 1.1 
 Unmarried 39.3 1.1 
Education Less than high 
school  
15.4 0.7 
 High school 26.0 0.9 
 College graduate 58.6 1.0 
Employment status Employed  93.1 0.5 
 Unemployed  6.9 0.5 
Family income <$20,000 22.4 0.9 
 $20,000-49,999 30.4 1.1 
 $50,000-$74,999 17.1 0.7 
 ≥$75,000 30.1 1.1 
Health insurance Insured 90.2 0.5 
 Uninsured 9.8 0.5 
County urbanicity Large urban 53.2 1.2 
 Small urban 31.8 1.0 






 Fair/poor 4.9 0.4 
Note. Imputed and recoded variables were used. Frequencies and weighted percentages 
do not include missing data addressing mental health. NSDUH = National Survey on 
Drug Use and Health; SE = Standard Error.  
aOther nonHispanics included Native American/Alaska Native, Native Hawaiian/Pacific 







Characteristics Associated with Receipt of Mental Health Treatment among Pregnant 
Women with Mental Health Problems Aged 18-44 Years, NSDUH 2008-2014 (N = 1,106) 






Wt. % (SE) 
Yes (n = 453) 
Wt. % (SE) 
No (n = 650) 





Age in years      
18-25 47.7 (2.4) 39.3 (3.4) 54.5 (3.0) 25.15 .001 
26-44 52.3 (2.4) 60.7 (3.4) 45.5 (3.0)   
Ethnicity      
White 66.9 (2.2) 79.7 (2.9) 56.7 (3.1) 66.82 <.001 
African American 12.7 (1.6) 6.8 (1.6) 17.3 (2.5)   
Other NonHispanica 5.2 (0.9) 2.8 (0.9) 7.1 (1.5)   
Hispanic 15.2 (1.5) 10.7 (2.1) 18.8 (2.3)   
Marital status      
Married  46.3 (2.8) 54.4 (3.6) 39.8 (4.3) 23.31 .013 
Unmarried 53.7 (2.8) 45.6 (3.6) 60.2 (4.3)   
Education      
<High school  18.3 (1.4) 14.0 (2.2) 21.7 (2.1) 31.39 .002 
High school 31.0 (2.1) 25.9 (3.2) 35.1 (3.0)   
College graduate 50.7 (2.1) 60.1 (3.7) 43.2 (2.9)   
Employment status      
Employed 90.4 (1.1) 91.1 (1.6) 89.9 (1.6) .47 .593 
Unemployed  9.6 (1.1) 8.9 (1.6) 10.1 (1.6)   
Family income      
<$20,000 28.8 (2.2) 24.7 (2.8) 32.1 (3.1) 31.83 .008 
$20,000-$49,999 32.5 (2.2) 27.6 (2.8) 36.5 (3.2)   
$50,000-$74,999 15.6 (1.8) 18.0 (3.2) 13.7 (2.1)   
≥$75,000 23.0 (2.3) 29.7 (3.5) 17.7 (2.9)   
Health insurance      
Insured 88.0 (1.6) 91.3 (1.9) 85.4 (2.3) 8.93 .036 
Uninsured 12.0 (1.6) 8.7 (1.9) 14.6 (2.3)   
County urbanicity      
Nonmetropolitan 18.8 (1.6) 21.2 (2.4) 16.9 (2.0) 3.52 .445 
Small 36.4 (2.5) 36.2 (3.5) 36.6 (3.3)   
Large 44.7 (2.5) 42.6 (3.8) 46.5 (3.5)   
    (Continued) 
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Wt. % (SE) 
Yes (n = 453) 
Wt. % (SE) 
No (n = 650) 







     
Poor/fair 10.4 (1.4) 9.0 (2.0) 11.5 (2.1) 1.84 .400 
Excellent/very/good 89.6 (1.4) 91.0 (2.0) 88.5 (2.1)   
Perceived need for 
treatment  
     
Yes 28.1 (2.5) 36.2 (3.6) 21.6 (2.7) 28.69 <.001 
No 71.9 (2.5) 63.8 (3.6) 78.4 (2.7)   
Serious psychological 
distress (Mean, SE) 15.54 (.24) 15.44 (.43) 15.62 (.29) 65.68 <.001 
Major depressive 
episode  
     
Yes 33.9 (2.3) 39.6 (3.5) 29.4 (2.6) 12.50 .014 
No 66.1 (2.3) 60.4 (3.5) 70.6 (2.6)   
Anxiety disorder       
Yes 33.6 (2.0) 59.1 (3.3) 13.2 (1.8) 256.05 <.001 
No 66.4 (2.0) 40.9 (3.3) 86.8 (1.8)   
Substance use 
disorderb 
     
Yes 20.0 (1.7) 20.3 (2.4) 19.8 (2.2) .03 .893 
No 80.0 (1.7) 79.7 (2.4) 80.2 (2.2)   
Note. Imputed and recoded variables were used. Frequencies and weighted percentages 
do not include missing data addressing mental health. NSDUH = National Survey on 
Drug Use and Health; SE = Standard Error; Wt. % = Weighted percentages.  
aOther nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific 
Islander, Asian, and more than one race. bSubstance use disorder includes alcohol or 
illicit drug use dependence or abuse measured based on the Diagnostic and Statistical 










Characteristics Associated with Receipt of Substance Use Treatment among Pregnant 
Women with Substance Use Disorders Aged 18-44 Years, NSDUH 2008-2014 (N = 521) 






Wt. % (SE) 
Yes (n = 68) 
Wt. % (SE) 
No (n = 453) 





Age in years      
18-25 53.2 (3.5) 51.1 (9.2) 53.5 (3.5) .15 .789 
26-44 46.8 (3.5) 48.9 (9.2) 46.5 (3.5)   
Ethnicity      
White 60.9 (3.1) 66.1 (7.3) 60.1 (3.4) .89 .480 
NonWhitea 39.1 (3.1) 33.9 (7.3) 39.9 (3.4)   
Marital status      
Married  30.7 (3.2) 18.9 (8.8) 32.5 (3.4) 5.14 .218 
Unmarried 69.3 (3.2) 81.1 (8.8) 67.5 (3.4)   
Education      
<High school  20.4 (2.1) 29.4 (8.2) 19.1 (2.1) 4.63 .281 
High school 26.6 (2.6) 27.9 (6.6) 26.4 (2.6)   
College graduate 52.9 (3.3) 42.8 (8.5) 54.5 (3.6)   
Employment      
Employed 89.5 (1.8) 88.7 (3.8) 89.6 (2.0) .05 .817 
Unemployed  10.5 (1.8) 11.3 (3.8) 10.4 (2.0)   
Family Income      
<$20,000 29.3 (2.9) 39.4 (8.6) 27.8 (3.2) 4.92 .297 
$20,000-49,999 29.5 (2.5) 30.2 (7.7) 29.4 (2.7)   
≥$50,000 41.2 (3.1) 30.4 (7.9) 42.8 (3.2)   
Health insurance      
Insured 91.8 (1.1) 92.6 (3.6) 91.7 (1.3) .07 .831 
Uninsured 8.2 (1.1) 7.4 (3.6) 8.3 (1.3)   
County urbanicity      
Nonmetropolitan  19.3 (2.2) 19.1 (5.6) 19.3 (2.5) 8.48 .059 
Small urban 29.5 (2.9) 15.3 (4.4) 31.7 (3.2)   
Large urban 51.2 (3.3) 65.5 (7.4) 49.1 (3.7)   
Self-rated health 
status 
     
Poor/Fair 9.4 (2.0) 10.8 (6.5) 9.2 (2.0) .19 .796 
Excellent/very/good 90.6 (2.0) 89.2 (6.5) 90.8 (2.0) (Continued) 
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Wt. % (SE) 
Yes (n = 68) 
Wt. % (SE) 
No (n = 453) 






Perceived need for 
treatment 
     
Yes 4.5 (1.0) 7.6 (4.6) 4.0 (0.9) 1.79 .316 
No 95.5 (1.0) 92.4 (4.6) 96.0 (0.9)   
Alcohol use disorder      
None 23.8 (2.7) 26.8 (6.6) 23.3 (2.8) 8.09 .128 
Abuseb 41.3 (3.6) 26.1 (8.1) 43.6 (3.9)   
Dependencec 34.9 (3.3) 47.2 (8.8) 33.1 (3.5)   
Illicit drug use 
disorderd 
     
None 58.9 (2.9) 27.7 (8.8) 63.6 (3.2) 31.81 .002 
Abuseb 10.0 (1.6) 19.3 (6.6) 8.6 (1.9)   
Dependencec 31.1 (2.4) 53.0 (8.3) 27.8 (2.4)   
Depression/anxiety 
disorders 
     
Yes 27.8 (2.7) 49.5 (8.6) 24.7 (3.1) 16.86 .007 
No 72.2 (2.7) 50.5 (8.6) 75.3 (3.1)   
Note. Imputed and recoded variables were used. Frequencies and weighted percentages 
do not include missing data addressing mental health. NSDUH = National Survey on 
Drug Use and Health; SE = Standard Error; Wt. Percentages = Weighted Percentages.  
aOther nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific 
Islander, Asian, and more than one race. bSubstance abuse involves not meeting the 
criteria for dependence on that substance but reporting at least one of four abuse criteria 
occur in a 12-month period (i.e., roles obligations, hazardous use, legal problems, and 
social problem). cDependence on a substance involves reporting at least three out of 
seven dependence symptoms occur in a 12-month period (i.e., engaging in activities 
related to substance use, tolerance, withdrawal, larger or longer use, unsuccessful 
attempts to cut down, physical health or emotional problems, and reduced activities). 
dIllicit drugs include heroin, marijuana, cocaine, inhalants, sedatives, tranquilizers, 









Logistic Regression Using Backward Elimination to Identify the Best Predictive Model of 
the Probability of Mental Health Treatment Receipt among Pregnant Women Aged 18-44 












Ethnicity     
White Reference  Reference  
African American .28 .16-.51** .38 .20-.74** 
Other nonHispanicsa .28 .13-.63 .17 .05-.59 
Hispanic .40 .23-.71 .72 .39-1.31 
Education     
<High school  Reference  Reference  
High school 1.15 .67-1.96 1.29 .67-2.50 
College graduate 2.16 1.31-3.54** 2.84 1.36-5.91** 
Health insurance status     
Uninsured Reference  Reference  
Insured 1.79 1.03-3.10* 2.34 1.16-4.71* 
Serious psychological 










Major depressive episode      
No Reference  Reference  
Yes  1.57 1.07-2.26* 2.48 1.44-4.27** 
Anxiety disorder      
No Reference  Reference  
Yes  9.51 6.19-14.61*** 17.34 8.64-34.81*** 
Note. Imputed and recoded variables were used. NSDUH = National Survey on Drug Use 
and Health; OR = Odds Ratio; CI = Confidence Intervals.  
aOther nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific 
Islander, Asian, and more than one race. 









Logistic Regression Using Backward Elimination to Identify the Best Predictive Model of 
the Probability of Substance Use Treatment Receipt among Pregnant Women Aged 18-44 











County urbanicity     
Small urban Reference  Reference  
Nonmetro 2.05 .85-4.95 2.570 .89-7.43 
Large urban 2.76 1.24-6.15* 4.40 1.82-10.62** 
Ethnicity     
Whites Reference  Reference  
NonWhitesa  .77 .38-1.59 .39 .19-.80* 
Alcohol use disorder      
None Reference  Reference  
Abuseb .52 .21-1.32 2.84 .95-8.48 
Dependencec 1.24 .57-2.71 2.99 1.37-6.49* 
Illicit drug use disorderd      
None Reference  Reference  
Abuseb 5.16 1.35-19.78** 7.89 1.81-34.40*** 
Dependencec 4.38 1.77-10.82 8.83 3.10-25.16 
Depression/Anxiety disorders     
No Reference  Reference  
Yes 2.98 1.32-6.71** 3.13 1.40-7.02** 
Note. Imputed and recoded variables were used. Frequencies and weighted percentages 
do not include missing data addressing mental health. NSDUH = National Survey on 
Drug Use and Health; OR = Odds Ratio; CI = Confidence Intervals.  
aNonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native 
American/Alaska Native, Native Hawaiian/Pacific Islander, Asian, and more than one 
race. bSubstance abuse involves not meeting the criteria for dependence on that substance 
but reporting at least one of four abuse criteria occur in a 12-month period (i.e., roles 
obligations, hazardous use, legal problems, and social problem). cDependence on a 
substance involves reporting at least three out of seven dependence symptoms occur in a 
12-month period (i.e., engaging in activities related to substance use, tolerance, 
withdrawal, larger or longer use, unsuccessful attempts to cut down, physical health or 
emotional problems, and reduced activities). dIllicit drugs include heroin, marijuana, 
cocaine, inhalants, sedatives, tranquilizers, hallucinogens, stimulants, and analgesics.  








Percentages of Mental Health Treatment Modalities in Non-Hispanic White and Nonwhite Pregnant Women with  
Mental Health and Substance Use Disorders and Aged 18-44 Years, NSDUH 2008-2014  
 
 
Mental health treatment 
Women with Depression (N = 381)   
Total sample 
Wt. % (SE) 
Whites (n = 227) 
Wt. % (SE) 






Any treatment  (n = 179) 51.8 (3.2) 55.8  (4.1) 42.9 (5.0) 5.38 .062 
Outpatient treatment (n = 105) 33.3 (3.7) 35.2 (4.8) 29.2 (4.6) 1.32 .373 
Inpatient treatment (n = 21) 3.9 (1.0) 3.3 (1.1) 5.2 (1.9) .80 .347 
Prescription drugs (n = 142) 40.5 (3.0) 44.8 (3.9) 30.9 (5.2) 6.53 .054 
 
Women with Anxiety (N = 379) 
  
 Total sample 
Wt. % (SE) 
Whites (n = 296) 
Wt. % (SE) 
NonWhites (n = 83) 
Wt. % (SE) 
  
Any treatment (n = 271) 78.2 (2.7) 79.4 (3.1) 73.7 (7.0) 1.22 .461 
Outpatient treatment (n = 141) 45.7 (3.6) 46.6 (3.8) 42.7 (8.5) .39 .673 
Inpatient treatment (n = 17) 3.0 (0.9) 2.5 (0.9) 4.9 (2.3) 1.20 .241 
Prescription drugs (n = 241) 67.9 (3.4) 69.6 (3.7) 61.6 (8.6) 1.90 .388 
 
Women with Serious Psychological Distress (N = 842) 
  
 Total sample 
Wt. % (SE) 
Whites (n = 482) 
Wt. % (SE) 
NonWhites (n = 360) 
Wt. % (SE) 
  
Any treatment (n = 308) 38.6 (2.5) 47.3 (3.4) 23.8 (3.4) 45.70 <.0001 
Outpatient treatment (n = 178) 24.5 (2.3) 29.7 (3.6) 15.7 (2.3) 20.61   .003 
Inpatient treatment (n = 35) 3.5 (0.9) 3.2 (1.0) 4.0 (1.5)    .45   .593 
Prescription drugs (n = 247) 30.4 (2.4) 37.7 (3.3) 18.2 (3.1) 35.08 <.0001 
      







 Women with Substance Use Disordersb (N = 521)   
 Total sample 
Wt. % (SE) 
Whites (n = 284) 
Wt. % (SE) 
NonWhites (n = 237) 





Any treatment (n = 140) 26.4 (2.9) 31.3 (4.1) 18.5 (3.4) 10.40 .019 
Outpatient treatment (n = 76) 14.8 (2.1) 16.7 (3.0) 11.8 (2.8) 2.32 .249 
Inpatient treatment (n = 21) 2.8 (1.0) 2.4 (1.1) 3.5 (2.1) .54 .619 
Prescription drugs (n = 104) 19.1 (2.5) 21.7 (3.5) 14.9 (3.0) 3.63 .145 
 
Women with Comorbid Mental Health and Substance Use 
Disorders (N = 244) 
  
 Total sample 
Wt. % (SE) 
Whites (n = 89) 
Wt. % (SE) 
NonWhites (n = 112) 
Wt. % (SE) 
  
Any treatment (n = 110) 44.9 (3.8) 54.8 (4.3) 30.7 (5.7) 13.83 . 003 
Outpatient treatment (n = 65) 26.6 (3.6) 30.6 (4.9) 20.9 (4.6) 2.89 .161 
Inpatient treatment (n = 18) 6.2 (2.4) 5.5 (2.6) 7.3 (4.3)  .34 .696 
Prescription drugs (n = 83) 33.4 (3.6) 39.1 (4.8) 25.2 (5.4) 5.12 .074 
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data 
addressing mental health. NSDUH = National Survey on Drug Use and Health; Wt. %= Weighted Percentages; SE = 
Standard Error.  
aNonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native American/Alaska Native, Native 
Hawaiian/Pacific Islander, Asian, and more than one race. bSubstance use disorders include alcohol or illicit drug use 




Logistic Regression Model of the Probability of the Receipt of Mental Health Treatment 
in Pregnant Women Aged 18-44Years by type of Mental Health and/or Substance Use 











     
1. Major depression (N = 381)     
NonWhitesa vs. Whites .60 .34-1.03 .49 .27-.92* 
2. Anxiety disorder (N = 379)     
NonWhites vs. Whites .73 .31-1.73 .91 .37-2.27 
3. Serious psychological  
distressb (N = 842) 
    
NonWhites vs. Whites .35 .22-.56*** .34 .20-59*** 
4. Substance use 
disordersc (N = 521) 
    
NonWhites vs. Whites .50 .27-.89* .46 .23-.93* 
5. Comorbid  
disordersd (N = 244) 
    
NonWhites vs. Whites .37 .19-.70** .27 .13-.57** 
Note. Control variables include predisposing factors (i.e., age, education, marital status, 
employment status); enabling factors (i.e., income, health insurance, and county type); 
need factors (i.e., self-rated health status and severity of distress symptoms); and time. 
Imputed and recoded variables were used. Frequencies and weighted percentages do not 
include missing data addressing mental health. NSDUH = National Survey on Drug Use 
and Health; OR = Odds Ratio; CI = Confidence Intervals.  
aNonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native 
American/Alaska Native, Native Hawaiian/Pacific Islander, Asian, and more than one 
race. bIncluded those who had a score of 13 or above on the Kessler-6 Psychological 
Distress Scale. cSubstance use disorders include alcohol or illicit drug use dependence or 
abuse measured based on the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) criteria. dComorbid disorders involve mental health (i.e, major depressive 
episode, anxiety disorder, or serious psychological distress) and substance use disorders.  







Table 15  
Differences in Perceived Barriers to Mental Health Treatment among Pregnant Women with Mental Health and/or Substance 
Use Disorders and Perceived Need for Treatment, NSDUH (2008-2014) (N = 391) 
   
Cost 




 Time/transportation  
limitations 
 Not knowing 
where to go 
Disorders   Wt.% (SE)  Wt.% (SE)  Wt.% (SE)  Wt.% (SE)  Wt.% (SE) 












      No 49.2 (7.0)  48.6 (7.3)  22.4 (5.4)  16.0 (4.9)  13.2 (3.4) 
Major depression:  Yes 61.1 (5.2)*  33.4 (3.3)*   23.7 (5.2)   17.8 (3.3)   24.2 (4.7)** 
        No 46.2 (3.9)  48.1 (4.6)  22.1 (4.0)  20.5 (3.2)  11.2 (2.0) 
Anxiety disorder:  Yes 51.7 (6.7)  35.9 (6.1)  17.7 (4.1)  31.1 (5.5)*  13.0 (3.5) 





            
52.3(4.4) 
                 
39.5 (4.0) 
         
22.9 (4.1) 
                           
17.9 (3.3) 
                          
18.0 (2.9) 
 No 51.0 (5.6)  48.5 (6.5)  21.6 (4.7)  22.8 (4.4)  11.5 (2.6) 
Substance use  disorders:b  Yes 57.5 (6.0)  45.2 (6.3)  38.1 (6.3)***  15.0 (4.3)  18.0 (6.0) 
 No 49.5 (4.1)  41.8 (4.3)  16.2 (3.3)  21.6 (3.1)  14.7 (3.0) 
Comorbid disorders:c  Yes 54.8 (6.0)  43.2 (4.0)  36.7(4.1)*  16.3 (3.3)  14.8 (2.9) 
  No 44.1 (7.9)  47.5 (8.2)  18.1 (6.0)  17.3 (5.6)  8.7 (3.5) 
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data addressing 
mental health. NSDUH = National Survey on Drug Use and Health; CI= Confidence Intervals.  
aIncluded those who had a score of 13 or above on the Kessler-6 Psychological Distress Scale. bSubstance use disorders include 
alcohol or illicit drug use dependence or abuse measured based on the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) criteria. cComorbid disorders involve mental health (i.e., major depressive episode, anxiety disorder, or serious 
psychological distress) and substance use disorders.  









Figure 7. The Behavioral Model of Health Services Use. Adapted from “Revisiting the Behavioral Model and Access to 
Medical Care: Does it Matter?” by R.M. Andersen, 1995, Journal of Health and Social Behavior, 36(1), p. 8. 
 






















Figure 8. Theoretical framework adapted the Behavioral Model of Health Services Use. Adapted from “Revisiting the Behavioral 
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Figure 9. Perceived barriers to mental health treatment in White and NonWhite pregnant 
women with mental health problems who perceived need for treatment, National Survey 
on Drug Use and Health, 2008-2014 (N = 296). Imputed and recoded variables were 
used. Frequencies and weighted percentages do not include missing data addressing 
mental health. NonWhites include African Americans, Hispanics, and other 
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander, 
Asian, and more than one race. 
 an = 195. bn = 101.  
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Figure 10. Perceived barriers to mental health treatment in White and NonWhite 
pregnant women with substance use disorders who perceived a need for treatment, 
National Survey on Drug Use and Health (N = 127). Imputed and recoded variables were 
used. Frequencies and weighted percentages do not include missing data addressing 
mental health. NonWhites include African Americans, Hispanics, and other 
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander, 
Asian, and more than one race. 
























Figure 11. Perceived barriers to mental health treatment in pregnant women with 
comorbid mental health and substance use disorders who perceived a need for treatment, 
National Survey on Drug Use and Health, 2008-2014 (N = 114).  NonWhites include 
African Americans, Hispanics, and other nonHispanics, i.e., Native American/Alaska 
Native, Native Hawaiian/Pacific Islander, Asian, and more than one race. 






DISCUSSION AND CONCLUSION 
 
The purposes of this dissertation were to: (1) systematically review literature of 
trend and population-based studies on mental health and substance use disorders and 
treatment receipt among pregnant women in the United States; (2) compare trends in 
mental health and substance use disorders and treatment receipt by pregnancy status from 
2008 to 2014; and (3) identify predictors of treatment receipt for mental health and 
substance use disorders and examine ethnic care disparities in mental health treatment 
among pregnant women with mental health and/or substance use disorders in the United 
States.  
Synthesis of Findings and Implications 
Trends in Mental Health and Substance Use Disorders 
Chapter Two was a systematic review of trend studies on mental health disorders, 
particularly depression, anxiety disorder, and psychological distress, among pregnant 
women in the United States. However, the review revealed a lack of recent evidence 
addressing trends in mental health disorders among pregnant women in the United States. 
Yet in Chapter Three, a significant increase was identified in the rates of past-year 
anxiety disorder and past-month serious psychological distress among women of 
childbearing age from 2008 to 2014. This is congruent with the increase in poor mental 
health for 15 days or more in the past month from 2001 to 2012 among the general
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population in the United States (Mojtabi & Jorm, 2015). Interestingly, Chapter Four 
findings revealed that past-year anxiety disorder was the best predictor of receipt of 
mental health treatment among pregnant women. This emphasizes the need to screen and 
treat these mental health problems during prenatal period. In addition, evidence-based 
prevention strategies are required to reduce the negative health consequences of mental 
health disorders for the mother and her child.   
 The systematic review of trend studies on maternal substance use disorders 
revealed that maternal abuse of opioid, cannabis and hallucinogens, and 
methamphetamine increased from 1999 to 2008; however, cocaine abuse decreased 
significantly while alcohol abuse declined slightly (Pan & Yi, 2013). Maeda et al. (2014) 
found that opioid use disorder increased from 1998 to 2011. Similarly, Chapter Three 
showed a significant linear trend in illicit drug use disorder from 2008 to 2014 among 
women of childbearing age. It is noteworthy that the studies reviewed did not compare 
trends in substance use disorders by pregnancy status; however, the findings in Chapter 
Three did not indicate a significant difference between pregnant and nonpregnant women 
in illicit drug or alcohol use disorders over time. Unfortunately, there is a paucity of 
studies specifically addressing trends in the national estimates of substance use disorders 
among pregnant and nonpregnant women in the United States. It is crucial to conduct 
such studies especially given that treatment admissions for illicit drug use disorders 
increased profoundly among pregnant women from 1998 to 2008 compared to 
nonpregnant women (McCabe & Arndt, 2012).  
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Trends in Treatment Receipt 
 The systematic review revealed an increase in antidepressant use among pregnant 
women from 1995 to 2010 (Andrade et al., 2008; Bobo et al., 2014; Meunier et al., 2013), 
whereas the rate of psychotropic medications use remained stable from 2006 to 2010 
(Hanley & Mintzes, 2014). These studies did not compare trends by pregnancy status. 
However, Hanley and Mintzes (2014) found that the rates of psychotropic medication use 
were higher before pregnancy than in the first and second trimesters of pregnancy.  
Although antidepressant use during pregnancy is controversial (Yamamoto et al., 
2015), there was only one study of a nationally representative sample on antidepressant 
use among pregnant women in the United States identified for review (Meunier et al., 
2013). Hence, further research is needed to reflect recent trends in antidepressant use 
among nationally representative sample of pregnant women. The systematic review also 
showed there is a lack of evidence regarding trends in the receipt of any mental health 
treatment modalities including prescription drugs, outpatient counseling, or inpatient 
treatment among pregnant women. In contrast, trends in the receipt of any of these 
modalities were examined in Chapter Three; thus, the findings from Chapters Two and 
Three are not comparable in regards to the receipt of mental health treatment. Chapter 
Three revealed no significant increase in the receipt of mental health treatment among 
women of childbearing age from 2008 to 2014. However, pregnant women had a lower 
likelihood of treatment receipt compared to nonpregnant women. The findings presented 
in Chapter Three revealed were similar. Trends in the receipt of mental health treatment 
among childbearing-aged women with mental illness were evaluated, controlling for 
severity of mental illness. The trends in receipt of mental health treatment among 
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pregnant women were inconsistent with the increase over time in mental health treatment 
among the general population (Mojtabi & Jorm, 2015). This suggests that women of 
childbearing age may have special mental health needs.  
Interestingly, there was no significant interaction between pregnancy status and 
time in predicting mental health treatment receipt as discussed in Chapter Three; pregnant 
women had a lower odds of mental health treatment receipt compared to nonpregnant 
women. On the other hand, the systematic review revealed mixed findings regarding the 
difference between pregnant and nonpregnant women in the receipt of mental health 
treatment which may be due to the heterogeneity of samples and measures of mental 
health problems. The Chapter Three findings were in accord with a study based on the 
2008-2012 NSDUH (Glasheen et al., 2015), although the two studies included different 
samples (e.g., women with past-year mental illness in Chapter Three versus women with 
past-month psychological distress in the study of Glasheen et al.). Thus, it is crucial to 
conduct more research about the difference between pregnant and nonpregnant women in 
the receipt of mental health treatment to tailor interventions according to the needs of 
pregnant women.   
The systematic review indicated an increase in treatment admissions for illicit 
drug use disorder from 1998 to 2008 (McCabe & Arndt, 2012), and for marijuana 
(Martin, Longinaker, Mark, et al., 2015) and opioid use disorders from 1992 to 2012 
(Martin, Longinaker, & Terplan, 2015). Yet, treatment admissions decreased over time 
for cocaine and alcohol use (Martin, Longinaker, Mark, et al., 2015; McCabe & Arndt, 
2012). Overall, treatment admissions for substance use disorders remained stable from 
1992 to 2012 at 4% among pregnant women (Martin, Longinaker, Mark, et al., 2015). 
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This suggests that there was no improvement in the utilization of substance use treatment 
services among pregnant women. The findings in Chapter Three supported this as the rate 
of unmet need for substance use treatment remained stable at 7% from 2008 to 2014 
among pregnant women. This is of critical concern because several states enacted laws 
that stigmatized prenatal illicit substance use in pregnant women (Guttmacher Institute, 
2017). Subsequently, many pregnant women do not seek treatment to avoid losing 
custody of their child (Tuchman, 2010). Legal and treatment initiatives should focus on 
the specific needs of pregnant women with substance use disorders. According to the 
CSAT (2009), an atmosphere of hope, acceptance, and support is essential for women to 
overcome the challenges of substance use disorder and receive substance use treatment.  
Factors Associated with Treatment Receipt  
The systematic review of population-based studies, although they were few, 
revealed that factors related to the receipt of mental health treatment included White 
ethnicity (Bennett et al., 2010; Byatt et al., 2016; Chang et al., 2016), older reproductive 
age, college education (Chang et al., 2016), having assistance/insurance coverage 
(Bennett et al., 2010; Chang et al., 2016), and having mental health problems (Byatt et 
al., 2016; Roberson et al., 2016). Multivariate analyses from Chapter Four supported 
these findings. The final predictive model for mental health treatment receipt contained 
six variables: White ethnicity, college education, health insurance coverage, past-year 
anxiety disorder, MDE, and serious psychological distress.  
While the only national study focused on depressive symptoms among pregnant 
women (Byatt et al., 2016), Chapter Four findings added to the literature by identifying 
the best predictors of mental health treatment receipt given the need factors for treatment.  
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Anxiety disorder was the strongest predictor, followed by MDE and serious 
psychological distress. These findings indicate the critical nature of screening and 
treatment initiatives for these mental health problems during pregnancy; emphasis on 
anxiety disorder is particularly warranted, especially since it is more often ignored than 
depression in pregnant women (Fairbrother et al., 2016; Fairbrother et al., 2015).  
Only two population-based studies identified for the systematic review examined 
factors associated with substance use treatment receipt among childbearing-aged women 
(Terplan et al., 2012) and pregnant women (Kotelchuck et al., 2017). Factors related to 
treatment receipt in these studies included college education, older reproductive age, and 
governmental assistance/private health insurance. Compared to those who did not receive 
treatment, Kotelchuck et al. (2017) also found that Black or Hispanic women were less 
likely to receive substance use treatment whereas those with fewer health or psychiatric 
conditions were more likely to receive treatment. The best predictive model of substance 
use treatment receipt in Chapter Four indicated that White ethnicity and comorbid 
depression/anxiety increased the likelihood of substance use treatment receipt. Similarly, 
the review of trend studies in Chapter Two indicated that substance use treatment 
admissions of Whites and pregnant women with comorbid psychiatric illness increased 
over time (Martin, Longinaker, Mark, et al., 2015). This supports the importance of 
addressing mental health needs of pregnant women with substance use disorders. Increase 
access to substance use treatment among ethnic minority pregnant women is essential. 
Chapter Four contributes to the literature by addressing how need factors for 
treatment differentiate the receipt of substance use treatment among pregnant women. 
Illicit drug dependence was the best predictor of treatment receipt followed by illicit drug 
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abuse and alcohol use dependence. This is congruent with the trend studies reviewed in 
Chapter Two which revealed an increase in treatment admissions for illicit drug use 
disorder over time (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, & 
Terplan, 2015; McCabe & Arndt, 2012). There is a need for evidence-based preventive 
strategies to minimize the burden of illicit drug use disorders for the mother, her child, 
and society. Given that substance use is a modifiable health behavior (Kuo et al., 2013; 
Massey et al., 2011), health care providers should screen and intervene early to prevent 
women from developing severe substance use disorders.   
Ethnic Care Disparities in Mental Health Treatment Receipt  
 Only three population-based studies reviewed in Chapter Two explicitly 
addressed ethnic care disparities in the receipt of mental health treatment (Chang et al., 
2016; Coleman-Cowger, 2012; Yamamoto et al., 2015). These studies indicated that 
White pregnant women were more likely to receive mental health treatment than 
nonWhites. A series of logistic regression models in Chapter Four also revealed that 
nonWhite ethnicity (versus White) decreased the likelihood of mental health treatment 
receipt in pregnant women with MDE, serious psychological distress, substance use 
disorders, and comorbid mental health and substance use disorders even after controlling 
for predisposing factors, enabling factors, and severity of distress symptoms. These 
findings indicate that ethnic minority pregnant women may have specific cultural beliefs 
and attitudes about seeking mental health treatment (O’Mahen & Flynn, 2008). Further 
research is needed to address potential cultural differences. Screening initiatives and 




Barriers to Treatment Receipt 
Findings from the population-based studies reviewed indicated that barriers to 
mental health treatment included cost, opposition to treatment, stigma, 
time/transportation limitations, and not knowing where to go (Ko et al., 2012) as well as 
provider-patient conversation regarding depression (Farr et al., 2016) and providers’ 
competency in treatment/referrals (Price et al., 2012). Chapter Three also indicated that 
cost, opposition to treatment, and stigma were the most common barriers among pregnant 
women. In addition, their rank order and percentages did not differ across two time 
periods, 2008-2010 and 2011-2014.  
Chapter Four also expanded these findings and added to the literature by 
comparing perceived barriers to mental health treatment across types of mental health 
and/or substance use disorders and ethnicity. Compared to pregnant women without 
MDE, those with MDE were more likely to perceive cost and not knowing where to go as 
barriers to mental health treatment and less likely to have opposition to treatment. 
Pregnant women with anxiety disorder were more likely to report the lack of 
time/transportations as barriers to mental health treatment compared to those without 
anxiety. Those who had substance use disorders or comorbid mental health and substance 
use disorders were more likely to perceive stigma attached to the receipt of mental health 
treatment as a barrier compared to pregnant women without these disorders.  
 Furthermore, the findings in Chapter Four indicated there were no differences 
between White and nonWhite pregnant women with mental health problems, substance 
use disorders, and comorbid mental health and substance use disorders in the proportions 
of perceived opposition to treatment, stigma, time/transportation limitations, and not 
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knowing where to go. These findings are congruent with those of one study in which 
there were no differences between White and African American perinatal women in the 
perceived structural (e.g., insurance, cost, and transportation), knowledge, and attitudinal 
barriers to depression treatment (O’Mahen & Flynn, 2008). However, in Chapter Four, 
Whites were more likely to perceive cost as an obstacle to mental health treatment. 
Findings from the systematic review and the two data based manuscripts in this 
dissertation reflect the complexity of barriers to mental health treatment and provide 
information relevant to health reform on the importance of addressing such barriers and 
increasing the sensitivity of healthcare providers in regards unique mental health needs of 
pregnant women to enhance their access to treatment. Further research is needed to 
compare barriers to mental health treatment across different ethnic groups.  
The systematic review demonstrated the paucity of studies addressing barriers to 
substance use treatment among pregnant women. In the first data based study, perceived 
barriers to substance use treatment among childbearing-aged women differed from 2008-
2010 to 2011-2014. For instance, in 2008-2010, cost ranked first and followed by stigma, 
whereas stigma ranked first and followed by cost in 2011-2014. Interestingly, women of 
childbearing age in 2011-2014 were more likely to report not knowing where to go and a 
lack of treatment programs as obstacles to the receipt of substance use treatment than 
women in 2008-2010. Upstream efforts are needed to meet the needs of pregnant women 
with substance use disorders. These women are stigmatized and their specific needs are 
still unmet (CSAT, 2009). Legal and treatment initiatives are critical to increase the 
availability of treatment facilities that acknowledge the “biopsychosocial uniqueness” of 
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women with substance use disorders (CSAT, 2009, p.1) and provide specific strategies to 
improve access to care such as trauma-informed care (SAMHSA, 2014c).   
Summary 
 This dissertation is innovative because it: (a) includes a systematic review of trend 
and population-based studies on mental health and substance use disorders among 
pregnant women in the United States, (b) contains one of the first studies that compared 
trends in both mental health and substance use disorders and treatment receipt by 
pregnancy status,  and (c) fills a gap in the literature by studying factors associated with 
the receipt of treatment for mental health and substance use disorders and addressing 
ethnic health care disparities and barriers to mental health treatment experienced by a 
national sample of pregnant women.  
The findings clearly support the gap between the need for and the receipt of 
treatment among pregnant women with mental health and substance use disorders. Trends 
in the receipt of mental health treatment and the unmet need for substance use treatment 
did not change from 2008-2014 among childbearing-aged women, whereas anxiety 
disorders, past-month psychological distress, and illicit drug use disorder increased over 
the same time period. Further research is needed to address the seriousness of these 
disorders, particularly mental health problems, among pregnant women in the United 
States over time.   
This research underscores that factors associated with both mental health and 
substance use treatment receipt are complex and involve predisposing (e.g., ethnicity), 
enabling (e.g., health insurance and urban residency), and need factors (e.g., anxiety 
disorder and illicit drug use disorder). This research also showed that numerous obstacles 
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impede women of childbearing age in accessing mental health and substance use 
treatment. In addition, disparities in mental health treatment also exist among pregnant 
women with mental health and/or substance use disorders.   
This dissertation provides new insights for improving maternal mental health. It 
has significant clinical implications because pregnancy provides an opportunity to screen 
and intervene with mental health and substance use problems. The information generated 
from this dissertation may help in designing programs according to the needs of pregnant 
women. There is a need for evidence-based preventive and treatment strategies to 
minimize the effects of mental health problems and substance use disorders for the 
mother, her child, and society. Health care providers play a significant role in screening 
and identifying pregnant women at risk for and those who have mental health and 
substance use disorders.  
 This research indicates needed changes in health policy to improve the health of a 
vulnerable population of pregnant women. There is a need to develop strategies 
addressing the unique barriers (e.g., cost, stigma, opposition to treatment, available 
treatment programs, and not knowing to go) that impede pregnant and nonpregnant 
women to access mental health and substance use treatment. Specific and evidence-based 
interventions tailored to the needs of ethnic minority pregnant women are essential. More 
research and clinical practice changes are required to focus on mental health needs of 
pregnant women with substance use disorders. Further research is needed to examine the 
association between the receipt of mental health and substance use treatment. Developing 
strategies integrating the two systems is also crucial.   
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To improve maternal mental health and to disseminate a message of hope for 
pregnant women, collaboration among researchers, policy makers, and healthcare 
providers is required. Hopefully, this dissertation provides a contribution for a better 
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